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Abstract 
Epilepsy is a chronic neurological disorder affecting around 1% of the human population 
worldwide. The antiepileptic drugs (AEDs) available on the market provide symptomatic relief 
from epilepsy but do not cure the disease. Moreover, around 30% of epileptic patients remain 
resistant to treatment with the available AEDs. There is an unmet need for new AEDs 
exhibiting novel mechanism(s) of action resulting in disease-modifying properties. The AEDs 
levetiracetam (LEV, Keppra®) and its more potent derivative brivaracetam (BRV, Briviact®) 
exert their anticonvulsive effects through a unique mechanism of action, which is, however, 
still not well understood. The synaptic vesicle protein 2A (SV2A) was previously identified as 
the main target of LEV and BRV. However, LEV was also shown to modulate connexin43 
(Cx43) gap junction (GJ) channels in astrocytes, which may also contribute to its antiepileptic 
efficacy.  
In the present study, a radioligand competition assay suitable for compound library screening 
was established using [3H]BRV and cellular homogenates of Chinese hamster ovary (CHO) 
cells stably expressing human SV2A. A library of 500 approved drugs was tested for 
interaction with SV2A resulting in the identification of three new SV2A-interacting 
compounds, loratadine, quinine, and rimonabant. This discovery prompted us to screen an 
in-house library of 80 cannabinoids, which resulted in the identification of cannabidiol (CBD) 
as a potent ligand of SV2A with a Ki value below 1 µM. Thus CBD (Ki 0.719 µM) is similarly 
potent as LEV (Ki 1.74 µM) at SV2A. Our results support the idea that the already established 
anticonvulsive properties of quinine might be – at least partly – attributed to its interaction with 
SV2A. In fact, CBD has shown antiepileptic effects and was recently approved for the 
treatment of epilepsy syndromes (Dravet syndrome and Lennox-Gastaut syndrome). SV2A 
interaction may contribute to its antiepileptic activity which has so far been unknown. Binding 
studies with [3H]BRV at SV2A variants to investigate a potential role of the long intracellular 
cytoplasmic loop 3 (ICL3) of SV2A for LEV/BRV binding point towards the importance of 
the ICL3 for racetam binding. Previously proposed interaction partners of SV2A, namely 
galactose and botulinum neurotoxin A (BoNT/A) did not modulate [3H]BRV binding. Binding 
studies with [3H]BRV on recombinant Cx43 did not indicate the presence of a high-affinity 
binding site. Moreover, we developed a new screening assay for Cx43 GJ modulators which 
should be suitable for high-throughput screening. Lastly, the development of a novel method 
using capillary gel electrophoresis with a laser-induced fluorescence detector (CGE-LIF) for 
the quantification of green fluorescent protein (GFP)-tagged membrane proteins in a 
complex matrix such as cellular homogenates was reported. In conclusion, herein identified 
compounds interacting with SV2A may provide a basis for the development of new classes of 
antiepileptic drugs. The newly developed Cx43 GJ screening assay will help to screen large 
compound libraries to identify selective and potent modulators of Cx43 GJ channels. 
Furthermore, the new CGE-LIF based method provides a fast, robust, and reproducible 
approach to quantify various classes of membrane proteins containing a fluorescent tag.  
 
Keywords: brivaracetam, cannabidiol, CGE-LIF, Cx43, epilepsy, gap junctions, HTS assay, 
levetiracetam, radioligand binding, SV2A 
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1 Introduction 
1.1 Epilepsy  
The term “epilepsy” originates from the Greek word “epilambanein”, which means to seize, to 
take hold of, or to attack.1 Epilepsy is one of the most common chronic neurological disorders 
affecting around 1% of the human population worldwide.2 One of the striking facts about 
epilepsy is that one third of the patients are under the age of 16.3 Epilepsy with a prevalence 
of about 3 million patients alone in the U.S. is the fourth most common neurological disorder 
after migraine, stroke, and Alzheimer’s disease.2  
Epilepsy is characterized by epileptic seizure(s) – a transient occurrence of signs and/or 
symptoms due to abnormal excessive or synchronous neuronal activity in the brain. This is a 
consensus definition of epileptic seizures proposed by the International League Against 
Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE).4 Seizures may vary from 
brief lapses of attention and muscle jerks to prolonged convulsions that can occur less than 
once per year to several times per day. Epilepsy is not characterized by one particular 
condition, but rather represents a spectrum of neurological conditions, all with the common 
hallmark characteristic of enhanced predisposition to epileptic seizures. The multifaceted 
nature of this brain disorder results in debatable diagnostic criteria, like on the one hand “two 
or more unprovoked seizures occurring more than 24 h apart” and on the other hand “at least 
one seizure with enduring alteration in the brain with the likelihood of future seizures”.1 
However, these definitions are of more theoretical nature and not sufficient for clinical 
diagnosis of epilepsy. Therefore, the ILAE in 2014 proposed revised diagnosis criteria for 
epilepsy; a person is considered to have epilepsy if any of the following criteria is met, i) two 
or more unprovoked seizures occurring more than 24 h apart, ii) one unprovoked seizure with 
60% probability of future seizures and two unprovoked seizures occurring within the next 10 
years, and iii) diagnosis of epilepsy syndrome. Epilepsy syndrome is defined by group of 
features occurring together such as type of seizures, typical age of seizures onset, and certain 
electroencephalogram (EEG) patterns and imaging features.5-6 Individuals with epilepsy 
syndrome are considered to be epilepsy free, in case they have either passed the typical age of 
seizures onset or they have been remained seizure-free for the last 10 years with no antiseizure 
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medication for the last 5 years.5 Under these criteria ILAE emphasizes to differentiate epilepsy-
mediated seizures from seizures due to other causes such as febrile seizures.4  
A synchronized release of excitatory and inhibitory neurotransmitters is required to maintain 
membrane potentials for signal transmission in the central nervous system (CNS).7 Seizures 
are a consequence of neuronal hypersynchronisation (“electrical storm”) impairing the normal 
activity of the brain. Based on the initial clinical findings like magnetic resonance imaging 
(MRI) and EEG patterns, seizures are divided into two broad categories, namely partial (focal) 
and generalized ones. Seizures initiated from a limited part of one cerebral hemisphere are 
classified as partial or focal seizures, whereas seizures with the involvement of both 
hemispheres are classified as generalized seizures.1 Based on the clinical manifestations 
seizures are further subclassified into absence, atonic, myoclonic, tonic-clonic seizures and so 
on. Epilepsy may be i) primary (idiopathic) due to unknown cause – presumably involving a 
genetic predisposition, ii) secondary (symptomatic) due to an underlying pathophysiological 
condition such as brain insults, infection, tumour, stroke, and syndromes, iii) provoked due to 
external factors like fever, alcohol, and photosensitivity, and iv) cryptogenic due to an 
unknown cause but presumably symptomatic.4, 8 Several epilepsy syndromes are described 
including the treatment-resistant Dravet syndrome and Lennox-Gastaut syndrome. Dravet 
syndrome is an infantile epileptic encephalopathy beginning in the first year of life and results 
in the development of different seizure types like prolonged febrile and generalized tonic-
clonic seizures. It is characterized by intractable epilepsy and neurodevelopmental disabilities. 
Up to 85% of children with Dravet syndrome exhibit a de novo mutation in the sodium channel 
1 α (SCN1A) gene.9 Lennox-Gastaut represents another form of treatment-resistant pediatric 
epilepsy which is characterized by multiple seizure types (tonic, atonic, and generalized tonic-
clonic seizures) and impaired cognition. Approximately 75% of children with Lennox-Gastaut 
syndrome have a brain malformation, which is likely the underlying cause of the syndrome.10 
It is worthy to note that six out of ten epileptic patients suffer from idiopathic epilepsy with no 
known pathology. Proper classification of epilepsy is decisive to understand the clinical course, 
prognosis, and treatment strategy.8  
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1.2 Antiepileptic drugs and their targets  
More than 20 antiepileptic drugs (AEDs) are available on the market including barbiturates, 
e.g. phenobarbital, phenytoin, ethosuximide, valproic acid, carbamazepine, and second 
generation AEDs such as felbamate, oxcarbazepine, lamotrigine, vigabatrin, gabapentin, 
pregabalin, tiagabine, topiramate, levetiracetam, and zonisamide (see Table 1).11 Most of the 
AEDs exert their antiseizure effects by either decreasing excitatory or by increasing inhibitory 
neurotransmission. Their main molecular mechanisms of action comprise modulation of 
voltage-gated ion channels (Na+, Ca2+ and K+), augmentation of -aminobutyric acid (GABA) 
or inhibition of glutamate neurotransmission.11 
Voltage-gated ion channels undergo conformational changes allowing ion flux in response to 
changes in membrane potential and thereby regulate the release of neurotransmitters. This 
common characteristic of voltage-gated sodium (Na+), calcium (Ca2+), and potassium (K+) 
channels make them key molecular targets for the majority of AEDs.7, 12  
Voltage-gated sodium channels (Na+-channels) are crucial for the generation and propagation 
of action potential (AP) in neurons.13 Sodium channels exhibit three conformational states, 
resting (closed), conducting (open), and non-conducting (inactive) depending on the AP 
threshold. Upon depolarization of neurons Na+-channels transit from the resting to the 
conducting state allowing the influx of Na+ ions into the neuron. The channels then enter 
immediately – within milliseconds – into a non-conducting state ceasing the ion influx. After 
hyperpolarization of the neuron, these channels return to their resting state and become 
responsive to new AP. The cycle of these three conformational states continue in response to 
high-frequency APs to ensure efficient neurotransmission.12 AEDs such as phenytoin, 
lamotrigine, carbamazepine, oxcarbazepine, and valproic acid bind to Na+-channels in their 
non-conducting state and by stabilizing this state inhibit Na+ currents (see Figure 1 & Table 
1).3 
The voltage-gated calcium channels are important targets for AEDs due to their involvement 
in neuronal excitability and neurotransmitter release. Based on their biophysical and 
pharmacological properties calcium channels in the brain can be classified into L-, N-, P/Q-, 
and T-type channels.14 L-, N-, and P/Q -type channels are high voltage-activated channels 
(HVA) opening at higher depolarization, while the T-type is a low voltage-activated (LVA) 
1 Introduction 
4 
 
channel opening at lower depolarization. L-type channels are mainly found in postsynaptic 
neurons and allow sustained calcium entry after depolarization due to their slow inactivation 
characteristic.15 Carbamazepine has been proposed to bind to these L-type channels. P/Q-, and 
N-type channels are present at boutons of the presynaptic neurons. These are fast inactivating 
channels mediating the calcium entry required for neurotransmitter release. AEDs such as 
gabapentin and pregabalin inhibit calcium channels by binding to their α2γ auxiliary subunit 
and significantly decrease the neurotransmitter release (see Figure 1 & Table 1).15 T-type 
channels are involved in the generation of physiological rhythms within the thalamus. AEDs 
like ethosuximide, zonisamide, and valproate are proposed to exert their antiepileptic effects 
via acting on T-type channels.15 Voltage-gated potassium channels are important for 
maintaining resting membrane potentials and for repolarization after AP. The AED retigabine 
or ezogabine (US adopted name) targets KCNQ2/3 potassium channels as a positive allosteric 
modulator and opens these channels (see Figure 1 & Table 1).16-17 
γ-Aminobutyric acid (GABA) is the most important inhibitory neurotransmitter in the brain. 
GABA is released in the synaptic cleft, where it acts through fast chloride-permeable 
ionotropic GABAA receptors and also through slow metabotropic GABAB receptors to 
decrease neuronal excitability.12 However, GABAA receptors are more relevant as AED targets 
due to the complex role of GABAB receptors in decreasing neuronal excitability both pre- and 
postsynaptically.15 Several AEDs like benzodiazepines (clonazepam), barbiturates 
(phenobarbital), and topiramate act as positive allosteric modulators at GABAA receptors, 
consequently increasing receptor affinity for GABA and potentiating sustained chloride 
channel opening.12 GABA is removed from the synaptic cleft by glial and neuronal cells 
through GABA transporters. Inhibition of GABA transporters for reuptake is also an 
antiepileptic mechanism for AEDs like tiagabine (see Figure 1 & Table 1).15 Glutamic acid 
decarboxylase (GAD) catalyzes the conversion of glutamate to GABA. GABA is then 
degraded by GABA transaminase (GABA-T) to succinic semialdehyde (SSA), which is further 
oxidized by SSA-dehydrogenase (SSA-D) to succinic acid. Succinic acid inhibits GAD in a 
negative-feedback mechanism inhibiting the conversion of glutamate to GABA. Some AEDs 
enhance the GABA concentration either by increasing the GAD activity or by inhibiting the 
GABA-T and SSA-D activity. Valproate presumably blocks GABA-T and SSA-D thereby 
exerting its antiepileptic effects (see Figure 1).3 Another AED vigabatrin exerts its 
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anticonvulsive activity by selectively and irreversibly inhibiting the GABA-T to increase the 
GABA supply in the brain.18  
Glutamate is the main excitatory neurotransmitter in the central nervous system.15 Glutamate 
receptors are subdivided into ionotropic and metabotropic receptors. Only ionotropic receptors, 
named after their ligands, N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4 
isoxazole propionoic acid (AMPA), and kainic acid (KA), currently represent targets for 
AEDs. NMDA receptors are blocked by Mg2+ at resting potential. However, upon activation 
by glutamate in the presence of the co-agonist glycine, the channel becomes permeable to Ca2+, 
Na+, and K+ ions.3, 19 The anticonvulsive effects of the AED felbamate are in part attributed to 
its ability to inhibit NMDA receptors.20 The recently approved AED perampanel for adjunctive 
therapy is the first selective and a non-competitive antagonist of AMPA receptors.21-22 The 
AED topiramate beside its other targets is reported to interact non-selectively with KA 
receptors which may also contribute to its anticonvulsive activity (see Figure 1 & Table 1).23 
It is worthy to mention that inhibition of these receptors may result in severe side effects like 
psychosis and neuropsychiatric disorders, e.g. memory impairment and cognitive decline.15, 24 
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Figure 1: Schematic drawing indicating the mechanism(s) of action of clinically used antiepileptic drugs on 
inhibitory and excitatory synapses. Na+-, Ca2+-, and K+-channels, voltage-gated sodium-, calcium, and 
potassium channels; NMDA, N-methyl-D-aspartate receptors, AMPA, α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid receptors; GABA, γ-Aminobutyric acid, GAT-1, sodium and chloride dependent 
GABA transporter 1; GABA-T, GABA transaminase;  KCNQ, family of voltage-gated potassium channels; 
*asterisk indicates drugs with more than one mechanism of action. Figure adapted from Löscher et al. (2016).25  
 
In addition to the aforementioned classical targets for AEDs, the ubiquitously expressed 
synaptic vesicle protein 2A (SV2A) in the brain represents a novel target for the broad 
spectrum AEDs levetiracetam (Keppra®) and its newly approved derivative brivaracetam 
(Briviact®) (see Figure 1). The SV2A has been discussed as an AED target in detail in section 
1.3.1. Furthermore, growing evidence regarding the role of non-neuronal cells such as 
astrocytes in the spread of epilepsy and depression suggests connexin 43 gap junctions as 
potential targets for novel AEDs. These gap junctions are described in detail in section 1.3.2 
and chapter 3.  
Approximately 70% of the epilepsy patients respond to initially provided pharmacological 
treatment. Of these, 50% of the patients get symptomatic relief from the first medication 
(monotherapy) and 20% need a second medication or polytherapy to respond. An alarmingly 
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high number of epilepsy patients (30%) suffer from drug resistant epilepsies and do not even 
respond to polytherapy.26-27 Most of the AEDs have been discovered based on their 
antiepileptic efficacy in animal models of seizures, more or less by chance without prior 
knowledge of their mechanism of action. Once the antiseizure efficacy of a drug was 
confirmed, investigation started to reveal the potential mechanism of action.15, 21 Levetiracetam 
is a good example of this scenario, where an AED was first approved for clinical use and later 
its binding site SV2A was identified and proposed as its main target. The currently available 
AEDs provide symptomatic relief from epilepsy but do not target the underlying cause.28 
Development of mechanism-driven AEDs should lead to highly selective, potent, and 
efficacious AEDs with less adverse effects. There is a significant unmet medical need for third 
generation AEDs, which are expected to show disease-modifying properties.25 
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Table 1: Mechanism(s) of action of clinically used antiepileptic drugs 21, 29-38 
Antiepileptic drugs1) Mechanism(s) of action Therapeutic Plasma concentrations (µM) Side-effects
2) 
First generation drugs    
 
Phenobarbital  
(1912) 
GABAA receptors 
(positive allosteric 
modulation) 
43-172  
↑↑↑ 
Somnolence 
Behavioral problems 
Cognitive issues 
 
Phenytoin  
(1938) 
Na+-channel blockade 40-79  
↑↑ 
Dizziness 
Encephalopathy 
Behavioral problems 
 
Ethosuximide 
 (1958) 
Ca2+-channel blockade 284-709  
↑↑ 
GI problems  
Psychotic episodes 
Depression 
 
Carbamazepine 
 (1964) 
Na+-channel blockade 13-51  
 
↑↑ 
Lukopenia 
Seizure exacerbation 
Cognition issues 
 
 
Valproic acid  
(1967) 
Na+-channel blockade 
Ca2+-channel blockade 
GABA supply increase 347-694  
↑↑↑ 
Thrombocytopenia 
Teratogenicity 
Retinal dysfunction  
 
Clonazepam 
 (1968) 
GABAA receptor 
(positive allosteric 
modulation) 
79-95  
 
↑ 
Behavioral problems 
Dizziness 
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Antiepileptic drugs1) Mechanism(s) of action Therapeutic Plasma concentrations (µM) Side-effects
2) 
Second generation drugs    
 
Vigabatrin  
(1989) 
 
Irreversible GABA-T 
inhibition 
6.2-279  
↑↑↑ 
Seizure exacerbation 
Encephalopathy 
Behavioral problems 
Psychotic episodes 
 
 
Lamotrigine  
(1990) 
Na+-channel blockade 
Ca2+-channel blockade 3.9-16  
↑ 
Somnolence  
Dizziness 
 
 
Oxcarbazepine  
(1990) 
Na+-channel blockade 
Ca2+-channel blockade 
29-79  
(Monohydroxy metabolite) 
↑ 
Dizziness 
GI problems 
 
 
 
Felbamate  
(1993) 
NMDA receptor blockade 
Na+-channel blockade 
Ca2+-channel blockade 
GABA modification 
 
76-348  
↑↑ 
Aplastic anemia  
Weight loss 
Hypersensitivity 
 
Gabapentin 
 (1993) 
Ca2+-channel blockade 
(α2δ subunit) ≥ 12  
↑ 
Somnolence  
Dizziness 
 
 
Topiramate 
 (1995) 
KA/AMPA receptor 
Na+-channel 
Ca2+- channel 
GABA modification 
carboanhydrase inhibition 
31  
↑↑↑ 
Somnolence  
Dizziness 
Behavioral problems 
 
 
Tiagabine (prodrug) 
 (1997) 
GABA transporter 
GAT-1 inhibition 0.05-0.5  
↑↑ 
Somnolence  
Dizziness 
Behavioral problems 
 
N
O NH2
O
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Antiepileptic drugs1) Mechanism(s) of action Therapeutic Plasma concentrations (µM) Side-effects
2) 
Second generation drugs    
 
Levetiracetam  
(1999) 
SV2A modulation 
Ca2+-channel blockade 
GABAA receptor 
modulation 
41-235  
↑ 
Somnolence  
Dizziness 
 
Zonisamide 
 (2000) 
Na+-channel blockade 
Ca2+-channel blockade 94-141  
↑ 
Somnolence  
Weight loss 
 
 
Pregabalin 
 (2004) 
Ca2+-channel blockade 
(α2δ subunit) 12-31  
↑ 
Weight gain 
Somnolence  
 
 
Retigabine or Ezogabine 
 (2011) 
K+-channel opener 
(KCNQ2/KCNQ3 subunits) nd 
↑ 
Retinal dysfunction 
 
Perampanel  
(2012) 
AMPA receptor blockade nd - Behavioral problems 
 
Brivaracetam  
(2016) 
SV2A modulation 10-16 
↑ 
Somnolence  
Dizziness 
↑, only one high risk early or late onset adverse event; ↑↑, two high risk early or late onset adverse events; ↑↑↑, 
three or more high risk early or late onset adverse events; -, one medium risk side-effect. n.d., not determined. 
1)Year of the drug approval or market entry in the USA or Europe.  
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1.2.1 Levetiracetam (Keppra®) and Brivaracetam (Briviact®) 
The majority of AEDs exhibits a large spectrum of side-effects. A considerable number of 
patients changes their medications due to severe side-effects such as psychotic episodes, 
anemia, leukopenia, osteoporosis etc., affecting their quality of life.39 Another challenge is the 
epilepsy treatment in special groups of patients such as pregnant women, elderly patients, and 
patients with comorbidities.21 Thus, there is a continued need for better tolerated and more 
effective AEDs for good clinical care.40 The approval of levetiracetam (Keppra®, LEV, (2S)-
2-(2-oxopyrrolidin-1-yl)butanamide) by the Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) in 1999 as a novel AED extended the spectrum for 
epilepsy treatment in terms of efficacy and safety.41 Initially LEV was approved for adjunctive 
therapy and later on approved as first-line monotherapy for partial and generalized seizures.21 
LEV is a relatively safe drug with a good pharmacokinetic profile in terms of absorption, 
binding to plasma protein, enzyme (cytochrome P450) induction, drug interactions and 
metabolism.42  
The exact mechanism of action of LEV is still not well understood, however it may modulate 
the release of neurotransmitters by binding to the synaptic vesicle 2A (SV2A) protein that is 
ubiquitously expressed in the brain.43 LEV, unlike other AEDs, lacks anticonvulsant activity 
in any of the two conventional acute seizure tests, e.g. maximal electroshock (MES) and s.c. 
pentylenetetrazole (PTZ) induced seizures.42, 44 However, LEV showed suppression of seizures 
in genetic animal models of partial and generalized epilepsy such as audiogenic seizure-
susceptible and amygdala-kindled models, which are difficult to treat with other AEDs.45-46 
Some evidence support the idea that LEV has additional mechanisms of action like inhibition 
of high-voltage gated (N-type) calcium channels and AMPA receptors, inhibition of 
intracellular calcium release, and reversal of the inhibitory effects of zinc on GABAA 
receptors.47 In addition, it was shown to modulate the function of connexion 43 (Cx43), the 
predominant gap junction (GJ) protein on astrocytes. LEV treatment fully restored the 
lipopolysaccharide-induced uncoupling of astrocytes in vivo.48 Despite involving additional 
mechanisms, the correlation of SV2A affinities of LEV analogs with their anticonvulsive 
effects in various mouse and rat models suggests that SV2A is the principal target site of LEV 
for its anticonvulsant activity.43, 49-50 
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As over time several mechanisms of action for LEV were revealed, it was hypothesized that a 
more selective and high-affinity ligand for SV2A may result in a more potent AED with less 
side-effects. Based on this rationale UCB Pharma, Belgium, started a drug discovery campaign 
and consequently identified two highly potent SV2A ligands, brivaracetam (BRV) and 
seletracetam (SEL) (see Figure 2).40 Both racetam compounds displayed antiseizure activity, 
however BRV was superior to SEL in inhibiting neuronal hyperexcitability in an in vitro 
model. Moreover, in contrast to SEL and LEV, BRV demonstrated seizure protection in the 
MES and s.c. PTZ seizure tests, although at higher concentrations.25 Eventually, development 
of SEL was discontinued after Phase II clinical trials by UCB and development of BRV was 
continued.51 
Brivaracetam (Briviact®, BRV, (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) is a 
4-propyl derivative of LEV and has been approved in February 2016 by the EMA and the FDA 
as an add-on AED to treat partial onset seizures.52-53 BRV selectively binds to SV2A and is 
almost 15-fold more potent than LEV.54 Moreover, BRV shows complete seizure protection in 
partial, generalized, and drug resistant animal models.40 Unlike LEV, BRV does not have a 
direct action on AMPA and GABAA receptors, and HVA calcium channels, however it shows 
weak inhibition of NMDA receptor at therapeutically irrelevant concentrations.40 In a small 
open-label study, switching of the treatment from LEV to BRV in patients showed reduction 
in LEV associated non-psychotic behavioral adverse events.55 The different pharmacological 
efficacies of LEV and BRV can probably be explained based on their differential binding 
characteristics at SV2A.  The positive allosteric modulator (UCB 1244283) increased the 
affinity of SV2A for [3H]BRV by 10-fold and to [3H]LEV by only 2-fold, while maximum 
binding capacity was increased by 1.3-fold for [3H]BRV compared to 2-fold for [3H]LEV.56 
Hence, to date BRV represents the first AED selectively binding to SV2A to exert its 
antiseizure effects.  
Our group has developed LEV and BRV in radiolabeled form and established radioligand 
binding assays with both radioligands.57-58 [3H]LEV and [3H]BRV were expected to be useful 
tools for (i) identifying their exact binding site on the SV2A, (ii) to potentially identify 
additional targets that might contribute to the compounds’ antiepileptic activity, and (iii) to 
find new compounds interacting with the SV2A by competition studies. 
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Figure 2: Chemical structures of the racetams levetiracetam, brivaracetam and seletracetam. 
1.3 Newer antiepileptic drug targets  
1.3.1 Biology of SV2A  
The elucidation of SV2A as the binding site for LEV led to an increased interest in the synaptic 
vesicle 2 (SV2) proteins in the epilepsy treatment scenario.43 To date three isoforms of synaptic 
vesicle protein 2 (SV2A, SV2B and SV2C) have been identified, which differ in size, sequence 
and distribution pattern in the brain.59-60 They are localized at the secretory vesicles of neurons 
and endocrine cells, with the highest prevalence in the brain.61 SV2A shows ubiquitous 
expression across the brain, while the expression of SV2B and SV2C is limited to certain brain 
regions.59, 62 SV2A shows 65% identity to SV2B and 62% identity to SV2C in the amino acid 
sequence.63-64 
The human SV2A (ca. 90 kDa) is encoded by the SV2A gene located in the q-arm of 
chromosome 1 at locus 21.2.64 SV2A is putatively a 12-transmembrane domain (TMD) protein 
and belongs to the major facilitator superfamily (MFS) comprising most of the membrane 
transporters, e.g. sugar, citrate and drug transporters in bacteria and glucose transporters in 
mammalian cells (see Figure 3).61, 64-65 Recently, the galactose transport function of SV2A has 
been demonstrated in Saccharomyces cerevisiae.65 Loops between the TMDs of SV2A are 
relatively short compared to the intracellular cytoplasmic loop three (ICL3) between TMDs 
six and seven, and a long luminal loop four (L4) between TMDs seven and eight containing 
three N-glycosylation sites.66 All three SV2 isoforms share a high degree of sequence 
homology within the 12-TMDs, whereas they are less conserved in ICL3 and least conserved 
in L4 and N-terminus.38 SV2A exists in two major conformations demonstrated by protein 
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tomography, one has a funnel-structure with an opening towards the cytosol and the other has 
a “V” shape broader opening towards the vesicular lumen.67 These conformations suggest a 
high-flexibility and valve-like transporter function of SV2A. Interestingly, LEV does not seem 
to cause a significant change of either conformation of SV2A, since both conformations were 
represented in control (saline) and LEV treated samples.67     
The exact role of SV2A in synaptic vesicle (SV) function under normal and pathological 
conditions is not well understood.25, 64 However, some important functions proposed for SV2A 
include calcium-dependent neurotransmitter release,68 neurotransmitter immobilization within 
SVs,69-70 galactose transport,65 function as an ATP-regulated protein,71 and a role in SV 
priming.72  
SV2A(-/-) knockout mice appeared normal at birth, but developed severe seizures and died 
within 2-3 weeks.73 Moreover, SV2A(+/-) audiogenic mice demonstrated a proepileptic 
phenotype with reduced anticonvulsive activity and binding of LEV by 50%.74 Furthermore, 
the established correlation of SV2A affinities of a series of LEV derivatives and analogs with 
their anticonvulsive effects in epilepsy models advocates for SV2A as a validated neuronal 
AED target.50 LEV and BRV have been described to reduce the synaptic transmission and 
neurotransmitter release.75-77 However, the exact mechanism of action and downstream 
changes upon LEV and BRV binding to SV2A still remain elusive. In addition, LEV was 
shown to be efficacious in treatment-resistant animal models such as phenytoin-resistant 
kindled rats suggesting that SV2A may be a valuable target for novel AEDs to combat 
pharmacoresistant epilepsies.78-79 Growing evidence suggests that LEV may also have disease-
modifying properties.25 
 
 
 
 
1 Introduction 
15 
 
 
 
Figure 3: Topology model of the human SV2A. The snake plot diagram was prepared by using the TOPO2 
program along with the transmembrane domain predictions using the HMMTOP software.80-81 The 12-
transmembrane domains (TMD) are indicated with Roman numbers. Amino acids depicted in dark blue color 
comprise the intracellular cytoplasmic loop 3 (ICL3). Amino acids presented in red color are the putative N-
glycosylation sites. N, N-terminus; C, C-terminus.  
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1.3.2 Gap junction channels 
Gap Junction (GJ) channels are important for cell-to-cell communication in almost all cells 
and tissues with some exceptions such as spermatocytes, erythrocytes, thrombocytes, skeletal 
muscles, and some neuronal subpopulations.82 GJs mediate the exchange of amino acids, 
second messengers, ions, glucose and its metabolites, and molecules < 1000 Da between the 
cytoplasm of connected cells.83 Gap junctional intercellular communication (GJIC) regulates 
embryonic development, coordinated smooth and cardiac muscle contraction, tissue 
homeostasis, apoptosis, metabolic transport, cell growth and cell differentiation.84 GJs are 
found in many different brain cell types but with the highest prevalence in glial cells, 
particularly in astrocytes. Astrocytes are involved in gliotransmission, extracellular 
neurotransmitter uptake, and metabolic processes, thereby contributing to neuronal 
transmission and plasticity.85  
Connexin (Cx) is a structural subunit of a GJ channel; 21 Cx subtypes have been identified in 
humans. Among all Cx types in humans, Cx43 is the most abundantly and widely expressed 
Cx with its presence in more than 34 tissues and 46 cell types.86 Cx43 and Cx30 are the major 
astroglial Cxs, which are not found in the other brain cell populations.85 Cx43 GJs are 
considered to be associated with several diseases, in particular brain disorders like epilepsy, 
depression, and brain metastasis.48, 85, 87 It has been recognized that astrocytic uncoupling 
occurs in patients with temporal lobe epilepsy, which leads to neuronal death and accelerated 
epileptogenesis. Most interestingly, LEV has been shown to restore the Cx43 GJ coupling in 
an animal model suggesting a novel therapeutic target to combat epilepsy.48 Although the 
importance of Cx43 GJs as a promising therapeutic target is rising, the development of its 
modulators is still impeded by the lack of suitable high-throughput screening assays. A more 
detailed introduction on Cx43 GJs and available functional assays is given in chapter 3. 
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1.4 Interaction of botulinum neurotoxins with SV2A 
Botulinum neurotoxins (BoNTs) are the most potent known protein toxins produced by the 
bacterium Clostridium botulinum.88 They cause flaccid paralysis by blocking neurotransmitter 
(acetylcholine) release from the presynaptic nerve terminals.89 There are seven distinct 
serotypes of BoNTs (BoNT/A – BoNT/G).90 BoNTs are produced as 150 kDa di-chain proteins 
containing a 50 kDa N-terminal catalytic light chain (LC) connected by a disulfide bond to a 
100 kDa C-terminal heavy chain (HC). The HC is further organized into two functional 
domains, the N-terminal translocation domain (HCT) and the C-terminal receptor binding 
domain (HCR).88 Enrichment of BoNTs at the nerve terminal takes place by binding to the 
non-protein polysialogangliosides which in turn facilitates the interaction of the toxin with its 
protein counterparts, the synaptic vesicle (SV) proteins. Dependent on the BoNT serotype, it 
binds either to SV2 proteins or to synaptotagmin at the presynaptic membrane.91-92 The HCR 
domains of BoNTs bind to the SV proteins and eventually the whole toxin gets internalized 
via the SV recycling pathway. Once inside the vesicle, owing to the acidification of the SV by 
the ATPase proton pump, HCT becomes active and translocates LC to the cytosol. LC is a Zn2+ 
metalloprotease domain which cleaves proteins of the SV release machinery and impairs 
neurotransmitter secretion.90, 93 
BoNT/A is one of the seven BoNTs serotypes with wide-spread applications ranging from 
serious clinical indications to cosmetic use. Three preparations of BoNT/A, namely 
onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), and incobotulinumtoxinA 
(Xeomin) have been approved by the FDA and EMA for different clinical indications such as 
strabismus, hemifacial spasm, and urinary tract disorders to cosmetic use.89, 94-95 The HCR of 
BoNT/A binds to the longest luminal loop four (L4) of SV2 homologous proteins (SV2A, 
SV2B and SV2C) for internalization into neuronal cells, and inhibits neurotransmitter release 
by cleaving the 25 kDa synaptosome-associated protein (SNAP-25).96 
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Figure 4: Mechanism of action of botulinum neurotoxin (BoNTs) serotypes. (1) The receptor binding heavy 
chain C-terminal domain (HC-C or HCR) of BoNTs initially binds to polysialoganglioside (PSG) for toxin 
enrichment at the nerve terminal. The BoNT serotype either binds to synaptotagmin (Syt) or to SV2 proteins 
located on the presynaptic nerve membrane. (2) The BoNT is then endocytosed via SV recycling. (3) Upon 
acidification of the vesicle via ATPase proton pump, the catalytic light chain (LC) is translocated into the 
cytosol and set free by the action of the thioredoxin reductase system (Trx) on the disulfide bond (S-S). (4) 
Eventually the LC (Zn2+-metalloprotease) of BoNTs cleave the proteins of the vesicle release machinery 
(VAMP, SNAP25, and syntaxin) resulting in the inhibition of neurotransmitter release. VAMP, vesicle-
associated membrane protein; SNAP25, synaptosomal-associated protein of 25 kDa (SNAP25). Adapted from 
Rossetto et al. (2014).97 
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1.5 Objectives  
Levetiracetam (LEV) is a widely prescribed antiepileptic drug (AED) for the treatment of 
generalized and partial epilepsy. LEV unlike other AEDs exerts its anticonvulsive effects via 
a unique mechanism of action by modulating the synaptic vesicle protein 2A (SV2A).43, 50, 74 
Considering the importance of SV2A as a novel AED target, a derivative of LEV 
brivaracetam (BRV), which is about 10-fold more potent and highly SV2A-selective has been 
developed. BRV was recently (2016) approved in Europe and the USA as an adjunctive therapy 
for the treatment of partial onset seizures. BRV has a better pharmacokinetic profile than LEV 
and is expected to be superior to LEV in terms of tolerability, onset of action, and 
antiepileptogenic potential. Nevertheless, the exact binding site of LEV/BRV within the SV2A 
is unknown and the underlying mechanism of action of these drugs is poorly understood.  
Only few SV2A ligands have been reported so far, and most of the published compounds are 
directly related to LEV (pyrrolidones) or to known antiepileptic drugs. The SV2A project was 
designed: 
i) to screen compounds of different chemical classes for binding to SV2A and  
ii) to contribute to the identification of the binding site of LEV/BRV on SV2A. 
Previously established binding assays using radiolabeled BRV – [3H]BRV – were performed 
with transiently transfected intact cells. This approach was not suitable for the screening of 
larger compound libraries in terms of costs and reproducibility. In order to be able to conduct 
the aforementioned studies, an improved assay using [3H]BRV binding to highly SV2A 
expressing preparations was to be established.  
Another goal was to investigate the potential involvement of the intracellular loop 3 (ICL3) 
of SV2A in the binding of LEV/BRV. To this end chimeric proteins in which the whole ICL3 
of SV2A was exchanged for that of SV2B, and the reverse chimera in which the ICL3 of SV2B 
was replaced by that of SV2A, as well as a specific point mutant observed in a LEV-resistant 
patient were to be cloned and heterologously expressed. Botulinum neurotoxin A (BoNT/A) 
was reported to enter neurons via binding to the luminal loop 4 (L4) of SV2 proteins.96 
Moreover, SV2A has recently been proposed to function as a galactose transporter.65 One goal 
of the present project was to investigate whether BoNT/A- and monosaccharides can modulate 
[3H]BRV binding to SV2A. 
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Astrocyte coupling occurs predominantly by connexin 43 (Cx43) gap junctions (GJ). 
Uncoupling of astrocytes was suggested to be involved in the etiology of mesial temporal lobe 
epilepsy (MTLE).48 Interestingly, Cx43 GJ coupling was restored upon LEV treatment.48, 98-99 
Whether LEV exerts these effects by directly binding to Cx43 GJs or by acting indirectly via 
some other mode of action remains elusive. The identification of molecules which can enhance 
GJ coupling may lead to the development of novel AEDs with disease-modifying properties. 
However, despite the potential of Cx43 GJs as novel AED targets, potent and selective ligands 
are not available most likely due to the difficulty in developing suitable high-throughput 
screening (HTS) assays. As a contribution to address the aforementioned issues we planned 
the following experiments: 
i) radioligand binding studies with [3H]BRV on Cx43 expressed in CHO cells;  
ii) establishment of a new HTS assay to screen for inhibitors as well as enhancers 
of the formation of GJs.   
Fluorescence microscopy, flow cytometry, and fluorimetric measurements can be used to 
detect and quantify green fluorescent protein (GFP)-tagged membrane proteins. However, 
these methods have limitations including low sensitivity, inaccurate quantification, and high 
background due to autofluorescence. Most of the recombinant proteins implemented in the 
current study were to be GFP-tagged to monitor their expression.  Therefore, an optimal 
method for the quantification of GFP-tagged membrane proteins was to be established using 
capillary gel electrophoresis with laser-induced fluorescence detector (CGE-LIF). This 
method should ideally be fast, robust, reproducible, and precise. 
In summary, the current project was designed to investigate two promising new AED targets, 
SV2A and Cx43. Studies on SV2A focused on the identification of novel SV2A ligands and 
on understanding the interaction of LEV/BRV with the ICL3 of SV2A. Studies on Cx43 were 
aimed at developing a new HTS assay for the identification of Cx43 GJ modulators. 
Additionally a novel analytical method using CGE-LIF was developed to quantify the 
expression of GFP-tagged membrane proteins. 
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2 Characterization of SV2A and its ligands 
2.1 Identification and characterization of new SV2A ligands  
2.1.1 Interaction of approved drugs with SV2A  
The AEDs levetiracetam (1, LEV, (2S)-2-(2-oxopyrrolidin-1-yl)butanamide) and its 4-propyl 
derivative brivaracetam (2, BRV, (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) 
(see Figure 5) have been reported to act via a unique mechanism of action – they interact with 
the synaptic vesicle protein 2A (SV2A).25 Only few studies demonstrating new SV2A ligands 
have been reported so far, and most of the published compounds are directly related to LEV 
(pyrrolidones) such as piracetam and aniracetam or to known antiepileptic drugs like, 
pentobarbital, ethosuximide, and chlordiazepoxide (see Figure 5 and see Table 2).49-50, 54, 57-58, 
100-103 
Interestingly, co-incubation of [3H]LEV with an allosteric modulator (UCB1244283) (see 
Figure 5) was shown to have only a minor effect on its SV2A affinity, however the maximum 
binding capacity of the radioligand was increased by 2-fold.102 Conversely, the same treatment 
on [3H]BRV resulted in a 10-fold increase in its affinity for SV2A but almost no effect on its 
maximum binding capacity.56 These findings are evidence for different interactions of LEV 
and BRV with the SV2A and probably the explanation for their distinct pharmacological 
effects.56 Similarly new ligands from diverse chemical classes may stabilize different SV2A 
conformations and open avenues for more effective novel AEDs.  
Several radioligands including a PET (positron emission tomography) ligand for the labeling 
of SV2A have been developed.54, 100, 104-108 Recently, [3H]LEV and [3H]BRV with high specific 
activity (> 90 Ci/mmol) were obtained by our group; the radioligands were demonstrated to be 
useful for binding studies at rat and human brain membrane preparations.57-58 Since BRV is 
about 10-fold more potent than LEV (see Table 2), [3H]BRV has been selected in the present 
study to search for compounds that compete with its binding and to identify suitable lead 
structures for the development of novel antiepileptic drugs. 
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Figure 5: Chemical structures of SV2A ligands.49, 54, 57-58, 100-101, 103 PET, Positron emission tomography; PAM, 
positive allosteric modulator.  
 
Approved drugs with well-established drug metabolism and pharmacokinetic and safety profile 
have been suggested as suitable starting points for the development of novel drugs. Already 
optimized physiochemical properties of a drug can accelerate the hit-to-lead as well as the lead 
optimization procedure.109 
In the present study, a radioligand competition binding assay was established, that is suitable 
for high-throughput screening, using [3H]BRV and crude cellular homogenates of monoclonal 
Chinese hamster ovary (CHO) cells stably overexpressing recombinant human SV2A. 
Subsequently a library of approved drugs was screened, a sublibrary of the Pharma-Zentrum 
Bonn compound library, to identify compounds that interact with SV2A. 
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Table 2: Potencies of selected compounds at SV2A 
 Ki values [µM] 
Compound 
vs. 
[3H]UCB30889 
vs. 
[3H]LEV 
vs. 
[3H]BRV 
rat rat human rat human 
1 LEV 1.25 56 1.26 56 3.16 56 1.71 60 2.05 39 
2 BRV 0.079 56 n.d. n.d. 0.079 56 0.126 56 
3 Seletracetam 0.079 103 n.d. n.d. n.d. - 
4 UCB308889 0.079 56 0.100 103 n.d. 0.063 56 0.100 56 
5 UCB-J  n.d. n.d. 0.006 105* n.d. n.d. 
6 Piracetam n.d. 31.6 51 n.d. 63.8 39 n.d. 
7 Ethosuximide n.d. 424 39 n.d. 312 39 n.d. 
8 Pentylenetetrazol 126 56 72.5 39 n.d. 116 39 n.d. 
9 Bemegride 20.0 56 6.68 39 n.d. 11.9 39 n.d. 
10 Aniracetam n.d. 1000 51 n.d. > 1000 39 n.d. 
11 Pentobarbital 158 102 158 102 n.d. n.d. n.d. 
54Gillard et al. 2011; 58Hildenbrand et al. 2012; 38Hildenbrand 2012; 49Noyer et al. 1995; 103Mercier et al. 2014; 
100Gillard et al. 2003; 101Matagne et al. 2009; rat, rat cortical membranes; human, recombinant human SV2A; 
*IC50; n.d., not determined. 
 
The results shown in the following section are included in this publication:  
- Danish, A.; Namasivayam, V.; Schiedel, A. C.; Müller, C. E. Interaction of Approved 
Drugs with Synaptic Vesicle Protein 2A. Arch. Pharm. 2017, DOI: 
10.1002/ardp.201700003 (ahead of print). 
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2.1.1.1 Plasmid design for SV2A expression  
Previously low stable heterologous expression of a wild-type human SV2A-GFP construct (ca. 
3.0 kbp) in CHO cells was reported using a retroviral transfection method.38 The reason could 
be that the insert (pQCXIH-hSV2A-GFP) is close to the packaging limit of 9-12 kb for 
retroviruses.110 In this study, reliable expression was achieved by transient transfection with 
linearized plasmids obtained after restriction digest.38 In order to improve the heterologous 
expression of hSV2A-GFP and to simplify the transfection procedure, a mammalian 
expression vector pcDNA™4/myc-His-A vector with a strong (cytomegalovirus) CMV 
promoter was selected.111 For construction of the plasmid pcDNA4-hSV2A-GFP (see Figure 
6), the cDNA of hSV2A-GFP was amplified from the mother plasmid by using a 5’-end 
forward primer with an overhang-containing HindIII restriction site and a 3’-end reverse 
primer with an overhang-containing XhoI restriction site (see Section 6.1.7 for primers). The 
amplified insert and the vector were digested with HindIII and XhoI restriction enzymes and 
ligated by following the procedure explained in Section 6.2.6. 
 
Figure 6: Plasmid map of the pcDNA4-hSV2A-GFP construct. The cDNA of wt hSV2A (blue) at its C-terminus 
tagged to GFP (green) was inserted into the vector using HindIII and XhoI restriction digest. Regions of the 
important functional elements such as cytomegalovirus promoter (PCMV), bovine growth hormone 
polyadenylation signal (BGH pA), zeocin, and ampicillin are indicated. 
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2.1.1.2 Characterization of SV2A expression in CHO cells  
CHO cells were chosen for recombinant expression of SV2A as previously described by 
Gillard et al. (2006).104 Transient transfection of the human SV2A in CHO cells, similarly as 
described by Lynch et al. for COS-7 cells (2004), resulted in measurable binding of [3H]BRV 
to the intact transfected CHO cells.43 However, for the screening of compound libraries, a 
stably transfected cell line was required to reduce costs and to ensure high reproducibility. 
Therefore, CHO cells were transfected by lipofection with human SV2A tagged at the C-
terminus with green fluorescent protein (GFP) using the pcDNA4-hSV2A-GFP plasmid. GFP 
tagging allowed to select strongly fluorescent monoclones by fluorescence-assisted cell sorting 
(FACS) to ensure high and stable SV2A expression. Crude cellular homogenates were 
prepared from the monoclonal cell culture of early passages (P5-P8). Moreover, it was 
discovered that instead of intact cells cellular homogenates were better suitable for performing 
radioligand binding assays with [3H]BRV. The exact procedure for performing the radioligand 
binding assays is described in the next Section 6.7.1. To further characterize the heterologous 
expression of SV2A in the cell membranes, the latter were separated from the cell debris by 
centrifugation using the cellular homogenate as explained in Section 6.5.3. As shown in Figure 
7A, the cellular homogenate displayed highest cpm values with [3H]BRV in radioligand 
binding assays. In contrast, the cell membranes and the cell debris resulted in lower specific 
binding of the radioligand (see Figure 7A). The cellular preparations demonstrated specific 
[3H]BRV binding according to the sequence: cell homogenate > membrane preparation > cell 
debris.  
Furthermore, all three protein fractions were monitored for the GFP-mediated fluorescence 
signal by direct fluorimetric measurements (for procedure see Section 6.6.3). For this 
experiment, homogenate of non-transfected CHO cells was used as a negative control. While 
cellular homogenate produced the strongest fluorescence signal followed by moderate 
fluorescence signal with cell membranes, much weaker fluorescence signal was observed in 
cell debris. The strength of fluorescence signal from different protein fractions was obtained 
in the following order: cell homogenate > membrane preparation > cell debris. These findings 
are well in line with the results obtained from the radioligand binding assays (Figure 7A and 
7B). The same protein samples were further used in Western blot to re-confirm the results. 
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Western blots were performed using the mouse monoclonal anti-GFP primary antibodies and 
horseradish peroxidase (HRP) conjugated anti-mouse secondary antibodies (see Section 6.6.6). 
The expression profile of hSV2A-GFP in various protein fractions obtained from the Western 
blot method indicated the same sequence: cell homogenate > membrane preparation > cell 
debris, determined by the intensity of the bands (see Figure 7c). These results are well in 
agreement with the data obtained from the radioligand binding assays and fluorimetric 
measurements.  
 
Figure 7: Characterization of recombinant human SV2A in CHO cells. (A) Radioligand binding assay with 
cell homogenate, membranes, and debris of CHO-hSV2A-GFP cells. Protein (200 µg) was incubated with 
[3H]BRV (3 nM) for 240 min at 4°C. Non-specific binding was obtained in the presence of LEV (1 mM). (B) 
Direct fluorimetric measurements (excitation = 450/30 nm and emission = 510/12 nm) of protein samples with 
a fluorimeter. (C) Western blot analysis of the expression of hSV2A-GFP. Homogenate of non-transfected 
CHO-0 cells was used as a negative control and samples include homogenate of CHO-hSV2A-GFP, separated 
membranes and cellular debris separated from homogenate. An amount of 50 µg protein sample was loaded 
on 10% SDS-gel. Primary mouse anti-GFP antibodies (1:3000) and secondary HRP conjugated anti-mouse 
antibodies (1:4500) were used for the detection of the protein. Data shown are means ± SEM of at least three 
independent experiments performed in duplicate.    
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Taken together the current data suggest that a fraction of the hSV2A is integrated into the cell 
membrane of the overexpressing CHO cells. Both, cell homogenate as well as membranes, can 
be used for [3H]BRV binding assays. However, cell homogenate can be more readily prepared 
without the requirement of ultracentrifugation as needed for membrane preparations, and they 
can be stored similarly as membranes at -80°C for long-term usage. Moreover, homogenates 
are more uniform than membrane suspensions and are therefore easier to handle and less prone 
to errors. Based on these results cellular homogenates were implemented for subsequent 
radioligand binding assays.   
2.1.1.3 Establishment of a [3H]BRV binding assay for compound screening  
Radioligand competition assays were performed by incubating [3H]BRV (3 nM), test 
compound and crude cellular homogenate of CHO cells expressing the human SV2A for 4 h. 
Non-specific binding of the radioligand was determined in the presence of a high concentration 
of LEV (1 mM) and amounted to approximately 10% of total binding (see Figure 8). The 
quality of the radioligand competition assay and its suitability for compound library screening 
was assessed by calculating the screening window co-efficient (Z´-factor), which is a 
dimensionless statistical characteristic for a screening assay.112 The Z´-factor was calculated 
to be 0.6, which represents a suitable assay with a large separation window between negative 
and positive controls (see Figure 8). The current assay with some further adaptations should 
be suitable for high-throughput screening (HTS) of large compound libraries. The execution 
of HTS will include transfer of the current assay to a 96-well plate format with an automated 
assay performance. Scintillation proximity assay would be another approach to upgrade the 
current assay for HTS purpose.113  
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Figure 8: Assay quality for compound screening was evaluated by calculating the Z´-factor. Total binding was 
determined by incubating [3H]BRV (3 nM) with cell homogenate (200 µg of protein) at 4°C for 240 min, and 
non-specific binding was determined in the presence of unlabeled LEV (1 mM). σc+, standard deviation of total 
binding; σc-, standard deviation of non-specific binding; µc+, mean of total binding (cpm); µc-, mean of non-specific 
binding (cpm). 
 
The applicability of the assay was further verified by performing concentration-dependent 
specific [3H]BRV inhibition by unlabeled LEV and BRV. As shown in Figure 9, LEV 
displayed a Ki value of 1.74 µM, which is in agreement with the previously reported Ki values 
of 3.16 µM,54 and 2.05 µM,38 respectively. Similary, BRV displayed a Ki value of 0.098 µM, 
which very well relates to the previously reported Ki value of 0.126 µM.54 
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Figure 9: Competitive radioligand binding assays. Concentration-dependent inhibition of [3H]BRV binding to 
recombinant hSV2A by levetiracetam resulting in a Ki value of 1.74 ± 0.27 µM, and by brivaracetam, Ki value: 
0.098 ± 0.015 µM. Increasing concentrations of unlabeled test compounds were incubated with cell homogenate 
(200 µg of protein) and [3H]BRV (3 nM) at 4°C for 240 min. Non-specific binding was determined in the presence 
of LEV (1 mM). Data points represent means ± SEM of at least three independent experiments performed in 
duplicate. 
 
2.1.1.4 Screening of an approved drugs library  
Using the established assay an in-house collection of 500 approved drugs was screened for 
their ability to compete with [3H]BRV at the SV2A. An initial screening concentration of 20 
µM was employed. Compounds that inhibited [3H]BRV binding by at least 90% were 
considered as hits. A hit rate of 3% (15 compounds) was obtained. These hits were further re-
evaluated at a 10-fold lower concentration of 2 µM. Three compounds, loratadine (13), quinine 
(18), and rimonabant (25a), from which the first two are listed by the WHO as essential 
medicines (WHO list of essential medicines 2015),114 displayed > 50% inhibition of [3H]BRV 
binding at that low concentration (hit rate: 0.6%). Subsequently concentration-dependent 
inhibition curves were determined for all three drugs. The inhibition curve with rimonabant 
and preliminary structure-activity relationships (SARs) with other cannabinoids are presented 
in Section 2.1.2.  
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2.1.1.5 Loratadine 
A Ki value of 1.16 µM was determined for loratadine (13), which is in the same order of 
magnitude as the affinity of LEV for SV2A (Ki 1.74 µM) (see Figure 10). Loratadine is a potent 
histamine H1 receptor antagonist prodrug and broadly used for its anti-allergic activity.115 It is 
a second generation non-sedative anti-histamine with a chemical structure related to tricyclic 
antidepressants.116-117 In vivo, loratadine, is hydrolyzed (see Figure 11) yielding the active 
metabolite desloratadine (Ki 0.9 nM).118 Peak therapeutic plasma concentrations of both 
loratadine and desloratadine were reported to be around 4 ng/mL (10 nM) in humans.119 Only 
minor amounts of loratadine are reported to cross the blood-brain barrier (BBB), and at a 
therapeutical dose of 10 mg/day the drug shows no sedative effects in humans.37, 116 The Ki 
value of loratadine for SV2A is 100-fold higher than the compound’s therapeutic plasma 
concentration in humans. Moreover, it does not penetrate the blood-brain barrier in significant 
amounts, and to date no anticonvulsive activity has been reported for loratadine. Nevertheless, 
the structure of loratadine may be used as a starting point for the development of novel SV2A-
interacting AEDs, e.g. by replacing the carbamate by a metabolically stable structure. This is 
expected to reduce interactions with histamine receptors, and to potentially increase the affinity 
for SV2A. 
 
Figure 10: Competitive radioligand binding assay. Concentration-dependent inhibition of [3H]BRV binding to 
recombinant human SV2A by loratadine resulting in a Ki value of 1.16 ± 0.44 µM. Increasing concentrations of 
unlabeled test compounds were incubated with cellular homogenate (200 µg of protein) and [3H]BRV (3 nM) at 
4°C for 240 min. Non-specific binding was determined in the presence of LEV (1 mM). Data points represent 
means ± SEM of at least three independent experiments performed in duplicate. 
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Figure 11: Hydrolysis of the prodrug loratadine releases the active metabolite desloratadine, a potent histamine 
H1 receptor antagonist.  
 
In contrast to loratadine, its metabolite desloratadine (14) showed very low affinity for SV2A 
inhibiting radioligand binding by only 25% at a high concentration of 20 µM (see Table 3). 
This result indicates that the substituent on the piperidine ring (ethoxycarbonyl) is essential for 
SV2A binding (also see Section 2.1.1.8 on pharmacophore modeling below). 
Additionally, several tricyclic antidepressants, structurally related to desloratadine, including 
amitryptiline (15), doxepine (16) and desipramine (17), were tested for their SV2A affinity. 
All of them displayed a low to moderate degree of specific interaction with SV2A and showed 
inhibition of radioligand binding according to the following order: doxepine (60%) > 
desipramine (30%) > amitriptyline (5%). The oxygen atom in the tricyclic ring system of 
doxepine appears to increase SV2A affinity (compare 15 and 16,). The current results indicate 
that the tricyclic drugs 14-17 only possess part of the pharmacophoric structure that is required 
for high SV2A affinity (see Table 3). 
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Table 3: Affinities of loratadine, desloratadine and selected tricylic drugs for human SV2A 
Compound Structure 
Human SV2A 
Ki ± SEM (µM) or 
(% inhibition at 20 µM) 
vs. [3H]BRV 
Loratadine (13) see Figure 11 1.16 ± 0.44  
Desloratadine (14)  see Figure 11 (25%)a) 
Amitriptyline (15) 
 
(5%)a) 
Doxepine (16) 
 
(60%)a) 
Desipramine (17)   
 
(30%)a) 
a) inhibition (%) of [3H]BRV binding by 20 µM of the test compound. Data represent means of three independent 
experiments performed in duplicate. 
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2.1.1.6 Quinine  
Quinine (18) is a natural product, which still plays an important role in the treatment of 
malaria.120 Its mechanism of action is not completely understood, however it is widely accepted 
that quinine interferes with the hemoglobin breakdown process in parasites resulting in the 
accumulation of free heme which intoxicates and eventually kills the parasites.121 In the 
competitive radioligand binding assay, quinine displaced [3H]BRV from SV2A with a Ki value 
of 2.03 µM (see Figure 12) and thus possesses the same affinity as the important antiepileptic 
drug LEV (Ki 1.74 µM). 
 
Figure 12: Competitive radioligand binding assay. Concentration-dependent inhibition of [3H]BRV binding at 
recombinant human SV2A by quinine resulted in a Ki value of 2.03 ± 0.31 µM. Data points represent means ± 
SEM of three independent experiments performed in duplicate.  
 
Subsequently six compounds were tested that are structurally related to quinine, i.e. quinidine 
(19), cinchonine (20), cinchonidine (21), (±)-mefloquine (22), chloroquine (23), and 
primaquine (24), at a concentration of 20 µM for their interaction with SV2A (see Table 4). 
Cinchonine and cinchonidine are diastereoisomers and differ from each other in the 
stereochemistry at positions C8 and C9 (see Table 4). While cinchonine exhibited relatively 
low inhibition of radioligand binding of 21% at 20 µM, cinchonidine was more potent 
inhibiting radioligand by around 80%. Therefore we determined a full inhibition curve and 
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calculated a Ki value of 12.2 µM for cinchonidine. Cinchonine (20) at position C9 has a 
hydroxyl group with (S)-configuration, whereas cinchonidine (21) - similarly to quinine - is 
(R)-configurated (see Table 4). This indicates that (R)-configuration of the OH group at 
position 9 improves the binding of cinchonidine to SV2A. Quinidine and quinine are 
diastereoisomers, again with different stereochemistry at C8 and C9, similar to cinchonine and 
cinchonidine, but with an additional 6’-methoxy substituent on the quinoline ring system. 
Quinidine in contrast to quinine displayed much lower affinity for SV2A with only 31% 
inhibition of radioligand binding, showing however slightly better affinity than cinchonine. 
The difference in the affinities of quinine and quinidine under the same assay conditions is due 
to stereoselective binding of SV2A. Interestingly, quinidine - like cinchonine - contains a 
hydroxyl group with (S)-configuration at position C9, but an additional methoxy group at 
position C6’, and the latter appears to be responsible for a slight improvement in its affinity.  
The synthetic anti-malaria drug mefloquine has a simplified structure as compared to quinine 
and related compounds. It showed inhibition of [3H]BRV binding to SV2A by 48% at 20 µM. 
Mefloquine has two trifluoromethyl substituents at position C2’ and C8’ of the quinoline core 
structure, and at the position corresponding to C9 in quinine a hydroxyl group is present; 
mefloquine is a racemate and represents a mixture of the R- and S-enantiomers. Chloroquine 
is a 4-aminoquinoline derivative and primaquine is an 8-aminoquinolone derivative. 
Chloroquine inhibited radioligand binding by 23%, whereas primaquine showed no inhibition 
at 20 µM.  
Altogether, these results suggest that (R)-configuration of the hydroxyl group at position C9 in 
quinine and related compounds has a strong impact on the compounds’ affinity for SV2A and 
a 6’-methoxy residue further potentiates their affinity for SV2A. Hence, among all quinine-
related compounds tested, quinine exhibited the highest affinity for SV2A with a low 
micromolar Ki value. 
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Table 4: Affinities of quinine and related antimalarial drugs for hSV2A 
Compound 
Human SV2A 
Compound 
Human SV2A 
Ki ± SEM (µM)  
(% inhibition) 
vs. [3H]BRV 
Ki ± SEM (µM) 
(% inhibition) 
vs. [3H]BRV 
 
Quinine (18) 
2.03 ± 0.31 
 
(R,S)-Mefloquine (22) 
(48%)a) 
N
O
(S)
HO
(R)
NH
 
Quinidine (19) 
(31%)a) 
 
(R,S)-Chloroquine (23) 
(23%)a) 
 
Cinchonine (20) 
(21%)a)  
(R,S)-Primaquine (24) 
(0%)a) 
 
Cinchonidine (21) 
12.2 ± 4.4 
  
a)inhibition (%) of [3H]BRV binding by 20 µM of test compound. Data represent means of three independent 
experiments performed in duplicate. 
2 Characterization of SV2A and its ligands 
36 
 
2.1.1.7 Anticonvulsive action of quinine 
Severe malaria infections can be associated with acute seizures that may lead to neurological 
damage.122 Interestingly, anticonvulsant activity of quinine has been demonstrated in several 
animal models of epilepsy including 4-aminopyridine-, penicillin-, and pentylenetetrazole 
(PTZ)-induced epilepsy at concentrations of 35 µM, 1 µM (intracerebroventricular 
administration), or 185 µM, respectively.123-125 In these studies, the anticonvulsant properties 
of quinine had been attributed to its ability to prevent connexin 36 (Cx36) GJ-mediated 
neuronal communication; an IC50 value of 32 µM was determined for Cx36 inhibition.126 In a 
recent study, quinine at high concentration (500 µM) was proconvulsive while paradoxically 
only lower doses (30 µM) resulted in anticonvulsive effects. This study questioned the 
involvement of Cx36 in quinine-mediated anticonvulsive effects and proposed the possibility 
of another, unknown target.127 Studies on the anticonvulsive effects of quinine in humans are 
still limited,122 although seizures are frequently observed in children with cerebral malaria 
infections. The average therapeutic plasma concentration for quinine was reported to be 3.4 
µg/ml (10.5 µM),128 which is 5-fold higher than its Ki value of 2.03 µM for the human SV2A. 
Data is scarce regarding quinine concentrations in brain, however the ratio of cerebrospinal 
fluid (CSF) to plasma was found to be 0.55 in patients infected with Plasmodium.129 Thus, the 
anticonvulsive effects of quinine observed in animal studies and also seen in some clinical 
studies might be due to its interaction with the SV2A. 
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2.1.1.8 Pharmacophore modeling  
To establish a pharmacophore model for SV2A, the structural features of the newly identified 
SV2A-binding drugs were compared with those of the known SV2A ligands LEV and its 
propyl derivative BRV. BRV is about 10-fold more potent than LEV.58 Figure 13A shows an 
overall alignment of BRV (orange), loratadine (magenta), and quinine (yellow) with the 
consensus pharmacophore model. Each drug is separately shown in Figure 13B with the 
consensus pharmacophore features. All three structures overlay very well with several features 
that are known to be important for high-affinity binding of the racetams:  
(i) two hydrogen bond acceptors: two carbonyl groups in brivarcetam, a pyridine N atom and 
a carbonyl group in loratadine, and a hydroxyl group and quinoline N atom in quinine 
(pharmacophore features F3 and F4 shown as cyan-colored spheres in Figure 13A-C); 
(ii) a lipophilic (cyclo)alkyl or an aromatic group: propyl in brivaracetam, chlorobenzene in 
loratadine, allyl-substituted cycloalkyl in quinine (pharmacophore feature F2 shown as orange-
colored large sphere in Figure 13A-C); 
(iii) a short alkyl or alkoxy group: ethyl in brivaracetam, ethoxy in loratadine, methoxy in 
quinine (pharmacophore feature F1 shown as orange-colored small sphere in Figure 13A-C). 
 
The steric and electronic fit of the three structures is excellent and in agreement with known 
structure-activity relationships (SARs). The additional amide-NH2 group in BRV, which is 
about 10-fold more potent than the other compounds, might improve its SV2A binding in 
comparison to loratadine and quinine. The created pharmacophore model may allow the 
transfer of SARs from the known SV2A modulators LEV and BRV to the newly identified 
scaffolds. 
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Figure 13. (A) The overall alignment of the selected drugs brivaracetam (orange), loratadine (magenta) and 
quinine (yellow) with the four pharmacophore features (F1 and F2: Aromatic/Hydrophobic, F3 and F4: Acceptor) 
and on the right side the distances between the pharmacophore features are shown in Å as red lines. (B) Each 
individual drug is shown with the four identified pharmacophore features (F1-F4). Oxygen atoms are colored in 
red, nitrogen atoms in blue, chlorine atoms in green, hydrogen atoms in silver white and non-polar hydrogen 
atoms are omitted. (C) Pharmacophore features are indicated in 2D representation of the selected drugs 
brivaracetam, loratadine and quinine (cyan = hydrogen bond acceptor atoms, orange = aromatic/hydrophobic). 
Molecular modeling was performed by Dr. Vigneshwaran Namasivayam. 
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2.1.2 Interaction of cannabinoids with SV2A 
In ancient times cannabis was used for different therapeutic applications including seizure 
management. However, it was scientifically evaluated and documented only in the early 19th 
century.130 131-132 Cannabinoid receptor (CB1R and CB2R) ligands can be subdivided into three 
major classes: i) endocannabinoids, ii) phytocannabinoids, and iii) synthetic cannabinoids.133 
Endocannabinoids refer to the lipids produced within the brain that interact with CB receptors. 
Two major endocannabinoids are N-arachidonylethanolamide (anandamide) and 2-
arachidonylglycerol (2-AG). They are synthesized from postsynaptic membrane phospholipid 
precursors and after release interact with presynaptic neurons. Upon binding of anandamide 
and 2-AG to CB1 receptors, a signaling cascade is triggered resulting in reduced presynaptic 
neurotransmitter release.134 The complexity of endocannabinoid-mediated signaling is due to 
the involvement of several targets such as the transient receptor potential vanilloid receptor 
type 1 (TRPV1), the voltage-gated potassium channels (Kv7), the orphan G protein-coupled 
receptor (GPR55) and the orphan GPR18.135-138 
In recent years there has been an increased research interest in exploring the therapeutic 
potential of cannabis in the treatment of seizures. The two major constituents (cannabinoids) 
of the cannabis plant which have gained most attention are the primary psychoactive 
component Δ9-Tetrahydrocannabinol (THC) and the non-psychoactive component cannabidiol 
(CBD).130 CBD was demonstrated to exhibit potential in managing intractable epilepsy, 
however its mode(s) of action in ameliorating epilepsy appears to be complex and may involve 
several targets, however it is not yet fully understood.139 Two CBD-enriched preparations 
Epidiolex® (98% CBD, 2% THC) and realm oil (94% CBD, 6% THC) made their way to 
clinical trials against Dravet and Lennox-Gastaut syndromes (for definition see Section 1.1) of 
intractable epilepsy in children.130 An open-label trial with Epidiolex® reported a significant 
reduction of seizure frequency in treatment-resistant epilepsy (TRE) patients. Oral Epidiolex® 
administration at a maximum dose of 25-50 mg/kg/day (80-160 µM) for 12 weeks significantly 
reduced seizure frequency in TRE patients and Dravet syndrome (DS) patients.140 Quite 
recently Epidiolex® received orphan drug designation from EMA and FDA for the treatment 
of childhood-onset epilepsy syndromes, Lennox-Gastaut syndrome (LGS) and Dravet 
syndrome.141 
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Several studies have demonstrated that the activation of cannabinoid receptors, particularly 
CB1R due to its predominance in the brain, led to anticonvulsive effects, and blockade of these 
receptors exerted proconvulsive effects.142-143 Rimonabant (25a, SR141716A, Acomplia®, see 
Figure 14), a potent CB1R antagonist and a proconvulsive compound was paradoxically found 
to have antiepileptogenic effects. Intriguingly, a single-time administration of rimonabant 
(2.16 µM) after a short interval of traumatic brain injury (TBI) in rats abolished the long-term 
seizure susceptibility.144 However, how the post-traumatic application of the proconvulsive 
drug rimonabant is translated into long-term antiepileptogenic effects remains to be clarified. 
The current study demonstrates the interaction of rimonabant with SV2A using radioligand 
binding with [3H]BRV. Moreover, within the scope of this study 80 cannabinoid-like 
compounds were tested for interaction with recombinant human SV2A versus [3H]BRV 
inhibition. This study identifies for the first time cannabinoids which compete with [3H]BRV 
for SV2A with Ki values in the low micomolar range. 
The results shown in the next section are included in the manuscript (in preparation):  
- Danish, A.; Namasivayam, V.; Müller, C. E. Cannabidiol (CBD) interacts with the 
levetiracetam binding site of synaptic vesicle protein SV2A. 
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2.1.2.1 Rimonabant  
Rimonabant (25a, SR141716A, Acomplia®, see Figure 14) is a potent synthetic CB1R 
antagonist with a Ki value of 1.98 nM (see Table 6). It was approved in 2006 as an antiobesity 
drug and for smoking cessation. However, due to severe side-effects like depression and 
emergence of suicidal tendencies, the drug was withdrawn from the market in 2007.134, 145 In 
our screening campaign of approved drugs at SV2A, rimonabant was identified to compete 
with [3H]BRV for binding to SV2A. As shown in Figure 14, concentration-dependent specific 
[3H]BRV inhibition by rimonabant resulted in a Ki value of 2.73 µM, which is similar to the 
Ki value of LEV (1.74 µM). The cannabinoid-like compounds AM-251 (25b) and AM-281 
(25c) (see Table 5 for structures) are close structural derivatives of rimonabant and potent 
CB1R antagonists with Ki values of 7.94 nM and 12.6 nM, respectively (see Table 6).146-147 
Similar to rimonabant, AM-251 competed with [3H]BRV for SV2A in the radioligand binding 
assay resulting in a Ki value of 2.75 µM (see Table 5). In contrast AM-281 displayed low 
affinity with a Ki value of 40.4 µM (see Table 5). The Ki values of both analogs rimonabant 
and AM-251 are almost identical. However, replacement of the piperidine in rimonabant and 
AM-251 for morpholine in AM-281 appears to drastically decrease its affinity for SV2A, 
whereas substitution of 4-chlorophenyl in rimonabant for 4-iodophenyl in AM-251 are 
equipotent (see Table 5).  
 
Figure 14: Concentration-dependent specific inhibition of [3H]BRV binding to recombinant SV2A by unlabeled 
rimonabant resulted in a Ki value of 2.73 ± 0.78 µM. For performing the competition experiments, cellular 
homogenate of CHO-hSV2A-GFP cells (200 µg of protein) was incubated at 4°C for 240 min with [3H]BRV (3 
nM) and increasing concentrations of test compound. Data points show means ± SEM of three independent 
experiments performed in duplicate. 
 
2 Characterization of SV2A and its ligands 
42 
 
2.1.2.2 Indole and pyrrole derivatives 
AM-2232 (26a, for structure see Figure 15) is an indole derivative, which acts as a highly 
potent agonist at CB1 and CB2 receptors with Ki values of 0.28 nM and 1.48 nM, respectively 
(see Table 6).148 In the present study, AM-2232, which contains a 2-napthyl carbonyl residue 
at position C3 and a 4-cyanobutyl residue at position N1 of indole, was identified as a relatively 
strong displacer of [3H]BRV at SV2A with a Ki value of 0.401 µM (see Table 5). Subsequently, 
a series of selected indoles such as STS-135 (26b), AM-679 (26c), JWH-234 (26d), JWH-175 
(26e), AM-630 (26f), JWH-016 (26g) and WIN55, 212-2 (26i) were also profiled for their 
SV2A affinity (see Table 5 for structures). However, they were all weaker than AM-2232.  
The compound STS-135 (26b) inhibited [3H]BRV binding by 79% at a high concentration of 
10 µM, which suggests that the substitution with an adamantylamino  residue connected via a 
carbonyl amide linkage at position C3 and a 5-fluoropentyl residue at position N1 of indole 
are tolerable for SV2A interaction (see Table 5). AM-679 (26c) with a 2-iodophenyl carbonyl 
residue at position C3 and a pentyl residue at position N1 of indole showed similar affinity as 
AM-2232 for SV2A with a Ki value of 8.43 µM. Comparison of AM-679 (26c) with JWH-234 
(26d) indicates that the replacement of the 2-iodophenyl moiety with a 7-ethyl-1-naphthyl 
residue abolished affinity for SV2A (9% inhibition at 2 µM). JWH-016 (26g) with a butyl 
residue at position N1 and a 1-naphthylcarbonyl residue at position C3 of indole displayed a 
Ki value of 4.88 µM. On the other hand, substituting butyl for pentyl and carbonyl for a 
methylene residue in compound JWH-175 (26e) resulted in inhibition of the radioligand by 
only 33% at 10 µM. Furthermore, AM-630 (26f) with a relatively bulky morpholinoethyl 
residue at N1 and a 4-methoxyphenyl moiety connected via a carbonyl linkage at position C3 
of indole resulted in a Ki of 19.9 µM. More detailed structure-relationship studies are warranted 
to elucidate a pharmacophore model. 
WIN55, 212-2 (26i, see Table 5 for structure) is a potent agonist of the CB2 receptor with a Ki 
value of 3.30 nM and a Ki value of 62.3 nM at CB1 receptor (see Table 6).149 WIN55, 212-2 
(26i) was found to compete with [3H]BRV for SV2A binding and displayed a Ki value of 4.15 
µM (see Table 5). According to a recent report, co-administration of WIN55, 212-2 (11.7 µM) 
in a 6 Hz seizure mouse model significantly enhanced the anticonvulsive effects of the AEDs 
LEV (42.9 µM) and gabapentin (249 µM).150 Comparing the in vivo effective dosage (11.7 
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µM) of WIN55, 212-2 and the herein determined Ki value of 4.15 µM at SV2A are in the same 
order of magnitude. In view of that, WIN55, 212-2 (26i) might potentially contribute to the 
enhancement of LEV-mediated anticonvulsive effects via acting on SV2A. Nonetheless, data 
is scarce on this topic and further studies are warranted to elucidate the downstream effects 
upon interaction of cannabinoids with SV2A.      
Among the pyrrole-derived cannabinoid-like compounds listed in Table 5, JWH-031 (27a, see 
Figure 15 for structure) was found to displace [3H]BRV with a Ki value of 0.618 µM. JWH-
031 shows similar affinity for CB1R (Ki 399 nM) where it acts as an agonist (see Table 6).151 
The related pyrroles JWH-368 (27b) and JWH-309 (27c) that bear rather bulky substituents at 
position C2 of pyrrole ring displayed much lower affinities for SV2A (see Table 5 for 
structures). JWH-368 (27b) inhibited [3H]BRV binding to SV2A by 28% at 2 µM and JWH-
309 (27c) by only 20% at 10 µM (see Table 5). Based on the compound structures and their 
affinities for SV2A, a pyrrole residue at position C4 connected to a 2-naphthyl residue via a 
carbonyl linkage and a long hydrophobic substituent at N1 of pyrrole are favorable for 
interaction with SV2A. Introducing a bulky substituent like 3-fluorobenzyl or 1-naphthyl at 
pyrrole reduces SV2A affinity, whereas a hexyl substituent at N1 of pyrrole in terms of SV2A 
affinity has a clear advantage over a pentyl substituent (see Table 5). 
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Figure 15: Concentration-dependent specific inhibition of [3H]BRV binding to SV2A by (A) AM-2232 resulted 
in a Ki value of 0.401 ± 0.144 µM, and by (B) JWH-031 a Ki value of 0.618 ± 0.083 µM. For performing the 
competition binding experiments, homogenate of CHO cells expressing recombinant SV2A (200 µg of protein) 
was incubated at 4°C for 240 min with [3H]BRV (3 nM) and increasing concentrations of test compound. Data 
points show means ± SEM of three independent experiments performed in duplicate. 
 
2.1.2.3 Δ9-Tetrahydrocannabinol (THC) and cannabidiol (CBD)   
Two of the most abundant phytocannabinoids, cannabidiol (28a, CBD) and Δ9-
tetrahydrocannabinol (28b, THC) (see Table 5 for structures), were evaluated in the current 
study for their SV2A affinity. THC and CBD are similar in structure, THC representing the 
cyclized form of CBD (see Table 5). THC has higher affinity for both CB1 and CB2 receptors 
with reported Ki values of 5.05 nM and 3.13 nM, respectively, as compared to CBD (Ki at CB1 
4.35 µM) and (Ki at CB2 2.86 µM) (see Table 6).152-153 While THC showed negligible affinity 
for SV2A and inhibited [3H]BRV by only 24% at 20 µM in competition binding assays, CBD 
displaced [3H]BRV with a Ki value of 0.719 µM for human SV2A and a Ki value of 4.85 µM  
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for rat SV2A (see Figure 16). Although the Ki values at human and rat SV2A are differed 
considerably from each other (two-tailed t-test, p < 0.05), both still lie in the same order of 
magnitude as the Ki value of LEV (see Figure 16). Interestingly, similar observations were 
made by Daniel et al. (2013) with the SV2A PAM (UCB1244283), which displayed higher 
potency (EC50 1 – 4 µM) for recombinant rat and human SV2A compared to native SV2A in 
rat cortical membranes (EC50 > 8µM).102 The exact mechanism(s) underlying these differences 
in affinities remains elusive. However, some potential contributing factors to these differences 
have been suggested like, i) differences in SV2A conformation between recombinant and 
native tissue, ii) interaction with synaptotagmin, adenine-containing nucleotides and 
macromolecules in native expression system, iii) and posttranslational modifications such as 
glycosylation.102  
CBD is a multi-target drug and around 65 distinct molecular targets for CBD have been 
described including transporters, receptors, ion channels and enzymes with which CBD 
interacts at low to high micromolar concentrations either as inhibitor or activator. Of these, 
only few represent relevant pharmacological targets for neurological disorders.154 CBD 
showed significant anticonvulsant effects in mouse models including classical seizure models 
of maximal electroshock (MES) and pentylenetetrazol (PTZ) with ED50 values of 381 µM and 
318 µM, respectively.131, 155 While LEV lacked anticonvulsant activity in both of these mouse 
models,44 BRV demonstrated seizure protection in MES and PTZ mouse models with ED50 
values of 359 µM and 95 µM, respectively.44 SV2A is considered to be the main target for 
LEV and BRV for their anticonvulsive effects. However, the plausible pharmacological targets 
and mechanism(s) by which CBD exerts its antiseizure effects are still not well understood.131, 
154  
It is noteworthy that both THC and CBD have been shown to exhibit anticonvulsant properties 
in a retrospective analysis of 34 preclinical studies. In contrast to THC (dosage 3 – 600 µM) 
none of these studies showed proconvulsive effects for CBD (dosage 3 – 1200 µM).134 The 
evaluation of anticonvulsant effects of cannabinoids for instance in MES model displayed an 
ED50 value of 134 µM for THC and an ED50 value of 255 µM for CBD.156 Furthermore, in 
another study CBD has been demonstrated to significantly synergize with the effect of LEV, 
when both administered at a 1:1 fixed ratio displaying an experimental ED50 value of 172 µM 
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in a preclinical seizure model.157 Due to scarce data on tissue distribution of CBD in humans, 
it is currently difficult to estimate the concentration of CBD in brain required for its 
antiepileptic effects and to compare it with the herein obtained Ki value of 0.719 µM at SV2A. 
Despite the high structural resemblance between CBD and THC, only CBD binds to SV2A 
with high affinity (see Figure 16 and Table 5). Further research is required to clarify the CBD-
mediated anticonvulsive effects, for example in the presence of negative allosteric modulator 
of SV2A in animal models.  
 
Figure 16: Concentration-dependent specific inhibition of [3H]BRV binding to SV2A by cannabidiol (CBD) at 
(A) rat brain cortical membranes, Ki value: 4.85 ± 1.01 µM, and (B) at recombinant human SV2A, Ki value: 0.719 
± 0.166 µM. For performing the competition binding assay, rat cortical membranes or cellular homogenate of 
CHO-hSV2A-GFP cells (200 µg of protein) was incubated at 4°C for 240 min with [3H]BRV (3 nM) and 
increasing concentrations of CBD. Data points show means ± SEM of three independent experiments performed 
in duplicate. 
 
2.1.2.4 Drug metabolism and pharmacokinetic profile of cannabidiol 
Cannabidiol (CBD) upon oral administration by humans undergoes excessive first-pass 
metabolism and therefore results in low peroral bioavailability of only about 6%. Conversely, 
administration in form of aerosols or vapors results in a rapid increase in peak plasma 
concentrations within less than 10 min and a bioavailability of around 31%. CBD is a highly 
lipophilic drug with high volume of distribution and rapid transport into brain and adipose 
tissue.131 Administration of a cannabis-based sublingual formulation (Sativex®) at a dose of 40 
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mg (20 mg THC + 20 mg CBD) resulted in mean peak plasma concentrations of CBD (ca. 8 
nM) and THC (ca. 21 nM) after 100 min.158 Interestingly, higher concentrations of CBD on 
average up to 21.3 nM were reported in the brains of 5 postmortem cases, however the amount 
of intake and time-point was unknown.159  
CBD is a substrate and inhibitor of cytochrome CYP450, predominantly via isozymes CYP3A 
(2/4) and CYP2C (8/9/19). Therefore, co-administration of CBD with other AEDs that are 
metabolized by these isozymes has to be considered. It may result in a change of serum 
concentrations of the background AEDs and their active metabolites, as shown for clobazam, 
levetiracetam, and other AEDs.160 Around 100 CBD metabolites from urinal excretion have 
been characterized in different species. Not much is known about CBD-derived metabolites 
regarding their biological activity in humans. However, CBD-derived hydroxylated 
metabolites are the most abundant ones, which are excreted either unchanged or as glucuronide 
conjugates.161  
2.1.2.5 Specific [3H]BRV inhibition by endocannabinoids  
In addition to synthetic and phytocannabinoids, we investigated the interaction of SV2A with 
highly lipophilic endocannabinoids, i.e. N-arachidonylethanolamide (29b, anandamide), 2-
arachidonylglycerol (29c, 2-AG), N-arachidonylserotonin (29d, AA-5HT), and the 
acetaminophen metabolite N-arachidonylaminophenol (29e, AM-404).162 All of these 
compounds share a membrane phospholipid precursor in synthesis and structurally resemble 
each other (see Table 5 for structures). However, upon evaluating their affinity for SV2A, 
anandamide and 2-AG displayed minor specific inhibition of [3H]BRV binding to SV2A (33% 
and 16% at 10 µM, respectively), while AA-5HT and AM-404 were found to be more potent 
with Ki values of 27.7 µM and 22.9 µM, respectively (see Table 5). However the affinity of 
these lipids was moderate. 
 
 
 
 
2 Characterization of SV2A and its ligands 
48 
 
Table 5: Affinities of selective cannabinoids at human SV2A 
 
 
 
 
 
 
 
25 Pyrazole derivatives 26 Indole derivatives 26i WIN55, 212-2  27 Pyrrole derivatives 
  
 
 
 
28a Cannabidiol (CBD) 28b Δ9-Tetrahydrocannabinol (THC) 29a Arachidonic acid derivatives 
   
      Human SV2A  [3H]BRV vs. 
Compound 
Compound R1 R2 R3 R4 X Ki ± SEM (µM) % inhibition ± SEMa 
1 Levetiracetam (LEV) For structure see Figure 5 1.74 ± 0.27 
2 Brivaracetam (BRV) For structure see Figure 5 0.098 ± 0.015 
Synthetic cannabinoids 
25 Pyrazole derivatives 
25a Rimonabant Cl 
 
 2.73 ± 0.78 
25b AM-251 I 
 
 2.75 ± 0.34 
25c AM-281 I  
 
 40.4 ± 20.0 
 Table 5 continued     
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     Human SV2A 
     [3H]BRV vs. Compound 
Compound R1 R2 R3 R4 X Ki ± SEM (µM) % inhibition ± SEMa 
26  Indole derivatives 
26a AM-2232 
 
 
H 
 
H C=O 0.401 ± 0.144 
26b STS-135  H 
NH  
H C=O 79% at 10 µM  
26c AM-679  H 
 
H C=O 8.43 ± 1.68 
26d JWH-234  H 
 
H C=O 9% at 2 µM  
26e JWH-175  H 
 
H CH2 33% at 10 µM 
26f AM-630 
 
CH3  
6-I C=O 19.9 ± 7.01 
26g JWH-016  CH3 
 
H C=O 4.88 ± 1.82 
26h AM-1235  H 
 
6-
NO2 C=O 18% at 10 µM 
26i WIN55, 212-2 For structure see above 4.15 ± 0.89 
    
 Table 5 continued  
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       Human SV2A 
        [3H]BRV vs. Compound 
 Compound R1 R2 R3 R4 X Ki ± SEM (µM) % inhibition ± SEMa 
27 Pyrrole derivatives     
27a JWH-031  H H  0.618 ± 0.083 
27b JWH-368  
 
H  28% at 2 µM 
27c JWH-309  
 
H  20% at 10 µM 
28 Phytocannabinoids     
28a CBD For structure see above   0.719 ± 0.166 
28b Δ9-THC For structure see above 24% at 20 µM 
29 Endocannabinoids  
29a Arachidonic acid    
29b Anandamide   33% at 10 µM 
29c 2-AG 
 
 16% at 10 µM 
29d AA-5HT 
 
 27.7 ± 10.3  
29e AM-404   22.9 ± 6.15 
aScreening was performed at one indicated test compound concentration and percent inhibition of [3H]BRV (3 nM) is 
given relative to LEV (1 mM) mediated 100% inhibition at hSV2A. Data show means ± SEM of at least three 
independent experiments performed in duplicate until and otherwise indicated. 
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Table 6: Potencies of selected cannabinoids at SV2A and cannabinoid receptors  
n.d., not determined; 163Pertwee et al. 2010; 148Makriyanis & Deng 2005; 164Hess et al. 2016; 165Huffman et al. 
2005; 166Huffman et al. 2003; 151Wiley et al. 1998; 167Huffman et al. 2006; 168Aung et al. 2000; 145Rinaldi et al. 
1995; 153Showalter et al. 1996; *AK Müller (determined by Clara Schöder and Andhika B Mahardhika). 
 
 
Cannabinoid Human SV2A CB1 CB2 Ki ± SEM (nM) Ki ± SEM (nM) Ki ± SEM (nM) 
25a Rimonabant  2730 ± 780 2.0145 12.6 ± 3.9* 
> 1000145 
900 ± 310* 
25b AM-251 2750 ± 340 7.49163  2290163 
25c AM-281 40400 ± 20000 12163 4200163 
26a AM-2232 401 ± 144 0.28148 1.48148 
26b STS-135 79%  at 10000 nM 2.51 ± 0.35164 0.794 ± 0.071164 
26c AM-679 8430 ± 1680 13.5148 49.5148 
26d JWH-234 9% at 2000 nM 8.4 ± 1.8165 3.8 ± 0.6165 
26e JWH-175 33% at 10000 nM 22 ± 2166 n.d. 
26f AM-630 19900 ± 7010 5152163 93.3 ± 23.8163 
26g JWH-016 4880 ± 1820 22.0 ± 1.5168 4.29 ± 1.63168 
26h AM-1235 18%  at 10000 nM 1.5148 20.4148 
26i WIN55,212-2 4150 ± 890 1.89-123163 0.28-16.2163 
27a JWH-031 618 ± 83.0 399 ± 109151 n.d. 
27b JWH-368 28% at 2000 nM 16 ± 1167 9.1 ± 0.7167 
27c JWH-309 20%  at 10000 nM 41 ± 3167 49 ± 7167 
28a CBD   719 ± 166 4350 ± 390153 2950 ± 2100* 
2860 ± 1230153 
2150 ± 4010* 
28b THC 24% at 20000 nM 40.7 ± 1.7153 3.89 ± 0.9* 
36.4 ± 10.0153 
71.6 ± 24.1* 
29b Anandamide 33% at 10000 nM 61-543163 279-1940163 
29c 2-AG 16% at 10000 nM 58.3-472163 145-1400163 
29d AA-5HT 27700 ± 10300  572 ± 148* 661 ± 81.7* 
29e AM-404 22900 ± 6150 2150 ± 105* 3080 ± 754* 
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2.1.3 Summary  
In the present study, 500 approved drugs were tested for their interaction with the human SV2A 
expressed in CHO cells. Competition binding studies were performed using [3H]brivaracetam 
as a radioligand. A hit rate of 3% was obtained defined as compounds that inhibited radioligand 
binding by more than 90% at a screening concentration of 20 µM. Subsequent concentration-
inhibition curves revealed the antihistaminic prodrug loratadine (Ki 1.16 µM), the antimalarial 
drug quinine (Ki 2.03 µM), and the anti-obesity drug rimonabant (Ki 2.73 µM) to be the most 
potent SV2A ligands of the investigated drug library. All three compounds were similarly 
potent as levetiracetam (Ki 1.74 µM). A pharmacophore model was established using flexible 
alignment of brivaracetam, loratadine, and quinine, which indicated steric and electronic 
conformities of brivaracetam with the new SV2A ligands, and preliminary structure-activity 
relationships were analyzed. The anticonvulsive effects of the natural product quinine 
previously observed in animal models may - at least in part - be explained by interaction with 
SV2A. Loratadine and quinine could serve as new lead structures for antiepileptic drug 
development.  
Based on the interaction of rimonabant with SV2A, a panel of 80 cannabinoids was screened 
against SV2A, which resulted in the identification of new potent ligands for SV2A, i.e. 
cannabidiol (CBD) (Ki 0.719), AM-2232 (Ki 0.401), and JWH-031 (Ki 0.618). THC displayed 
very low binding affinity for SV2A. Subsequently, selected derivatives of CBD, AM-2232, 
and JWH-031 with diverse substitutional patterns were analysed for preliminary structure-
activity relationships (SARs). The resulting SARs may provide a basis for the development of 
dual-target drugs for epilepsy. Although further rigorous research is required this study 
supports the idea that the anticonvulsive effects of CBD might be – at least partly – attributed 
to its interaction with SV2A.  
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2.2 Modulation of [3H]BRV binding 
2.2.1 Impact of monosaccharides on [3H]BRV binding  
A transporter like function of SV2A has been widely discussed, owing to its homology with 
the major facilitator superfamily (MFS) of transporters, however its substrate has not been 
elucidated so far.59, 61, 64 Recently Madeo et al. (2014) claimed that SV2A may be a transporter 
for galactose.65 Authors of this study have demonstrated that expression of recombinant human 
SV2A in hexose transport-deficient yeast cells enables them to grow on galactose-containing 
medium. However, these yeast cells with recombinant SV2A were not able to grow on other 
sugars such as sucrose, glucose, or fructose. Furthermore, growth of these yeast cells could be 
inhibited by LEV (4 µM) treatment. Moreover, this study demonstrated the cellular uptake of 
[3H]galactose and time-dependent accumulation of the radioligand in yeast cells expressing 
recombinant SV2A.65 This study prompted us to investigate the potential interaction of 
galactose and glucose with [3H]BRV binding to SV2A. Increasing concentrations (10 mM – 
300 mM) of each sugar was added, and the radioligand binding assay was performed as 
described in Section 6.7.1. High concentration of LEV (1 mM) was used to determine the non-
specific binding of the radioligand. As shown in Figure 17 neither galactose nor glucose up to 
concentrations of 300 mM significantly modulated the binding of the radioligand to SV2A.  
Normal physiological blood concentrations of galactose and glucose in humans are reported to 
be 0.08 mM and 4.72 mM, respectively.170 If at supraphysiological concentrations galactose 
does not modulate the [3H]BRV binding, it is not likely that it shares the same binding site 
with LEV/BRV on SV2A and that it may modulate LEV/BRV binding to SV2A. It is tempting 
to speculate that LEV may block the SV2A pore, thereby impeding the transport of galactose. 
Galactose is an important structural component of membrane carbohydrates and 
glycoproteins.171 Furthermore, a disaccharide fucose-α(1-2)galactose is proposed to have an 
effect on cognition, synaptic plasticity, and turnover of synaptic vesicle-associated protein, 
synapsin.65, 172 Understanding the association of SV2A with galactose will help to elucidate 
the exact role of SV2A in the brain and the mode of action of LEV/BRV. Further research is 
warranted in this area and LEV-mediated inhibition of galactose via SV2A should be assessed 
in primary neuronal cultures for their reproducibility.  
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Figure 17: [3H]BRV binding to recombinant SV2A in the presence of glucose and galactose. Bars demonstrate 
[3H]BRV binding to SV2A in the presence of different concentrations of monosaccharaides. Cellular 
homogenate preparation (200 µg of protein) was incubated with [3H]BRV (3 nM) together with sugar for 240 
min at 4°C. Total binding was determined in the absence of LEV and non-specific binding was measured in 
the presence of LEV (1 mM). Data shown are means ± SEM of four individual experiments performed in 
duplicate. Statistical analysis was performed by one-way-ANOVA with Dunnett’s test for multiple 
comparisons, where control assay was compared with sugar-treated assays. ns, not significant (p > 0.05). 
 
2.2.2 Impact of botulinum neurotoxin A on [3H]BRV binding 
Botulinum neurotoxin A (BoNT/A) first binds to gangliosides to facilitate anchoring at the 
synaptic membrane and then enters neurons by specifically binding to synaptic vesicle SV2 
proteins.89 The heavy chain C-terminal receptor binding domain (HCR) of BoNT/A was 
mapped to be the critical region for associating with the luminal loop 4 (L4) of SV2 (SV2A, 
SV2B and SV2C) proteins in the pull-down assays.96 In the present study potential HCR-
mediated modulation of [3H]BRV binding to SV2A was investigated. The 6xHis-tagged 
BoNT/A-HCR (~50 kDa) was expressed in E. coli and purified over Ni-columns via affinity 
chromatography (see Figure 18).  
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Figure 18: Purification and SDS-PAGE analysis of the C-terminal receptor binding domain (HCR) of BoNT/A 
(BoNT/A-HCR). Lysate containing the 6xHis-tagged BoNT/A-HCR was incubated in the Ni-NTA-columns for 
1 h at 4°C under mild shaking. The flow-through of lysate was collected and the column was washed three times 
with wash buffer (10 mM imidazole). Subsequently, BoNT/A-HCR was eluted in elution buffer (250 mM 
imidazole). 
 
For the assay, a constant amount of cellular homogenate containing exogenous human SV2A 
(200 µg of protein) was incubated with three different concentrations of BoNT/A-HCR, i.e. 
6.7 µM, 5.0 µM, 2.5 µM, and control without BoNT/A-HCR, respectively. After an overnight 
incubation at 4°C under shaking, the mixture of proteins was used in the assay. As illustrated 
in Figure 19, there is no significant impact of BoNT/A-HCR on the binding of [3H]BRV to 
SV2A compared to control without BoNT/A-HCR.  
Recently Benoit et al. (2014) have determined the high-resolution crystal structure of the 
BoNT/A-HCR in complex with the luminal loop four of the SV2C (SV2C-L4) to characterize 
the molecular interactions between the toxin and the SV2C.173 In that study, they have reported 
a dissociation constant Kd of 0.26 µM for the SV2C-L4 at the BoNT/A-HCR by performing 
fluorescence anisotropy experiments.173 Although the same amino-acid sequence of BoNT/A-
HCR as described by Benoit et al. was used in this study and even with 25-fold Kd 
concentration (6.7 µM) of BoNT/A-HCR at pH 7.4, no significant change in [3H]BRV binding 
was observed. It is noteworthy that BoNT/A displays affinity for SV2 protein isoforms 
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following the order SV2C > SV2A > SV2B.96 The lethal dose of BoNTs is around 1 ng/kg (6.7 
fM),90 which indicates its extremely high potency. Since SV2A was expressed in CHO cells, 
presumably the N-linked glycosylation at Asp573 of SV2A was preserved, which is known to 
enhance the BoNT/A-HCR binding.174 Overall, our findings demonstrate that the BoNT/A 
binding site within SV2A-L4 does not overlap with the [3H]BRV binding site, and BoNT/A 
does not affect [3H]BRV binding by allosteric modulation.  
 
Figure 19: Analysis of BoNT/A-HCR-mediated modulation of [3H]BRV binding to SV2A using radioligand 
binding assay. No significant difference in the [3H]BRV binding to SV2A in the presence of BoNT/A-HCR was 
observed as compared to control without BoNT/A-HCR. Statistical analysis was performed by one-way-ANOVA 
with Dunnett’s test for multiple comparisons, in which [3H]BRV binding expressed in counts per minute (cpm) 
in control assay was compared to BoNT/A-HCR treated assays (p > 0.05). For performing the assay, a constant 
amount of CHO cells homogenate expressing SV2A (200 µg of protein) was incubated with different 
concentrations of purified BoNT/A-HCR for 16 h at 4°C under shaking. Control proteins without BoNT/A-HCR 
were also treated under same conditions. These pre-inubated protein mixtures were then incubated with [3H]BRV 
(3 nM) at 4°C for 240 min prior to harvesting of the radioligand-protein complex. Total [3H]BRV binding was 
determined in the absence of unlabeled compound and non-specific binding was determined in the presence of 
unlabeled LEV (1 mM). Data represent the means ± SEM of at least three independent experiments performed in 
duplicate. cpm, counts per minute; and ns, not significant. 
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2.3 Potential interaction of the intracellular loop 3 of SV2A with [3H]BRV  
2.3.1 Introduction 
Data is scarce on genetic variations (polymorphisms) of SV2A which may be present in LEV 
non-responders. 175 However, a point mutation from nucleotide guanine (G) to adenine (A) at 
position 169 in intron 6 leading to a splice variant of SV2A with a deleted portion of exon 6 
and complete exon 7 was previously reported to result in a LEV non-responder phenotype.175 
Recently, a homozygous mutation resulting in the exchange of arginine to glutamine in 
position 383 (Arg383Gln) in exon 5 of SV2A, has been suggested to be a candidate mutation 
causing intractable epilepsy. Moreover, a patient exhibiting this mutation was found to be a 
LEV non-responder.176 It is noteworthy that exon 5 (Asn364 – Ser393), exon 6 (Val394 – Gln430) 
and large portion of exon 7 (Val431 – Ser460) constitute the longest cytosolic loop of the SV2A 
(UniProt: Q7L0J3). Knowledge of the amino acid residues in SV2A involved in LEV and BRV 
binding will help to design better SV2A-binding drugs. Moreover, mutations of these amino 
acid residues may additionally serve as a biomarker to predict treatment response to LEV in 
epileptic patients harbouring these mutations. 
Radiolabeled LEV surrogate [3H]UCB30889 and [3H]BRV have been shown to bind to SV2A 
(see Figure 20), but they exclusively bind to SV2A and not to SV2B and SV2C.38, 43, 64 This 
implies that there is a unique binding site for pyrrolidone derivatives in SV2A, which is absent 
in SV2B and SV2C. The SV2A contains a long, relatively non-conserved N-terminus, an 
intracellular cytoplasmic loop three (ICL3) between TMDs 6 and 7, a highly glycosylated long 
intravesicular/luminal loop four (L4) between TMDs 7 and 8, and a short C-terminus (see 
Figure 21).61-62 
 
Figure 20: Chemical structures of pyrrolidone derivatives levetiracetam (LEV), and radiolabeled brivaracetam 
(BRV), and UCB30889. *) 3H-label. 
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Within the major facilitator superfamily (MFS), lactose permease (LacY) with a known crystal 
structure is the closest homolog to SV2A with 16% sequence identity.177 From the homology 
model of SV2A based on the LacY transporter and mutagenesis studies, 14 amino acid residues 
in the TMDs interacting with LEV were proposed (see Figure 21).178 This work was further 
extended by implementing the SV2A homology model with inward-open and outward-open 
conformational states, which led to the identification of Asp670, conserved in all three SV2 
isoforms, as an indispensable racetam interaction partner.177 Asp670 is the third last amino acid 
of TMD 10 (UniProtKB: Q7L0J3). It is noteworthy that these studies used [3H]UCB30889, 
which possesses a rather bulky, aromatic phenyl residue, which may not accurately represent 
LEV and BRV. Shortly after this work, again several new amino acid residues were identified 
as putative racetam-interaction partners by docking studies (see Figure 21).179 However, 
among these newly identified amino acid residues, only Trp666 as a racetam-interaction partner 
was found to be consistent with previous studies.179 
Previously reported homology models focused on the TMDs of SV2A to elucidate LEV 
binding residues.177-179 Interestingly, most of the proposed amino acid residues are conserved 
in all three SV2 protein isoforms. Moreover, the role of the ICL3 and the L4 that contain 
several SV2A-unique and non-conserved amino acids for LEV binding has not been 
investigated. The ICL3 of SV2A contains 25 unique amino acids and the TMDs 6 and 7 are 
relatively rich in amino acid residues specific for the SV2A isoform (see multiple sequence 
alignment in appendix Figure A3).  
It has been previously shown by Hildenbrand (2012) that [3H]BRV binding was abolished in 
the exon 5 and/or 6 deletion mutants of rat SV2A.38 Furthermore, single and double mutants 
containing amino acid mutations within the ICL3 of SV2A, i.e. N364K, H387Q, H387Q-
T3951, T395I, and E403D did not show any significant effect on the IC50 value of LEV.38 The 
current study is an extension to the previous work to further investigate the role of ICL3 in the 
binding of LEV. Within this study, the point mutant R383Q of hSV2A was expressed in CHO 
cells and affinities of LEV, BRV, JWH-031, and CBD were evaluated. Subsequently, chimeric 
human SV2A with the ICL3 of the human SV2B (hSV2A-hSV2B-ICL3) and the chimeric 
human SV2B with the ICL3 of the human SV2A (hSV2B-hSV2A-ICL3) were expressed in 
CHO cells and evaluated for their [3H]BRV affinity.  
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Figure 21: Topology model of the human SV2A. The snake plot diagram was prepared by using the TOPO2 
program along with the transmembrane domain predictions using the HMMTOP software.80-81 Transmembrane 
domains are indicated with Roman numbers and N & C represent N-and C-termini. The amino acids depicted in 
blue color have been previously demonstrated to alter racetam binding by mutagenesis and docking studies.177-179 
Amino acids shown in purple within ICL3 have been previously mutated to test the affinity of mutants for 
racetams, however binding was not altered.38 The mutation of arginine within ICL3 depicted in orange color at 
position 383 is suggested to be a causal factor in intractable epilepsy. The green GFP tag at the C-terminus 
indicates a green fluorescent protein (GFP) and the amino acids in red color are the N-glycosylation sites.    
 
  
The results shown in the following section are planned to be included in a manuscript (in 
preparation). 
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2.3.2 Molecular cloning and recombinant expression  
2.3.2.1 Construct of the SV2A-R383Q mutant and heterologous expression  
The mutation replacing arginine at position 383 for glutamine is the first identified point 
mutation in SV2A suggested to be linked with intractable epilepsy (see Figure 22).176 
Considering the significance of this mutation for proper SV2A function, it was decided to 
characterize the SV2A-R383Q protein variant for its affinity to LEV/BRV. To construct the 
SV2A-R383Q mutant, mutagenesis primers with exchanged nucleotides at the corresponding 
position were designed (see Section 6.1.7 for primers). Site-directed mutagenesis was 
performed by using the plasmid pcDNA4-hSV2A-GFP and mutagenesis primers. 
Subsequently, SV2A-R383Q-GFP was excised out of the mother plasmid by restriction digest 
using XhoI and HindIII enzymes. The SV2A-R383Q-GFP was subcloned into a linearized 
vector pcDNA™4/myc-His A also digested with XhoI and HindIII enzymes. The plasmid map 
is the same as shown in the Figure 6 with the only exception of the introduced point mutation 
(Arg383Gln). 
 
Figure 22: Point mutation located in the hSV2A-ICL3. Mutation of arginine at position 383 in SV2A to glutamine 
is a candidate mutation for intractable epilepsy.176 
 
2.3.2.2 Constructs of SV2A and SV2B chimeras  
In the previous study, four out of 25 amino acids unique to the ICL3 of SV2A were randomly 
exchanged against another amino acid, i.e. N364K, H387Q, T395I and E403D.38 However, 
none of these mutants showed significant difference in LEV affinity in competition radioligand 
binding assay against [3H]BRV.38 Generating and testing of single point mutants of the 
cga
caa Glutamine
Argininewt SV2A‐R383
DNA
SV2A‐R383Q
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remaining 21 amino acids at first place would have been tedious and time-consuming. 
Therefore, to study a potential role of the ICL3 of SV2A for the binding of LEV/BRV, chimeric 
proteins were designed: chimeric SV2A containing the ICL3 of SV2B (SV2A-SV2B-ICL3) 
and chimeric SV2B protein containing the ICL3 of SV2A (SV2B-SV2A-ICL3). Construction 
of chimeric proteins posed various challenges due to absence of suitable restriction sites that 
do not cut within the vector-backbone. Initial attempts such as, i) loop exchange by introducing 
restriction sites using site-directed mutagenesis,180 ii) ligation of multiple DNA fragments,181 
and iii) PCR-after-ligation of multiple DNA inserts,182 did not result in intact plasmids. 
Consequently, a novel strategy – the Gibson assembly method – designed for ligation of 
multiple DNA fragments was employed.183-184 In order to use this method overlapping primers 
were designed to amplify adjacent DNA fragments with overlaps sharing terminal sequence 
(see Section 6.1.7 for primers).  
The Gibson assembly collectively makes use of three enzymes, a) 5’-T5 exonuclease (5’-exo), 
b) Phusion® DNA polymerase (DNA pol), and c) Thermus aquaticus ligase (Taq ligase), in a 
one-step isothermal reaction.184 When the double-stranded DNA (dsDNA) fragments to be 
ligated are subjected to the Gibson assembly mixture, 5’-exo cuts off nucleotides at the 5’-end 
of (dsDNA) leaving behind a 3’-overhang. The complementary 3’-overhangs of adjacent DNA 
fragments are annealed and gaps are filled by the action of DNA pol and subsequently nicks 
are sealed by Taq ligase resulting in a seamless DNA construct.184 As shown in the Figure 23, 
for construction of the plasmid pcDNA4-hSV2A-hSV2B-ICL3, vector pcDNA™4/myc-His A 
was linearized by the restriction digest using XhoI and HindIII enzymes, followed by mixing 
the linearized vector and amplified DNA fragments with Gibson assembly mixture as 
explained in Section 6.2.11. Similarly, the plasmid pcDNA4-hSV2B-hSV2A-ICL3 was 
constructed, however initially the vector was linearized by the restriction digest using XbaI 
and HindIII (see Figure 23).  
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Figure 23: Plasmid maps of the hSV2A and hSV2B chimeric constructs. (A) The wt hSV2A sequence (blue) 
contains the ICL3 (red) from wt hSV2B and a GFP-tag (green) is fused at its C-terminus. (B) The wt hSV2B 
sequence (red) contains the ICL3 (blue) from wt hSV2A and a GFP-tag (green) is fused at its C-terminus. Regions 
of the most important functional elements such as promoter region (PCMV), termination/polyadenylation signal 
(BGH pA), zeocin, and ampicillin are indicated accordingly within the map.  
 
2.3.3 Heterologous expression of wt SV2A and its variants  
Expression and intracellular localization of the GFP-tagged wt SV2A, SV2A-R383Q, and 
chimeric proteins was investigated by fluorescence microscopy. CHO cells were transiently 
transfected with each plasmid and slides were prepared for confocal fluorescence microscopy 
(see Section 6.6.1). As shown in the Figure 24, the expression of wt SV2A and SV2A-R383Q 
was found to be similar in CHO cells and both proteins were not only localized to the plasma 
membrane but also to intracellular compartments. However, lower fractions of chimeric 
proteins were found to be localized at the plasma membrane compared to the intracellular 
compartments. To further specify the compartments for protein localization, detailed and more 
specialized studies using the plasma membrane, cytosolic and nuclear markers could be 
conducted, which however lies out of the focus of this study. Nevertheless, these results 
demonstrate that all aforementioned proteins tagged with GFP at their C-terminus were 
successfully expressed in CHO cells. 
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Nuclei GFP Merge 
Figure 24: Fluorescence microscope images of CHO cells expressing GFP-tagged proteins, (A) wt hSV2A, (B) 
hSV2A-R383Q, (C) chimeric hSV2A (hSV2A-hSV2B-ICL3), and (D) chimeric hSV2B (hSV2B-hSV2A-ICL3). 
Nuclei were stained with DAPI and a DAPI filter was used for detection. GFP fused proteins were detected by a 
FITC filter indicating protein expression. The scale bar represents 10 µm. DAPI, 4’,6-diamidino-2-phenylindole; 
FITC, fluorescein isothiocyanate. 
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2.3.4 Binding of [3H]BRV to SV2A-R383Q mutant 
The homozygous missense mutation R383Q in a LEV non-responder patient lies within the 
ICL3 of SV2A.176 Notably, arginine at this position is conserved in all three SV2 isoforms 
(alignment performed with ClustalW, NCBI). SV2A contains two ATP binding sites, the first 
at the N-terminus and the second at the ICL3 within which Arg383 is located and perhaps has 
influence on ATP and/or LEV binding to SV2A.64, 71 Recombinant wt SV2A and SV2A-
R383Q were expressed in CHO cells with the goal to perform radioligand competition assays 
using [3H]BRV. Both proteins expressed a GFP-tag at their C-termini which allowed 
monitoring of expression by direct fluorimetric measurements using a fluorimeter (see Figure 
25). 
 
Figure 25: Expression of recombinant wt hSV2A-GFP and hSV2A-R383Q-GFP proteins in CHO cells 
determined by fluorimetric measurements. The same amount of cellular homogenate for all three cell lines was 
used for measurements. Bars shown are means ± SEM of three individual experiments performed in duplicate. 
 
Concentration-dependent inhibition of specific [3H]BRV binding by LEV, BRV, JWH-031 and 
cannabidiol (CBD) was determined. LEV displayed similar affinity for wt SV2A and SV2A-
R383Q with IC50 values of 1.81 ± 0.28 µM and 2.14 ± 0.46 µM, respectively. Similarly, BRV 
also showed comparable affinities with an IC50 value of 0.099 ± 0.015 µM for wt SV2A and 
an IC50 value of 0.116 ± 0.054 µM for SV2A-R383Q. The differences in IC50 values of LEV 
and BRV for wt and mutant SV2A proteins are not significantly different as determined by a 
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two tailed t-test analysis. These results suggest that R383Q mutation does not directly affect 
the affinity of LEV and BRV for SV2A. Previously binding of LEV was observed in both 
inside-open and outside-open conformations of SV2A identified by protein tomography, and 
LEV binding had no major impact on either of the conformations.67 This finding implies the 
presence of more than one LEV binding site in SV2A. This idea was further supported by the 
work of Daniels et al. (2013), which showed that the SV2A PAM UCB1244283 had no 
significant effect on LEV affinity but on that of UCB30889.102 Based on the latter findings 
Daniels et al. concluded that LEV has multiple binding sites on SV2A which are dependent on 
SV2A conformations.102 Since LEV and BRV display similar affinity for SV2A and SV2A-
R383Q, respectively, this mutation does not interfere with LEV/BRV binding but may interact 
with the compounds function. The mutation may cause a conformational change disturbing 
ATP binding or transporter like physiological function of SV2A contributing to intractable 
epilepsy and a LEV non-responder phenotype.  
 Intriguingly, the newly identified cannabinoid ligands of SV2A displayed significant 
differences in their IC50 values at wt SV2A and SV2A-R383Q. Competitive binding of the 
synthetic cannabinoid JWH-031 versus [3H]BRV resulted in an IC50 value of 0.643 ± 0.086 
µM for SV2A, whereas an IC50 value of 5.99 ± 1.47 µM corresponding to a 9-fold shift was 
observed for SV2A-R383Q. Similarly, while CBD exhibited an IC50 value of 0.748 ± 0.173 
µM for wt SV2A, an IC50 value of 20.7 µM was obtained for SV2A-R383Q (28-fold shift) (see 
Table 7 and Figure 26). The shifts in the IC50 values for JWH-031 and CBD at SV2A-R383Q 
are significantly different from those at wt SV2A as concluded per unpaired two tailed t-test 
with p < 0.05. An explanation for this shift in the IC50 values for both compounds could either 
be their direct interaction with Arg383 and/or a mutation-mediated change in the protein 
conformation. How exactly this mutation affects the downstream consequences of LEV 
binding to SV2A and translates into LEV non-responsiveness is still to be elucidated. 
Nonetheless, it is warranted to further characterize the R383Q mutation using in vitro and in 
vivo models. 
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Figure 26: Concentration-dependent inhibition of specific [3H]BRV binding to recombinantly expressed wt 
human SV2A (green) and SV2A-R383Q (red) by selected compounds, (A) levetiracetam, (B) brivaracetam, (C) 
JWH-031, and (D) cannabidiol (CBD). For performing the assay cellular homogenate of each cell line (200 µg of 
protein) was incubated at 4°C for 240 min with [3H]BRV (3 nM) and increasing concentrations of compound. 
Total binding was determined in the absence of LEV and non-specific binding was obtained in the presence of 
LEV (1 mM). Data shown are means ± SEM of three individual experiments performed in duplicate until 
otherwise indicated. 
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Table 7: Affinities of selected ligands for SV2A and SV2A-R383Q determined by inhibition of [3H]BRV binding 
Compound wt hSV2A IC50 ± SEM (µM) 
hSV2A-R383Q 
IC50 ± SEM (µM) Fold shift
a 
Levetiracetam  1.81 ± 0.28 2.14 ± 0.46 ns 1.2 
Brivaracetam 0.099 ± 0.015 0.116 ± 0.054 ns 1.2 
JWH-031 0.643 ± 0.086 5.99 ± 1.47 * 8.9 
Cannabidiol (CBD) 0.748 ± 0.173 20.7 ± 1.11 **** 27.7 
Data show means ± SEM of at least three independent experiments performed in duplicate until otherwise 
indicated. a Fold shift = IC50 (mutant) / IC50 (wild-type); h, Human; ns, no significant difference as per two tailed 
t-test; * p < 0.05; *** p < 0.0001 
 
2.3.5 Binding of [3H]BRV to chimeric SV2A and SV2B proteins 
Using radioligand binding assays with [3H]BRV and exons 5 and/or 6 deletion mutants of 
SV2A, it has been already demonstrated that the deletion of large parts of ICL3 abolished 
radioligand binding.38 However these results have to be interpreted carefully. It cannot be 
completely excluded that deletion of a protein region in SV2A may perhaps alter the native 
protein conformation, which might lead to the alteration of the LEV/BRV binding site or hinder 
the access of the ligand to the binding site. A more suitable strategy is to exchange all amino 
acids unique to the SV2A-ICL3. To exchange all of these amino acids simultaneously a SV2A 
chimeric protein containing the ICL3 of SV2B was constructed. Similarly, a chimeric SV2B 
protein containing ICL3 of SV2A was constructed to evaluate any gain in [3H]BRV binding to 
chimeric SV2B protein due to SV2A-specific amino acids. Both chimeric proteins were tagged 
with GFP at their C-terminus and recombinant protein expression was monitored by direct 
fluorimetry (see Figure 25a). To ensure high chimeric protein expression, early cell culture 
passages (P4-P5) of FACS-selected clones were used for the preparation of cellular 
homogenate (see Figure 25a). 
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Figure 27: (A) Cartoon representation of chimeric constructs of human SV2A and SV2B proteins. The 
intracellular cytosolic loop (ICL3) of SV2A was exchanged for the ICL3 of SV2B in the SV2A chimera and the 
ICL3 of SV2B for the ICL3 of SV2A in the SV2B chimera by designing the corresponding overlapping primers 
and using the Gibson assembly method for multiple DNA fragments. (B) Native ICL3 amino acid sequences of 
SV2A (green) and SV2B (red) as per HMMTOP prediction located between TMDs 6 & 7 (grey shading).81 For 
ICL3 chimera construction 93 amino acids were exchanged in either chimera. 
 
Radioligand competition assays were performed using [3H]BRV as described earlier and high 
unlabeled LEV concentration (1 mM) was used to determine non-specific binding. While high 
specific [3H]BRV binding was determined with wt SV2A, no specific binding of the 
radioligand neither to SV2A- nor to SV2B-chimeric proteins could be detected (see Figure 
28A). One possible explanation of these findings can be that besides previously reported 
residues in TMDs and ICL3,38, 177-179 other non-conserved SV2A-specific amino acids are also 
involved in LEV binding. These results have to be again interpreted with caution, since the 
ICL3 in SV2A (93 aa) and SV2B (82 aa) differ in size by 11 amino acids as per TMDs 
predictions by HMMTOP.81 Nevertheless, the addition of 11 amino acids from the 7th TMD of 
SV2B to the ICL3 of SV2A and of 11 amino acids from the ICL3 of SV2A to the 7th TMD of 
SV2B in chimeric constructs, might have compromised the proteins’ native architecture. A 
GFP tag was fused to the C-terminus of all proteins to monitor their expression in CHO cells. 
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The chimeric protein approach appeared to be more suitable than deletion mutants for 
deciphering the binding pocket of LEV within the large SV2A (742 aa). In the future, it may 
be more rational to systematically exchange shorter regions of SV2A with corresponding 
regions of SV2B protein. In conclusion, the current data highlights the possible involvement 
of ICL3 of SV2A in LEV/BRV binding and suggests an important strategy of chimeric protein 
construction to study the interaction of SV2A with its ligands.  
 Figure 28: (A) Evaluation of [3H]BRV binding to recombinant wt hSV2A-GFP (green), hSV2A chimera (red), 
and hSV2B chimera (blue). For performing the assay cellular homogenate (200 µg of protein) of each cell line 
was incubated at 4°C for 240 min with [3H]BRV (2 nM). Total binding was determined in the absence of LEV 
and non-specific binding was determined in the presence of LEV (1 mM). (B) The expression of GFP-tagged wt 
SV2A and chimeric proteins in CHO cells was determined by direct fluorimetric measurements using a 
fluorimeter. The color of the bars corresponds to the respective bars indicated in figure A. Data shown are means 
± SEM of three individual experiments performed in duplicate. 
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2.3.6 Summary  
The main target of LEV is believed to be SV2A to which it binds with moderate affinity (Ki 
1.74 µM). Efforts involving homology modeling and site-directed mutagenesis indicated 
several amino acid residues in the TMDs of SV2A, to be potentially involved in the interaction 
with racetams. Despite several approaches, however, the LEV binding site within SV2A has 
remained elusive. However, its identification and characterization may lead to the design of 
improved SV2A-binding drugs. Moreover, it will help to understand the unique mode of action 
of LEV. The third long intracellular cytoplasmic loop (ICL3) of SV2A contains an ATP 
binding site, which may have a functional role and potentially be modulated by interactions 
with small molecules. The point mutation R383Q, which is located in the ICL3 of human 
SV2A, has been described in a patient as a candidate point mutation responsible for intractable 
epilepsy and LEV non-responsiveness. The rationale of the current study was to investigate 
the interaction of racetams (LEV and BRV) and two newly identified SV2A ligands (CBD and 
the synthetic cannabinoid JWH-031) with the SV2A variants using radioligand binding assays 
with [3H]BRV. In this study, concentration-dependent inhibition of specific [3H]BRV binding 
on wt SV2A and SV2A-R383Q by LEV, BRV, JWH-031 and CBD was determined. While 
LEV and BRV displayed no significantly altered binding on the SV2A-R383Q mutant, 
statistically significant differences in IC50 values of JWH-031 (9-fold rightward shift) and CBD 
(28-fold rightward shift) were observed. The ICL3 of SV2A contains several non-conserved 
SV2A-specific amino acid residues. To investigate a potential role of the ICL3 for the binding 
of LEV/BRV, chimeric proteins were constructed: chimeric SV2A containing the ICL3 of 
SV2B (SV2A-SV2B-ICL3) and chimeric SV2B containing the ICL3 of SV2A (SV2B-SV2A-
ICL3). It should be noted that LEV/BRV do not bind to SV2B. Similar to the previously 
reported exon 5 and/or 6 deletion mutants of SV2A, specific [3H]BRV binding was completely 
abolished in both chimeric proteins.38 The current data suggest a possible involvement of the 
ICL3 of SV2A in addition to other TMD residues reported previously in the binding of LEV 
and BRV.  
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3 Screening assay for connexin 43 (Cx43) gap junctions 
3.1 Introduction  
3.1.1 Gap junction channels  
Gap Junction (GJ) channels between two adjacent cells are formed by the head-to-head 
docking of hemichannels (Connexons). Undocked hemichannels (HCs) are also 
physiologically relevant and mediate the release of small molecules like prostaglandins, NAD+, 
ATP, neurotransmitters like glutamate in an autocrine and/or paracrine fashion. However, the 
effect of HCs is less pronounced than that of GJs under normal physiological conditions.185 A 
single connexon is formed by hexameric assembly of structural protein subunits called 
connexins (Cxs).186 Cxs are a class of integral membrane proteins, comprising four-
transmembrane domains (TMDs), two extracellular loops (ELs), one cytoplasmic loop (CL), 
and cytosolic C- and N-termini (see Figure 29). 
 Cxs constitute a multigene family whose members are distinguished based on their molecular 
weight. In humans, 21 Cx types have been identified and more than one Cx types can be found 
on the same cell.185-186 Oligomerization of six Cxs to form a single connexon can either be 
heteromeric or homomeric. Furthermore, docking of two connexons to form intercellular 
channel may also result in either homotypic or heterotypic, or combined 
heterotypic/heteromeric arrangements of GJs.84, 187 Among all Cxs in humans, Cx43 is the most 
abundantly and widely expressed Cx type with its presence in many tissues and cell types.86 
Cx43 and Cx30 are exclusively expressed in astroglial cells and are not found in other brain 
cell populations.85 
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Figure 29: Topology model of the human connexin 43 (Cx43) protein. The transmembrane domains are predicted 
using the HMMTOP software and the snake plot diagram is prepared by using the TOPO2 program.80-81 The 
transmembrane domains, extracellular loops and cytoplasmic loop have been indicated with their respective 
abbreviations. Hemichannels (connexons) are formed by the hexameric oligomerization of Cxs and the adjoining 
of two connexons on the neighboring cells give rise to GJ channels spanning the plasma membranes of two cells. 
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3.1.2 Synthesis and degradation of Cx43 GJs 
Like other integral membrane proteins, Cx43 follows the secretory pathway from the ER 
through the Golgi apparatus. The half-life of Cx43 is rather short as compared to many other 
proteins and ranges between 1 and 5 h. The Cx43 mRNA is transcribed from the GJ alpha-1 
gene (GJA1) located on chromosome 6 in humans.188 The nascent Cx43 protein, P0 (42 kDa) 
matures by undergoing several phosphorylation steps to produce isoforms with lower 
electrophoretic mobilities on SDS-PAGE, i.e. P1 (44 kDa) phosphorylated at Ser365 and P2 (46 
kDa) phosphorylated at Ser325/Ser328/Ser330.86, 186 As a next step, oligomerization of Cx43 into 
a hexameric connexon takes place in the trans-Golgi network. Following the secretory 
pathway, connexons are trafficked within vesicles to the plasma membrane to become a part 
of the GJ plaque (see Figure 30). Eventually, calcium-dependent cell adhesion molecules 
cadherins (L, A, and N) and cadherin-associated intracellular protein α-catenin facilitate the 
head-on docking of two connexons of neighboring cells to form functional GJs. It is 
noteworthy to mention another important Cx43 interaction protein zona occludens-1 (ZO-1) 
of around 220 kDa, a scaffolding protein facilitating the assembly of multi-protein complexes 
at the plasma membrane. It has been demonstrated that the hydrophobic C-terminus of Cx43 
specifically fits in the hydrophobic cleft of ZO-1. Fusion of a GFP tag at the C-terminus of 
Cx43 resulted in GJ plaques of unusually large size. The significance of ZO-1 for GJ at various 
stages from assembly to degradation is widely accepted, however its exact mechanism of 
action is yet to be clarified.189  
Once GJs are formed, they are not separable into hemichannels under physiological conditions 
and are internalized by either of the cell as a double-membrane vesicle known as annular 
junction or connexosome for lysosomal degradation. Presumably the misfolded Cx proteins 
from the ER/Golgi apparatus undergo proteasomal degradation, whereas GJs from the plasma 
membrane follow lysosomal degradation (see Figure 30). It has been shown that a tyrosine-
based sorting signal in the C-terminus initiates the invagination of Cx43 GJs for lysosomal 
degradation.190 In general cellular proteins doomed to undergo proteasomal degradation are 
marked by polyubiquitination, which is recognized by proteasomes. Polyubiquitination in 
Cx43 has been already demonstrated and it is considered to be the main pathway of Cx43 
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degradation.191 However, it is still under debate which of the two mechanisms of Cx43 
degradation, is the major one.186 
 Figure 30: Life cycle of Cx43 GJs. (1) The Cx43 protein is synthesized by endoplasmic reticulum (ER) bound 
ribosomes and co-translationally inserted in the ER. (2) Upon reaching the Golgi apparatus six Cx43 molecules 
oligomerize into connexons (hemichannels) which are transported in vesicles to the plasma membrane to the 
periphery of preexisting GJ plaques. (3) Any misfolded proteins are degraded by proteasomes. (4) The older GJs 
are either degraded by internalization as double-membrane structure “annular junction” and their fusion with 
lysosomes or (5) by proteasomes if polyubiquitinated. (6) New connexons from the periphery replace the older 
GJs. Subsequently, new functional GJs capable of intercellular exchange of small molecules (< 1000 Da) are 
formed by the head-to-head docking of connexons from the neighboring cells. Figure taken and modified from 
Naus et al. 2010.192 
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3.1.3 Phosphorylation mediated regulation of Cx43 GJs 
GJ turnover, assembly, and size in cells dynamically changes depending on the 
phosphorylation pattern at specific sites within Cxs.193 Since Cx43 is the most abundantly 
expressed one, phosphorylation-mediated regulation of Cx43 is well researched. Gap 
junctional communication (GJIC) is controlled in response to various extracellular cues such 
as growth factors, neurotransmitters, and cytokines. These molecules act as the activators of 
downstream kinases, which upon activation phosphorylates Cx43 at specific sites leading to 
channel closure and opening. The long cytosolic C-terminal domain in Cx43 is the major site 
of phosphorylation, however with exception some Cxs such as Cx36 and Cx56 can be 
phosphorylated within cytoplasmic loops.86  
A total of 19 phosphorylation sites have been identified within Cx43. Early phosphorylation 
occurs in the ER and Golgi apparatus which may facilitate the transport of Cx43 to the plasma 
membrane, and initial phosphorylation at membrane can occur within 15 min of Cx43 
connexon synthesis.193 Activation of cAMP dependent protein kinase A (PKA) promotes Cx43 
synthesis, export to the plasma membrane, and enhances the GJ assembly.194 It is well 
established that increased cAMP concentration leads to phosphorylation of Ser364 and Ser365 at 
the C-terminus with substantial increase in the export of Cx43 to the GJ plaques.86 
Phosphorylation of Cx43 at the sites Ser325, Ser328, and/or Ser330 by casein kinase 1 (CK1) has 
been shown to promote GJ assembly at the plasma membrane.193 Activated protein kinase C 
(PKC) phosphorylates Ser368 at the C-terminus resulting in the down-regulation of the Cx43 
expression and impairment of GJ assembly. Similarly, activation of Src kinases negatively 
regulates the GJ communication by phosphorylating Cx43 via Src, MAPK and PKC at the sites 
Tyr247, Tyr265, Ser262, Ser279, Ser282 and Ser368. Additionally, activation of Src decreases the 
PKA-mediated phosphorylation at Ser364 and Ser365.193 Both, cGMP dependent protein kinase 
(PKG) and PKC are reported to exert similar effects on Cx43.194 
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3.1.4 Pharmacological relevance of GJs 
More than ten distinct human diseases have been linked to germline mutations of Cx family 
members.193 For instance mutations in Cx26 result in Keratitis-ichthyosis-deafness and 
mutations in Cx32 causes an X-linked Charcot-Marie-Tooth disease.195 Other Cxs are also 
linked to diseases, however the current project focuses on Cx43, the predominant GJ protein 
found in astrocytes.  
Mutations in Cx43 are linked to the disease ODDD (Oculodentodigital Dysplasia) 
characterized by developmental abnormalities, and total disruption of this gene causes cardiac 
arrhythmias.195 Changes in the expression levels of Cx43 has been reported for some 
neurological disorders in humans such as epilepsy, depression, and brain metastasis, implying 
its crucial role in the etiologies of these diseases.48, 85, 87 It has been demonstrated that Cx43 
knockout mice died shortly after birth. Moreover, mouse models with a truncated Cx43 at the 
C-terminus exhibited rigid, easy-to-peel skin with mislocalized Cx43 GJs, which also resulted 
in the death of animals soon after birth.193  
Pharmacological modulators of GJ channels are therefore considered to have promising 
therapeutic potentials. For instance, naturally occurring antiarrhythmic peptide AAP10 exerts 
its effects by enhancing Cx43 and Cx45 GJs activities.196 The active non-peptide derivative of 
AAP10, GAP134 reduces post-operative atrial fibrillation. Another synthetic peptide, Gap26, 
protects the heart from ischemic injury by specifically blocking Cx43 hemichannel activity.195 
Tonabersat, a GJ inhibitor is suggested to be beneficial against cortical spreading depression 
and could be a potential remedy against migraine.197 Some of the important Cx43 GJ 
modulators with their effects on GJ activity are listed in Table 8.   
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Table 8: Cx43 gap junction modulators (adapted and modified from Jeanson et al., 2015).85 
Compound Cx43 expression 
Cx43 GJ 
coupling Test model 
Treatment 
conditions References 
Antidepressants  
Amitriptyline ↑ 
n.e. 
↑ 
↓ 
Primary rat astrocytes culture 
Primary mouse astrocytes culture 
25 µM, 48 h 
20 µM, 24 h 
Marioka et al., 2014198 
Jeanson et al., 201585 
Clomipramine  ↑ n.d. Primary rat astrocytes culture 10 µM, 48 h Marioka et al., 2014198 
Fluoxetine  ↑ 
↑ 
↑ 
n.e. 
↓ 
n.d. 
n.d. 
ne 
↓ 
↓ 
Rat prefrontal cortex (in vivo)  
Native human Astrocytoma cell line 
Rat prefrontal cortex (in vivo) 
Primary mouse astrocytes culture 
Mouse hippocampus (in vivo) 
64 µM, 21 days 
32.5 - 65 µM, 24 h 
32 µM, 21 days   
10 µM, 24 h 
52 µM, 30 days 
Fatemi et al., 2008199 
Mostafavi et al., 2014200 
Sun et al., 2012201 
Jeanson et al., 201585 
Quesseveur et al., 2015202 
Duloxetine ↑ 
n.e. 
n.e. 
n.e. 
Rat prefrontal cortex (in vivo) 
Primary mouse astrocytes culture 
34 µM, 21 days 
5 µM, 24 h 
Sun et al., 2012201 
Jeanson et al., 201585 
Fluvoxamine ↑ n.d. Primary rat astrocytes culture 25 µM, 48 h Marioka et al., 2014198 
Imipramine n.e. n.e. Primary mouse astrocytes culture 20 µM, 24 h 
Jeanson et al., 201585 Paroxetine n.e. ↑ Primary mouse astrocytes culture 5 µM, 24 h Reboxetine n.e. n.e. Primary mouse astrocytes culture 10 µM, 24 h 
Venlafaxine n.e. ↓ Primary mouse astrocytes culture 5 µM, 24 h 
Tonabersat  n.d. ↓ Primary human astrocytes culture 200 µM, 12 h Chen et al., 201687 
      
Anesthetics      
Propofol n.d. ↓ Mouse acute cortical slices (in situ) 150 µM, 30 min  
Liu et al., 2015203 Ketamine n.d. Weak ↓ Mouse acute cortical slices (in situ) 300 µM, 30 min 
Dexmedetomidine n.d. Weak ↓ Mouse acute cortical slices (in situ) 10 µM, 30 min 
      
Antiarrhythmic      
Gap26 n.d. ↓ Mouse  acute cortical slices (in situ) 200 µM, 90 min Liu et al., 2015203 
Flecainide n.d. n.d. 
↓ (Cx30) 
↓  
Mouse acute cortical slices (in situ) 
Cx43 transfected RIN cell line 
500 µM, 2 h  
100 µM*, 3 h Duchene et al., 2016204 
Rotigaptide 
(ZP123) n.e. 
↑ HL-1 atrial cardiomyocytes culture 
Rat neonatal cardiomyocytes culture 
Cx43 transfected HeLa cell line  
0.05 µM, 5 h  Clarke et al., 2006288 
      
Analgesics  
Meclofenamate n.d. 
n.d. 
↓  
↓ 
Cx43 transfected RIN cell line 
Primary human astrocytes culture 
50 µM*, 3 h 
100 µM, 12 h 
Duchene et al., 2016204 
Chen et al., 201687 
Psychotropics       
Modafinil  n.d. ↑ (Cx30) Mouse acute cortical slices (in situ) 200 µM, 2 h Duchene et al., 2016204 
      
Antiepileptics      
Levetiracetam  ↑ ↑ Primary rat astrocytes culture 300 µM, 24 h  Haghikia et al., 200898 
      
Macromolecules      
LPS ↓ ↓ Mouse  acute cortical slices (in situ) 1 µg/ml, 3 - 4.5 h  Bedner et al., 201548 IL-1β n.d. ↓ Mouse  acute cortical slices (in situ) 10 ng/ml, 3 - 4.5 h 
      
Glycyrrhetinic acid derivatives    
18α-GA n.d. ↓ Cx43 transfected HeLa cell line  17 µM*, Instantly Haq et al., 2013195 
18β-GA  ↓ ↓ Native WB-F344 rat liver cell line  40 µM, 1 - 4 h Guan et al., 1996205 
Carbenoxolone  n.d. ↓ Native LN215 cell line  2.1 µM*, 10 min  Lee et al., 2015206 
      
cAMP analog        
db-cAMP n.d. ↑ Mouse  acute cortical slices (in situ) 100 µM, 3 - 4.5 h Bedner et al., 201548 
      
Quinoline derivative     
PQ1 ↑  ↑ 
Mouse mammary carcinoma cell 
line  
5 µM, 24 h 
1 µM, 2 h Shishido et al., 2016289 
↑, increase; ↓, decrease; n.e., no effect; n.d., no data; *IC50, half maximal inhibitory concentration; RIN, rat insulinoma; IL-1β, Interleukin-1β; 
LPS, lipopolysaccharide; 18α-GA, 18α-glycyrrhetinic acid; 18β-GA, 18β-glycyrrhetinic acid; db-cAMP, Dibutyryl-cyclic AMP. 
3 Screening assay for connexin 43 gap junctions 
78 
3.1.5 Interaction of levetiracetam with Cx43 GJs 
In the past, a dysfunction of neurons was considered to be involved in the pathogenesis of 
epilepsy. In the development of novel antiepileptic drugs (AEDs) the focus was therefore on 
compounds affecting neuronal functions. However, the recognition of glial cells as active 
communication partners in the CNS has raised the question of their putative role in the 
pathogenesis of epilepsy. Glial cells, in particular astrocytes have multiple functions, e.g. 
metabolic support of neurons, and maintenance of extracellular K+ ions and neurotransmitter 
homeostasis. These functions can be properly performed when the astrocytic syncytium is 
intact through GJ proteins. Functional GJ coupling in astrocytes is constituted predominantly 
by Cx43 and Cx30. A clinically effective and well established AED, LEV (294 µM) 
successfully restored functional GJ coupling and impaired resting membrane potentials in an 
in vitro astrocytic inflammatory model.98 Moreover, in the same model LEV treatment rescued 
inflammation-mediated disruption of gap junctional coupling to the same functional levels as 
the antiinflammatory cytokine transforming growth factor β1 (TGFβ1).99 
More recently, it has been recognized that the surviving glial cells in the hippocampi of patients 
with mesial temporal lobe epilepsy (MTLE) have a major loss of GJ coupling. Additionally, 
by implementing a mouse model of MTLE and hippocampal sclerosis (MTLE-HS), it has been 
shown that astrocytic uncoupling leads to neuronal death and hyperactivity, thus supporting 
the strong role of GJ uncoupling in epileptogenesis. In mice, the lipopolysaccharide-induced 
(5 mg/kg) inhibition of coupling was reversed to normal coupling upon i.p. administration of 
LEV (882 µM) for 5 days (first LEV injection 6 h post LPS).48 
Cumulatively, taken into consideration the above presented results, it is tempting to speculate 
that there might be a direct effect of LEV on Cx43, which restores the uncoupled GJs in 
astrocytes. One possibility is the presence of a LEV binding site on Cx43 protein. To answer 
this question, we investigated the binding of [3H]BRV, a 10-fold more active analogue of LEV, 
at Cx43 protein using radioligand binding assay. The results of these studies will give us a 
better understanding of mechanism of action of LEV on the restoration of uncoupled GJs in 
astrocytes.   
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3.1.6 GJ functional assays  
Until recently, no high-throughput screening (HTS) assays were established to identify 
modulators of GJs. The majority of the techniques established to assess the GJIC are either 
based on measuring cell-to-cell dye transfer, electrical conductance, or metabolic 
interdependence. The dye transfer experiments make use of non-toxic tracers (<1 kDa) which 
on their own shall be ideally impermeable across the non-junctional membranes or upon 
entering into the cells acquire charge and become trapped inside the cell.82 Lucifer yellow (LY) 
is a fluorescent dye with a molecular weight of 443 Da and is extensively employed in 
microinjection,207 scrape loading,208 and electroporation209 techniques for investigating GJ 
activities.82 Another tracer is calcein-acetoxymethyl ester (calcein-AM) which is non-
fluorescent and cell-permeable, however once inside the cell the acetomethoxy group is 
cleaved by cytoplasmic esterases resulting in highly fluorescent, hydrophilic, and membrane 
impermeable free calcein. This fluorescent tracer is used in techniques such as fluorescence 
recovery after photobleaching (gap-FRAP) and preloading assays with flow cytometry 
(FC).210-211 Other techniques to study coupling in individual cell pairs include local activation 
of molecular fluorescence probe (LAMP) imaging assays using photocaged fluorescent dyes, 
and the dual whole-cell patch clamp conductance measurement method.212-213 Despite the 
diverse applicability of all aforementioned techniques in investigating GJs, none of them is 
well suited for screening compound libraries for GJ modulators. These methods have certain 
constraints in terms of applicability in screening assays such as i) only limited numbers of cells 
can be analyzed, ii) requirement of special equipment or expertise, and iii) time-consuming 
experimental set-up.82  
The first HTS assay for Cx43 GJ modulators based on real-time detection of intercellular Ca2+ 
transport was designed and established by Haq et al. (2013) from GlaxoSmithKline.195 This 
assay system used HeLa donor cells and recipient cells. Donor cells co-expressed Cx43 and a 
Gq protein-coupled α1A adrenergic receptor or TrpVI ion channel, whereas recipient cells co-
expressed Cx43 and Ca2+-sensitive codon-optimized cytoplasmic aequorin (cytoAeq) protein. 
Both donor and recipient cells were co-cultured to allow formation of Cx43 GJs. Activation of 
α1AR by epinephrine or in case of TrpVI ion channel by capsaicin led to an increase in 
intracellular Ca2+ ions in the donor cells which diffused into the recipient cells via Cx43 GJs. 
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The cytoAeq protein detects the free calcium producing a luminescence readout.195 Although 
the assay has been excellently executed in 40 s for single-point measurement, it is noteworthy 
that Ca2+ activates PKC-mediated phosphorylation of Cxs, which impairs the Cx43 GJ 
channels.194 It is well established that increased intracellular Ca2+ binds to calmodulin (CaM), 
which directly inhibits the Cx43 GJs within seconds (30-90 s).214-215 Furthermore, alone 
intracellular Ca2+ overload can close GJ, however it is not well understood whether Ca2+ ions 
directly bind to GJs and close them. 194 The authors of this method have also proposed the 
development of an alternative assay using other second messengers like cAMP and cGMP.    
Another HTS assay was reported for modulators of Cx43 GJs by Lee et al., (2015).206 For this 
assay system LN215 glioma cells with endogenous Cx43 expression were used for establishing 
donor and acceptor cells. Donor cells were engineered to express the iodide transporter (solute 
carrier family 26 anion exchanger member 4, SLC2A4) and acceptor cells to express the iodide 
ion-sensing yellow fluorescent protein H148Q/I152L (YFPQL). The donor and acceptor cells 
were co-cultured to allow GJ formation and when iodide was added to the co-culture, the iodide 
ions which are otherwise cell membrane impermeable entered through SLC2A4 transporters 
into the donor cells, diffused via GJs to the acceptor cells and quenched fluorescent YFPQL. In 
the absence of SLC2A4 in donor cells or the presence of Cx43 GJ inhibitors, the fluorescence 
of YFPQL was not quenched.206 Despite the low cost of this method, maximum fluorescence 
quenching of around 45% has been shown for a control co-culture. The small signal window 
of this method may pose a challenge to identify hits in screening campaigns, especially for GJ 
inhibitors that are not highly potent. Additionally, this assay system requires a cell line which 
is impermeable to iodide ions.  
In addition to these assays some other Cx43 GJ HTS assays have also been reported, however 
they are based on sophisticated experimental setups requiring high expertise such as automated 
fluorescence microscopy imaging,216 automated incuCyte imaging,217 and microfluidic 
method.218   
Taking into consideration the limitations of the aforementioned Cx43 GJ HTS assays, the 
current project focuses on the development of a relatively simple and new GJ HTS assay for a 
96-well format based on intracellular cAMP detection.  
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3.2 Development of Cx43 GJ assay  
3.2.1 Evaluation of levetiracetam binding to Cx43 protein  
It had been shown that LEV successfully restored the functional coupling in inflammation-
induced uncoupled Cx43 GJs in astrocytes.48 To investigate whether LEV exerts these effects 
by directly binding to Cx43 GJs, two stable CHO cell lines expressing human and mouse Cx43 
respectively, were established using the mCherry lentiviral expression system.219-220 Since 
mCherry is a red fluorescent protein, this characteristic allowed the selection of strongly 
fluorescent monoclones by fluorescence-assisted cell sorting (FACS) to ensure high and stable 
Cx43 expression.  
Using homogenates of the cells expressing Cx43 protein, radioligand binding assays with 
[3H]BRV (5 nM) was performed. To validate the assay, homogenate of SV2A expressing cells 
were incubated and treated in parallel under the same assay conditions. Non-specific binding 
of the radioligand was determined in the presence of a high concentration of LEV (1 mM). As 
shown in Figure 31 total binding in counts per minute (cpm) of radioligand to SV2A containing 
cell homogenate (positive control) is around 6-fold higher than non-specific binding (negative 
control). The screening window between the positive and negative controls is well separated 
which confirms the successful execution of the assay. However, no specific binding (difference 
of total and non-specific binding) of the radioligand could be observed either with mCx43 or 
with hCx43 proteins. More importantly, non-specific binding of the radioligand for all different 
protein samples including homogenate of SV2A expressing cells displayed similar cpm values 
signifying assay uniformity. Similar results were obtained when assays were performed with 
higher concentration (15 nM) of the radioligands [3H]BRV and [3H]LEV (preliminary data).  
FACS-picked monoclones were used to prepare homogenates to ensure high expression of 
Cx43. However, they resulted in a similar expression level of Cx43 as for that of nontransfected 
CHO cells, which is also relatively high (see Section 3.2.2). One reason could be the absence 
of a resistance (selection) marker in the mCherry system, which may allow non-transfected 
cells to outnumber transfected cells in culture. These results in general indicate that Cx43 might 
not possess a direct high-affinity LEV binding site, and LEV may act on Cx43 through another 
mechanism of action. However, it cannot be excluded that the affinity of LEV/BRV and the 
3 Screening assay for connexin 43 gap junctions 
82 
expression level of Cx43 are too low to demonstrate specific binding in a radioligand binding 
assay.     
 
Figure 31: Evaluation of [3H]BRV binding to recombinant human and mouse Cx43 expressed in CHO cells using 
radioligand binding assays. Cellular homogenate (200 µg of protein) of each cell line per vial was incubated with 
[3H]BRV (5 nM) for 240 min at 4°C. Non-specific binding was determined in the presence of unlabeled LEV (1 
mM) and total binding was determined in the absence of LEV. Data are means ± SEM of at least three individual 
experiments performed in duplicate.  
 
3.2.2 Cx43 expression in cell lines  
Cx43 is the most widely expressed and predominant GJ protein found in almost all mammalian 
cell types with the exception of brain cell populations, where it is exclusively expressed in 
astrocytes.85 This wide expression pattern of Cx43 makes it difficult to find a mammalian cell 
line for experiments where low to no expression of Cx43 is desired. In this context, human 
cervix carcinoma (HeLa) cell line is the first choice when it comes to investigate GJs, since 
HeLa cells are known to be communication deficient.221 Western blotting was performed to 
investigate the endogenous and/or heterologous Cx43 expression levels in CHO, astrocytoma 
1321N1, and HeLa cell line. As shown in Figure 32A, non-transfected CHO cells show 
endogenous expression of Cx43, which is comparable to that of the stably transfected CHO 
cells, expressing mouse or human Cx43, respectively. One explanation for the similar 
expression levels is the use of mCherry system,220 which lacks a resistance marker for selection 
in culture. This might result in the outgrowth of the non-transfected CHO cells in culture. On 
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the other hand as expected non-transfected astrocytoma cells showed much high endogenous 
expression compared to CHO cells. In contrast to CHO and astrocytoma cell lines, non-
transfected HeLa cell line showed much lower endogenous expression of Cx43, which was 
improve in HeLa cells transiently transfected with mCx43 (see Figure 32B). Low expression 
of Cx43 in non-transfected HeLa cell line is in agreement as reported earlier.221 Overall these 
results suggest that among CHO, astrocytoma, and HeLa cell line, the latter exhibits the lowest 
Cx43 expression and is well suited for experiments where the lowest possible background of 
Cx43 GJs is desired. Based on these findings and previous reports, HeLa cells were selected 
for the development of a new functional Cx43 GJ assay.     
 
Figure 32: Expression profiling of Cx43 in wild-type and Cx43-transfected cell lines. (A) Western blot analysis 
of heterologous expression of human and mouse Cx43 in stable CHO cell lines and endogenous expression of 
Cx43 in native CHO and astrocytoma cell lines. For the analyses 30 µg of each protein sample per well was 
loaded onto SDS-gel. (B) Western blot analysis of endogenous Cx43 expression in native HeLa cell line and 
heterologous expression of mouse Cx43 in HeLa cells post 48 h transient transfection. Cells were lysed using 
radioimmunoprecipitation assay (RIPA) buffer, cleared by centrifugation, and the supernatants were subsequently 
used for analysis. The Cx43 protein bands were detected using primary polyclonal rabbit anti-Cx43 antibodies 
(1:2500) and secondary horseradish peroxidase (HRP) conjugated anti-rabbit antibodies (1:4000). The 
chemoluminescence from nitrocellulose blots was captured on X-ray films which were developed in fixing 
solutions.  
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3.2.3 Strategies for developing a new Cx43 GJ screening assay 
Despite the established pharmacological relevance as a potential druggable target, only few 
moderately selective and potent modulators of Cx43 GJ (see Table 8) are available which may 
be due to difficulties in developing suitable HTS assays. In order to establish a new assay 
system to screen modulators of Cx43 GJ, several strategies were taken into consideration. Of 
these only the following ones were subsequently executed and evaluated in the lab.  
3.2.3.1 Cx43 GJ assay using Renilla luciferase 
HeLa cells were constructed as biosensor cells that exogenously co-express mouse Cx43 and 
Renilla luciferase8 (R. luc8). On the other hand HeLa cells were created as donor cells that 
express only mCx43 and were loaded with the substrate of R. luc8 coelenterazine. The enzyme 
R. luc8 catalyzes the mono-oxygenation of coelenterazine to coelenteramide yielding 
luminescence. Most of the commercially available preparations of coelenterazine and its 
analogs designed for high intensity luminescence such as coelenterazine-h require cell lysis to 
be used with recombinant R. luc8. The availability of R. luc8 substrates for intact living cells 
is however limited, therefore a protected form of coelenterazine-h (EnduRen™ Live Cell 
Substrate, Promega) was used in this study. In the EnduRen™ substrate, the active site of 
oxygenation within coelenterazine-h is protected by esters which is available for R. luc8 only 
when the protecting groups are cleaved by esterases inside the living cells and no luminescence 
is produced in dead or lysed cells.222 Other advantages of EnduRen™ substrate over native 
coelenterazine-h included a reduced rate of degradation, high signal-to-background ratios, and 
a luminescence signal measurable for at least 24 hours. The strategy behind using EnduRen™ 
was that upon loading of the donor cells with EnduRen™ substrate, hydrolysis of esters will 
increase retention of the active substrate coelenterazine-h in the donor cells, which can then be 
transported to the R. luc8 containing biosensor cells via Cx43 GJs producing a luminescence 
signal. The intensity of the luminescence signal will be associated with GJ formation. 
Typically a ratio of three donor cells to one recipient cell is recommended for the assessment 
of coupling using nonfluorescent fluorogenic esters.223 Once inside the cell, the ester groups 
are cleaved by cellular esterases making this compound fluorescent. In these experiments 
fluorogenic ester-loaded donor cells were co-cultured with unloaded recipient cells, which 
have labeled cell membranes with a lipophilic dye such as dialkylcarbocyanine (Di-l), for 15 
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min to 24 h dependent on the type of cell and assay. The coupling of donor and recipient cells 
is then analyzed by fluorescence microscopy.223  
Preliminary experiments performed with biosensor cells (40,000 cells/well in a 96-well plate) 
and 15 µM EnduRen™ substrate produced a good luminescence signal. For the Cx43 GJ assay 
both cell types were mixed and co-cultured in a ratio of two donor cells (80,000 cells/well) to 
one biosensor cell (40,000 cells/well) in a 96-well plate for 3 h at 37°C to allow the formation 
of GJs. It was observed that exceeding a total number of 120,000 cells/well resulted in floating 
cell clumps and poor adherence to the well surface. That is why the ratio of donor cells in co-
culture was reduced from 3 to 2 cells. The duration of 3 h has was previously demonstrated to 
be optimal for the Cx43 GJs formation in HeLa cells.195  
The luminescence signal obtained from the co-culture of donor and biosensor cells was found 
to be not significantly different to that of the control co-culture of donor and biosensor cells 
not transfected with Cx43 protein (preliminary data). One reason of this outcome was the poor 
retention of the EnduRen™ substrate within the cells, since after hydrolysis of the ester it is 
still uncharged and therefore can still move across the cell membrane based on the 
concentration gradient. Thus the substrate may have directly permeated from the medium into 
the control biosensor cells independent of Cx43 GJs, which resulted in a poorly distinguishable 
luminescence window between Cx43 transfected and non-transfected co-cultures.  
Based on these results it was hypothesized that using another fluorogenic acetoxymethyl ester 
designed for cell loading may fulfill the criteria for developing the Cx43 GJ assay. To evaluate 
this hypothesis, two acetoxymethyl esters (AMs) of Ca2+-sensing dyes namely Fluo-4 
(ThermoFischer Scientific) and Calcium-5 (Molecular Devices) were selected. After their 
hydrolysis by cellular esterases both AM dyes are negatively charged and become highly polar, 
which prevents them from exiting the cells. These dyes are frequently used by our group in 
HTS assays to measure intracellular Ca2+ concentration inside living cells in response to 
activation of Gq protein-coupled receptors.  
In the preliminary experiments to test the duration of dye retention inside the cells, the 
astrocytoma 1321N1 cell line that expressed Gq protein-coupled P2Y2-receptor already 
existing in our group was used. Cells were loaded with each dye followed by incubation for 1 
h, 2 h, and 3 h at 37°C. Cells incubated for 1 h produced the highest fluorescent signal for both 
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dyes upon stimulating the P2Y2-receptor with UTP (1 µM). However, the fluorescence signal 
for the dye-loaded cells incubated for 2 h and 3 h reduced to control levels (preliminary data). 
The retention of AM dyes inside the cells for a maximum of about one hour is much shorter 
than the duration of 3 h required for the formation of Cx43 GJs. Moreover, the AM dyes can 
be actively exported out of cells by multidrug resistance proteins.224 These findings indicated 
that AM dyes may not be a suitable choice for developing the Cx43 GJ screening assay.   
3.2.3.2 Cx43 GJ assay using cAMP-sensing luciferase 
This assay system employed HeLa cells which were engineered to co-express the human 
adenosine receptor (A2AAR) and the mouse Cx43 in donor cells, and the cAMP-sensing 
GloSensor luciferase (GSL) and Cx43 in biosensor cells. Activation of A2AAR by its selective 
agonist (CGS21680) generated intracellular cAMP in the donor cells which then diffused via 
Cx43 GJs to the biosensor cells activating GSL, and eventually producing a luminescence 
signal, that can be quantified. Development of this assay is detailed in section 3.2.4.  
3.2.4 Cx43 GJ screening assay design  
Assays to investigate cell-to-cell transfer of the second messenger cAMP through Cx43 and 
Cx32 GJs have been previously reported.225-226 In these assays donor cells capable of 
generating cAMP via Gs protein-coupled receptor were co-cultured with biosensor cells 
harboring a cAMP-sensitive reporter – cAMP response element (CRE- luciferase reporter) – 
responding to cAMP by producing luminescence.225-226 These assays despite their usefulness 
require disruption of the cells to be able to measure the cAMP-dependent activity of the CRE- 
luciferase reporter and do not monitor cAMP transfer in real-time. This method is tedious, 
costly, and less suitable for screening larger compound libraries for GJ modulators.    
In the current project, a new strategy was developed to investigate the Cx43 GJs based on the 
transport of cAMP molecules from donor to biosensor cells. HeLa cells exogenously co-
expressing the human adenosine receptor (A2AAR) and the mouse Cx43 were designed as 
donor cells, while cells co-expressing GloSensor luciferase (GSL) and mCx43 were created as 
biosensor cells.  
The current assay design is based on the detection of (cAMP). It employs a genetically 
engineered firefly luciferase known as cAMP GloSensor-20F from Promega (GSL) which 
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allows real-time detection of intracellular cAMP (Figure 33A). Another variant of this protein 
GloSensor-22F (GSL-22F) from Promega has been previously demonstrated to be useful for 
monitoring endogenous Gs protein-coupled receptors-induced cAMP generation in primary 
cells and HEK-293 cells co-cultured with biosensor cells harboring GSL-22F.227 This assay 
system is primarily developed to monitor GPCR activity in primary cells indirectly through 
biosensor cells connected via GJs, since transfection of primary cells is less efficient. This 
assay is based on endogenous connexins of primary neurons and HEK-293 cells, 
predominantly Cx32, and it does not report the background against other connexin subtypes. 
Native firefly luciferase catalyzes the oxidation of its substrate luciferin in the presence of 
Mg2+, ATP and O2 to produce oxyluciferin, AMP, CO2 and luminescence signal (Figure 33B). 
GSL is a circularly permuted form of firefly luciferase where between native N- and C-
terminus, a conserved cAMP- binding domain B from PKA regulatory subunit type IIβ (RIIβB) 
is introduced. The binding of intracellular cAMP to GSL favors the functional conformation 
of luciferase which in turn metabolizes the luciferin containing cAMP GloSensor substrate 
(GSS) giving off yellow-green light.228 
 
Figure 33: Principle of cAMP detection using engineered GloSensor luciferase (GSL). (A) GSL in the open 
conformation shows negligible luminescence activity, whereas binding of cAMP to (RIIβB), the cAMP binding 
site within GSL, favors the closed conformation and hence activates the luciferase, which metabolizes luciferin 
to produce luminescence. (B) Luciferase catalyzes the oxygenation of luciferin using molecular oxygen and ATP 
in the presence of Mg2+ to produce oxyluciferin, which is highly unstable in electronically excited state and 
produces light upon falling back to its ground state. Figure taken and modified from Fan et al. (2008).228 
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According to the assay design the two cell populations will be co-cultured in a ratio of three 
donor cells to one biosensor cell for 4 h to allow the formation of GJs. The growth medium 
will then be replaced by the assay buffer supplemented with the luciferase substrate luciferin 
and the co-culture will be further incubated for 45 min in the dark at room temperature. 
Thereafter, stimulation of the A2AAR by its selective agonist CGS21680 in the donor cells will 
activate adenylate cyclase, which converts ATP to cAMP. Binding of cAMP to GSL favors its 
functional conformation allowing it to metabolize luciferin and producing luminescence (see 
Figure 34). The mobilization of generated cAMP from donor to biosensor cells will take place 
via the heterologously expressed mCx43 GJs and could be detected in real-time by the GSL 
reaction in the established system. To initially evaluate the feasibility of the current assay 
design two preliminary experiments were performed:  
i) Endogenous expression of adenosine receptors in HeLa cells: HeLa cells were selected 
for the development of a GJ assay due to low levels of endogenous Cx43 to maintain low 
background noise. In a preliminary study, the responses of endogenous Gs protein-coupled 
adenosine receptors, A2A and A2B, to non-selective and selective agonists in native HeLa cells 
were evaluated. HeLa cells were transiently transfected either with human A2AAR and GSL 
(HeLa-hA2A-GSL) or only with GSL (HeLa-GSL). HeLa-GSL produced a luminescence 
readout upon stimulation with forskolin (10 µM) that was used as an internal positive control. 
However, activation of HeLa-GSL with A2AAR selective agonist CGS21680 (100 µM) 
produced a luminescence signal similar to vehicle (DMSO, 1%). A relatively moderate signal 
with HeLa-GSL was obtained with 50 µM NECA, a compound that is known to non-
selectively activate A2A and A2B receptors. On the contrary, activation of HeLa-hA2A-GSL with 
either NECA (50 µM) or CGS21680 (100 µM) produced luminescence readouts even higher 
than those produced by forskolin (10 µM). These results indicated that generation of cAMP in 
HeLa-GSL cells in response to NECA can be primarily attributed to A2BARs, since activation 
by the A2AAR-selective agonist (CGS21680) did not generate detectable cAMP levels. In 
contrast, the high luminescence signal observed in HeLa-hA2A-GSL in response to CGS21680 
was primarily due to activation of overexpressed A2AAR and that induced by NECA was due 
to activation of both, overexpressed A2AAR and endogenous A2BAR receptors. 
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Based on this preliminary experiment, it was concluded that native HeLa cells do not or only 
weakly express A2AARs. It makes the A2AAR an excellent and selective cAMP generating tool 
using stimulation with the A2AAR-selective agonist (CGS21680) in HeLa cells against a nearly 
zero background. These results were in good agreement with the previously reported 
expression profile of A2A- and A2BARs in native HeLa cells, where A2BAR expression was 
found to be higher than that of A2AAR.229 
ii) Effect of co-expression of proteins on luminescence signal: Co-expression of two or more 
proteins in the same cell may result in the reduced expression levels of each protein due to high 
occupancy of the cellular translational machinery. In the currently designed assay, biosensor 
cells transiently co-express GSL and mCx43. A comparison was therefore made between the 
transiently transfected HeLa cells expressing only GSL with the cells co-expressing GSL and 
mCx43 for their luminescence activity. Forskolin (10 µM) mediated activation of singly 
transfected HeLa cells with GSL gave an about 2-fold increased luminescence readout 
compared to the doubly transfected HeLa cells with GSL and mCx43. Similar results were 
obtained upon activation of both cell types with either 50 µM NECA or 50 µM adenosine with 
a 2-fold higher luminescence in singly transfected HeLa-GSL cells. Activation of both cell 
types by CGS21680 (10 & 100 µM) did not elicit luminescence signal indicating no expression 
of functional hA2AARs in native HeLa cells.  
These preliminary results supported the concept that co-expression of Cx43 and GSL in HeLa 
cells appears to reduce the luminescence activity. Beside co-expression of proteins another 
reason could be that cAMP is released in the extracellular space through Cx43 hemichannels, 
since these channels are permeable to cAMP.230 However, luminescence readout in doubly 
transfected cells is still considerably above the basal luminescence, which indicates that the 
expressed amount of GSL is sufficient to detect changes in cellular cAMP levels.   
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Figure 34: Design of the Cx43 GJ assay. HeLa cells expressing hA2AAR and mCx43 are denoted as donor cells 
and HeLa cells expressing GSL and mCx43 are indicated as biosensor cells. Both cell lines are co-cultured in a 
ratio 3:1 of donor to biosensor cells for 4 h to allow the formation of Cx43 GJs. The coupled cells are then 
equilibrated with buffer containing the substrate (luciferin) of engineered luciferase. Upon activation of Gs-
coupled A2AARs, cAMP levels are elevated in the donor cells, cAMP molecules move to biosensor cells via Cx43 
GJs formed between donor and biosensor cells. Once inside the biosensor cells, cAMP binds to GSL causing a 
conformational shift activating GSL, which creates a luminescence signal by oxidizing luciferin.  
 
3.2.5 Optimization of cAMP detection in Cx43 GJ assay 
To investigate the GJ-mediated coupling, we next co-cultured the donor cells and biosensor 
cells in a ratio of three to one, and incubated then at 37°C for 4 h in full DMEM medium to 
allow the formation of GJs (see Section 6.8.2). Culture medium was then replaced by assay 
buffer containing the substrate of GSL without any phosphodiesterase (PDE) inhibitor and 
incubated the cells at room temperature for 2 h. Upon activation of the A2AAR in donor cells 
with CGS21680 (1 µM), a subtle luminescence signal above that of the vehicle (DMSO, 1%) 
was detected. However, the A2AAR-dependent luminescence signal was not sufficiently 
separable from the background to obtain a good assay window (see Figure 35).  
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Figure 35: GJ-mediated transfer of cAMP from donor cells to biosensor cells in the absence of PDE inhibitor. 
(A) Activation of A2AAR by the selective agonist CGS21680 in co-cultures produced a very small luminescence 
signal. Activation of adenylate cyclase by forskolin (10 µM) for cAMP generation represented an internal positive 
control and vehicle (DMSO, 1%) was used as a negative control. (B) Normalized representation of data. Data 
shown are means ± SEM of three individual experiments performed in duplicate.  
 
It has been described previously that the addition of the non-specific PDE inhibitor 3-isobutyl-
1-methylxanthine (IBMX) reduces the degradation of cAMP, allows cAMP accumulation and 
thereby enhances GSL activity.227 Therefore, co-cultures 4 h after incubation in full medium 
were transferred to incubation in assay buffer containing 200 µM IBMX for 45 min at room 
temperature in the dark. To monitor the intrinsic cAMP dependent luminescence activity in the 
biosensor cells, they were treated exactly like co-cultures in parallel experiments used as 
controls. Biosensor cells for control purpose were stimulated with either, i) 10 µM forskolin 
(positive control), ii) 1 µM CGS21680 (potential A2AAR background signal), iii) 1% DMSO 
(vehicle), and iv) assay buffer (luminescence background). As expected, only forskolin-
activated biosensor cells produced a high luminescence readout. Forskolin directly activates 
the adenylate cyclase resulting in the generation of cAMP. Biosensor cells treated with 
CGS21680, DMSO, or assay buffer, all produced similarly low background luminescence (see 
Figure 36A). The co-cultures were stimulated under the same conditions. Activation of co-
cultures with forskolin elicited almost the same luminescence signal as that displayed by the 
biosensor cells alone, indicating no effect of the co-culture on the viability of the biosensor 
cells. On the other hand, CGS21680 activated A2AARs in co-culture producing an increase in 
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the luminescence readout which was significantly different from that produced by the vehicle 
(DMSO, 1%) and that observed in cells with assay buffer only (Figure 36C). These results 
suggest that without IBMX, the transport of cAMP from donor cells to biosensor cells is 
difficult to detect with reliability, similar issue was reported earlier by Trehan et al. (2014).227  
The luminescence signal in response to A2AAR activation by CGS21680 in co-culture is around 
40% of the signal obtained in response to forskolin. The, increase in cAMP in response to 
forskolin is rapid and reaches the signal plateau much faster than the A2AAR-dependent cAMP 
signal (see Figure 36D). This difference might be due to the fact, that only a fraction of cAMP 
generated in donor cells is transported via Cx43 GJs to the biosensor cells, whereas cAMP in 
response to forskolin is generated within the biosensor cells in addition to the donor cells. 
Similarly, in the previously reported Cx43 GJ assay, the Ca2+-dependent luminescence signal 
decreased in co-cultured cells compared to the intrinsic Ca2+ signal from control cells 
expressing both, receptor and sensor protein.195  
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Figure 36: GJ-mediated transfer of cAMP from donor cells to biosensor cells in the presence of the PDE inhibitor 
IBMX. (A) Biosensor cells alone did not produce any luminescence in response to the A2AAR-selective agonist 
CGS21680 (1 µM). (B) Normalized representation of data obtained with biosensor cells. (C) Activation of 
hA2AARs in co-cultures by CGS21680 produced a strong luminescence signal. (D) Normalized representation of 
data obtained with co-cultures. Data are means ± SEM of at least three individual experiments performed in 
duplicate. 
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3.2.6 Cell-to-cell communication in native HeLa cells  
In order to verify that in the co-cultures, activation of GSL in the biosensor cells is entirely 
mediated by cAMP coming from the donor cells via Cx43 GJs, both, donor and biosensor cells, 
not transfected with mCx43 were studied. Donor cells (HeLa-hA2AAR) and biosensor cells 
(HeLa-GSL) lacking mCx43 protein were co-cultured in a ratio of 3:1. The same procedure 
was followed as explained previously for the mCx43 GJs assay. As shown in Figure 37A, 
biosensor cells alone produced luminescence only in response to forskolin (10 µM), whereas 
no luminescence was detected in response to DMSO (1%) or CGS21680 (1 µM). However, 
this time in the absence of GJ proteins, upon stimulation of the co-cultured cells with 
CGS21680 (1 µM) no increase in the luminescence signal above the basal luminescence level 
could be measured. In contrast, activation of co-cultured cells with forskolin (10 µM) still 
elicited a high luminescence readout indicating the activity of the biosensor cells. These results 
suggest that native HeLa cells are devoid of efficient cell-to-cell communication and therefore 
cAMP generated in the donor cells can only be transported via transfected GJ proteins to the 
biosensor cells yielding luminescence. These results are well in line with our Western blot 
findings, performed to analyze endogenous Cx43 expression in HeLa cells. Although in the 
blots low levels of endogenous Cx43 were found in HeLa cells these are apparently not capable 
of forming GJs or at least not at detectable levels.  
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Figure 37: Evaluation of GJ-mediated intercellular transport of cAMP from donor cells to biosensor cells in 
native HeLa cells not transfected with Cx43. (A) Biosensor cells produced luminescence only in response to 
forskolin (10 µM) used as a positive control and no luminescence in response to DMSO (1%) or A2AAR-selective 
agonist CGS21680 (1 µM) was measured. (B) Normalized representation of data obtained with biosensor cells. 
(C) Activation of co-cultures by forskolin (10 µM) produced luminescence, whereas no luminescence could be 
detected in response to CGS21680 (1 µM) or DMSO (1%). (D)  Normalized representation of data obtained from 
co-cultured cells. Data are means ± SEM of three individual experiments. 
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3.2.7 Inhibition of Cx43 GJs with carbenoxolone  
As another proof of concept that the activation of GSL by cAMP in our Cx43 GJ assay is 
entirely attributed to GJs, we analyzed concentration-dependent inhibition of GJ by a broad-
spectrum GJ inhibitor, carbenoxolone. The assay was exactly performed as explained earlier, 
except that after the replacement of full growth medium in the co-cultures by assay buffer, the 
GJ inhibitor carbenoxolone (CBX) was added followed by incubation for 45 min. To rule out 
that the inhibitor-mediated drop in the luminescence signal might not be Cx43 GJ-specific, 
biosensor cells were incubated with increasing concentrations of CBX under the same 
conditions.  
As illustrated in Figure 38A CBX up to 30 µM had minor effects on the luminescence readout 
as compared to control. Conversely, as further depicted in Figure 38C, treatment with CBX 
(30 µM) completely blocked the GJ-mediated cAMP transfer in co-cultures, leading to a drop 
in the luminescence signal to control level. Treatment with CBX (3 µM) and (10 µM) resulted 
in about 50% and 80% reduction in luminescence after 30 min, respectively. The inhibition of 
cAMP-dependent luminescence determined by CBX is thought to be GJ-specific. In order to 
simplify the visualization of CBX-mediated inhibition of GJs, the maximal luminescence 
signals at a specific time point (19 min) for all samples are plotted as a bar-diagram (Figure 
38B & 38D). These values were further used to draw an inhibition curve of CBX, resulting in 
an estimated IC50 value of 10.4 ± 6.60 µM (Figure 38E). This estimated IC50 value is in the 
same order of magnitude as the previously reported IC50 value of 2.1 µM determined by iodide-
sensing YFPQL assay.206 The herein calculated IC50 value of 10.4 µM is an estimation, a more 
precise value can be obtained by performing the assay using stably transfected cell lines and 
using a broader range of CBX concentrations. However, our results clearly indicate that the 
current assay should be suitable for the identification of Cx43 GJ modulators in compound 
library screening campaigns.  
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Figure 38: Concentration-dependent inhibition of Cx43 GJs by carbenoxolone (CBX). (A) Biosensor cells co-
expressing mCx43 and GSL were incubated with increasing concentrations of CBX together with assay buffer 
for 45 min prior to activation by forskolin (10 µM). Activation with Forskolin without inhibitor was taken as a 
positive control and incubation with 1% DMSO served as a negative control. (B) Concentration-dependent 
inhibition of maximal luminescence at a single time point after 19 min. (C) Co-cultured donor and biosensor cells 
(3:1) incubated with increasing concentrations of CBX together with assay buffer for 45 min prior to activation 
with CGS21680 (1 µM). Activation of co-cultures with CGS21680 represents the positive control and incubation 
with 1% DMSO served as a negative control. (D) Concentration-dependent inhibition of GJs by CBX at a single 
time point after 19 min. (E) Estimated IC50 value (10.4 ± 6.60 µM) of carbenoxolone at mCx43 GJs. Data are 
means ± SEM of two to three individual experiments.  
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3.2.8 Suitability as a HTS assay  
The ultimate goal of developing an HTS Cx43 GJ-assay was to efficiently and easily screen 
large compound libraries for Cx43 GJ modulators. We evaluated the suitability of the current 
assay by calculating the screening window coefficient known as Z´-factor. It is a dimensionless 
and statistical characteristic which provides valuable information that how good is the 
separation between positive and negative controls. The luminescence pre-readout of the co-
cultures was used as a negative control and the luminescence signal upon reaching a plateau 
after 19 min of stimulation with CGS21680 (1 µM) was taken as a positive control (see Figure 
39). The Z´-factor for the current assay was calculated to be 0.5 corresponding to an HTS assay 
of good quality.112 Thus, based on the evaluation of quality, the current assay can be 
implemented as an HTS platform.  
Previously reported HTS assay measuring Ca2+ propagations through Cx43 GJs determined a 
Z’ > 0.4.195 In that assay Ca2+ generated in donor cells (HeLa-α1A-Cx43) diffused via Cx43 
GJs into recipient cells (HeLa- aequorin-Cx43), where the free calcium sensing protein 
aequorin produced a luminescence signal. It is well established that increased intracellular Ca2+ 
concentration can close Cx43 GJs via two key mechanisms, i) PKC-mediated phosphorylation 
of Ser368, and ii) Ca2+  bound calmodulin (CaM)-mediated direct inhibition. Since the reported 
assay measured integrated luminescence for only 40 s after the agonist addition, it is less likely 
that PKC-mediated GJ closure occurs, which was measured between 6 and 15 min. However 
CaM-mediated GJ closure was observed within seconds (30-90 s) particularly in the presence 
of extracellular Ca2+ up to 5 mM.214-215 Furthermore, alone intracellular Ca2+ overload can close 
GJ, however it is not well understood whether Ca2+ ions directly bind to GJs and close them.194 
Thus an assay based on Ca2+ propagation to investigate Cx43 GJs may only reflect a partial 
number of open GJ channels. In contrast, our assay holds a clear advantage over this assay, 
since cAMP-mediated closure of GJs has not been reported.  
Another newly described Cx43 GJ assay, which measures the iodide propagations through the 
GJs reported a Z´ of 0.7.206 This assay used a selective iodide transporter in donor cells and 
measured the iodide-mediated quenching of a yellow fluorescent protein variant (YFPQL) in 
the recipient cells. However only a maximum quenching of about 45% in response to high 
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concentrations of NaI (70 mM) was demonstrated. This assay does not measure a physiological 
event which may additionally contribute to false-positive results.  
 Generally the GJ-mediated coupling in HTS format is measured indirectly with the aid of other 
components such as receptors, transporters, and ion sensing proteins, due to which the 
likelihood of false positive hits increases. Therefore hits should be reconfirmed using another 
testing system such as the scrape loading method. A detailed comparison of all three assays is 
presented in Table 9.  
 
Figure 39: Suitability of cAMP assisted Cx43 GJ assay as a HTS assay. The quality of the assay was assesed by 
calculating the screening window co-efficient (Z´-Factor) as previously described by Zhang et al., (1999).112 A 
co-culture of donor (90,000 cells/well) and biosensor (30,000 cells/well) cells at a ratio of 3:1 was incubated in 
assay buffer for 45 min as described in methods section. Prior to addition of CGS21680 (1 µM) to the co-culture, 
a pre-read of wells was taken which represented the negative control (red). The co-culture was then activated by 
adding CGS21680 (1 µM). The stabilized luminescence signal 19 min after stimulation was taken as a positve 
control (green). σ, standard deviation; µ, mean; c+, positive control; c-, negative control. 
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Table 9: Comparison of cell based Cx43 gap junction high-throughput screening assays 
 Ca2+-sensing aequorin 
assay195 
Iodide-sensing YFPQL 
assay206 
cAMP-sensing luciferase 
assay 
Invasiveness Noninvasive Noninvasive Noninvasive 
Cell line used  HeLa (Heterologous Cx43) 
LN215 & HOS 
(Endogenous Cx43) 
HeLa 
(Heterologous Cx43) 
Reagent used Coelenterazine NaI Luciferin 
Read-out format Luminescence enhancement Fluorescence quenching 
Luminescence 
enhancement 
Measurement time 40 s / well 10 s / well 10 min / well 
Cells / well in a 96-well 
plate 60,000* not given 120,000 
Z’-Factor > 0.4 0.7 0.5 
Advantages 
Measures a 
physiological event 
(intracellular Ca2+) 
 
Short measurement time 
in kinetic mode (40 s) 
 
Fully automated in 384-
well format  
Cost effective 
 
Short measurement 
time in kinetic mode 
(10 s) 
 
Partially automated in 
96-well format 
Measures a physiological 
event (intracellular 
cAMP) 
 
No cAMP-mediated GJ 
channel closure 
 
Highly potent A2A- 
selective agonist 
CGS21680 (Ki 17.8 
nM)231 
 
Stable luminescence 
signal for up to 30 min 
 
Disadvantages 
Onset of Ca2+ /CaM-
mediated inhibition of 
GJs after ca. 30-90 s214-
215 
 
Costly substrate  
 
Luminescence signal 
above background with 5 
µM of phenylephrine in 
control co-culture with 
no Cx43 
 
Moderately potent and 
less selective α1A 
agonist phenylephrine 
(Ki 6.3 µM)232-233 
 
Sources of false 
positives: 
i) α1A or TrpVI 
ii) Aequorin 
iii) Intracellular Ca2+ 
Measures a non-
physiological event (I--
transport) 
 
High expression of a 
large SLC26A4 (780 
aa) may be difficult 
 
Maximum quenching of 
YFPQL of  about 45% by 
70 mM NaI 
 
Background of other 
connexin subtypes not 
known 
 
Sources of false 
positives: 
i) SLC26A4 
ii) I—permeability 
iii) YFPQL 
 
Long measurement time 
in kinetic mode after 
about 10 min the agonist 
addition 
 
Costly substrate  
 
Temperature sensitive 
 
Sources of false positives: 
i) A2AAR 
ii) Luciferase 
iii) Intracellular cAMP 
 
 
LN215, LN215 glioma cells; HOS, Human osteosarcoma cells; CaM, calmodulin protein. DeFilippo et al. 
2016,231 (Churchill et al. 2001, Lurtz and Louis 2007),214-215 (Takanobu et al. 1999, Crassous et al. 2009).232-233  
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3.3 Summary 
Cx43 is the most abundant and widely expressed GJ protein in humans, and it is the 
predominant Cx found in astrocytes. Changes in the expression pattern of Cx43 have been 
linked to neurological disorders such as depression, epilepsy, and brain metastasis. Lately it 
has been reported that the antiepileptic drug levetiracetam (LEV) restored the functional 
coupling of GJs in inflammation-induced uncoupled astrocytes. Due to the crucial role of Cx43 
GJs in the crosstalk between astrocytes and of astrocytes and neurons to maintain a healthy 
neuronal microenvironment, Cx43 GJs are gaining increased attention as promising 
therapeutic targets for treating brain disorders.  
In this project, we initially investigated the affinity of the Cx43 protein for the LEV derivative 
brivaracetam (BRV) in its 3H-labeled form using radioligand binding assay. The results from 
the binding assays indicated that there appears to be no direct high-affinity binding site for 
BRV neither on human nor on mouse Cx43. To date, only few, moderately potent and selective 
ligands of Cx43 are known. The development of potent Cx43 GJ modulators is probably 
hindered by the lack of suitable screening assays. The first HTS assay using the second 
messenger Ca2+ and its sensor aequorin to investigate Cx43 GJs was reported in 2013 by 
GlaxoSmithKline.195 Another Cx43 GJ assay was reported by Lee et al. (2015), which used 
iodide and its sensor YFPQL.206 Both assays exhibit a number of drawbacks, and therefore 
improved HTS assays are urgently required for the detection and characterization of Cx43 GJ 
modulators.  
In this chapter the development of a new HTS assay was described for Cx43 GJ modulators. 
To execute the assay we established a donor cell line co-expressing A2AARs and Cx43, and a 
biosensor cell line co-expressing cAMP sensing luciferase and mCx43. The assay principle is 
relatively simple: activation of the Gs protein-coupled A2AAR in the donor cells with a specific 
agonist (CGS21680) generates cAMP, which traverses via Cx43 GJs into the biosensor cells. 
Upon cAMP-mediated activation the luciferase catalyzes the oxidation of luciferin producing 
luminescence. The screening window coefficient Z’-factor of the current assay was calculated 
to be 0.5, which confirms its suitability as an HTS assay. The newly established assay has the 
potential to be applied to other Cx subtypes and may also be implemented for investigating 
heterotypic GJ coupling. 
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4 Quantification of GFP-tagged membrane proteins by CGE-LIF 
4.1 Introduction  
Proteins represent biological targets of the vast majority of approved drugs.234 The protein 
targets mainly include receptors (44%), enzymes (29%), and transporters (15%).235 Of these 
membrane proteins constitute targets for about 60% of all approved drugs, alone ca. 36% of 
the available drugs target G protein-coupled receptors (GPCRs).235-236 Detection and 
quantification of recombinant membrane proteins is mostly crucial for pharmacological 
investigations and therefore usually a reporter tag is attached to the N- or C-terminus of protein 
of interest (POI). Fluorescent labeling is the most powerful and widely used method for the 
detection of POIs. For such investigations POIs can be tagged with i) autofluorescent protein 
(e.g. green fluorescent protein, GFP), ii) self-labeling enzyme (e.g. Halo tags and SNAP/CLIP 
tags), and iii) short peptide sequence that covalently react with biarsenical dyes (e.g. FLAsH 
and ReAsH).237 However, autofluorescent proteins particularly GFP is still extensively used, 
since it offers robustness, produce low autofluorescent background, and do not require a 
secondary reaction component.237-238  
The wild-type GFP (wt GFP) extracted from the jelly fish Aequorea victoria is a naturally 
fluorescent protein with a molecular mass of around 27 kDa.239 A tripeptide sequence of Ser65-
Tyr66-Gly67 in wt GFP makes up the chromophore located in the center of a β-sheet barrel 
structure.240 GFP is a very stable protein and resistant to high pressure (600 MPa), heat, alkaline 
pH, detergents, chaotropic salts, organic solvents, and several proteases.241 GFP fused as a tag 
on either terminal of the protein of interest in most cases does not interfere with protein’s native 
function. 240, 242 Several mutants of GFP have been generated to improve and modify its 
stability and fluorescent properties. A commonly used variant is enhanced GFP which has a 
higher signal intensity than wt GFP. This variant displays two mutations (Phe64Leu and 
Ser65Thr) in the chromophore region with an excitation peak at 488 nm and an emission peak 
at 509 nm.243 GFP has a wide range of applications. It has been extensively used as a reporter 
for transfection and gene expression in mammalian cells.239 The applicability of GFP as a 
fluorescent reporter offers valuable information about the expression level and localization of 
the labeled protein in the given system, such as mammalian cells.244 
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Frequently applied methods to analyze GFP-fused proteins are fluorescence microscopy, flow 
cytometry, and fluorescence measurement in suspension or after solubilization by direct 
fluorimetry.245-246 Despite the usefulness of these methods, they pose limitations to, for 
example quantification of low-abundance GFP-tagged proteins and detection limit due to 
autofluorescence of cellular components, particularly in cellular homogenates.246 Western 
blotting, a gold standard for protein detection, can be also utilized to roughly quantify the GFP-
tagged proteins by using primary antibodies against the GFP-tag.247 However, Western blotting 
is an error-prone multistep procedure and it can last up to more than 24 hours to obtain the 
final results.  
Capillary electrophoresis (CE) is a fast, low-cost and powerful separation technique that has 
been highly useful in genomics and proteomics.248-249 CE coupled to a laser-induced 
fluorescence detector (CE-LIF) has been successfully used for the analysis of proteins,250-
252especially free GFP or GFP-tagged proteins in various biological materials.246, 253-256 The 
CE-LIF has, for example, been successfully used to separate free GFP from the GFP-antibody 
complex with high resolution and sensitivity.253 Furthermore, the CE-LIF has been applied to 
analyze cell-to-cell variation in GFP expression in single bacteria.246 This technique has been 
also employed to analyze the conversion of I-form of GFP-tagged microtubule-associated 
protein light chain 3 (GFP-LC3), an autophagy marker, to its II-form in an extract of HeLa  
cells which were pretreated by starvation or application of chloroquine (CQ).254 The CE-LIF 
method has been also used to investigate the autophagy organelles isolated from rat L6 cells 
by counting GFP-LC3.255 Swearingen et al. (2010) has also applied the CE-LIF to quantify cell 
death by measuring the GFP released from cells due to membrane degradation in treating with 
staurosporine or exposing to H2O2.256 However, all those CE-LIF methods have limitation to 
quantify the GFP and GFP-labeled proteins since the protein adsorption on the capillary inner 
surface due to application of bare fused silica capillaries cannot be avoided in an aqueous 
buffer system.   
To address this issue we came up with the idea of establishing a capillary gel electrophoresis 
method with laser-induced fluorescence detection (CGE-LIF) method to quantify 
recombinantly expressed GFP-fused proteins in a complex mixture of cellular homogenates. 
Here we have demonstrated that the CGE-LIF can be used to quantify different types of GFP-
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fused membrane proteins in a crude cellular homogenate. Furthermore, we compared the newly 
developed CGE-LIF method with commonly used simple fluorimetric measurements. Finally, 
we compared the determined amounts of the GFP-fused proteins by using the CGE-LIF method 
with those obtained by applying radioligand binding assays. 
The results shown in the next section are included in the manuscript (in preparation):  
- Danish, A.*; Lee, SY.*; Müller, C. E. Quantification of green fluorescent protein 
(GFP)-tagged membrane proteins by capillary gel electrophoresis  
*Both authors contributed equally to this study. 
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4.1.1 CGE-LIF setup 
In order to avoid protein adsorption on the capillary inner surface, we applied here the capillary 
electrophoresis coupled with the laser-induced fluorescence detector (CE-LIF). The design of 
the detection set-up is illustrated in Figure 40. Firstly, a semi-liquid gel is filled into the fused-
silica capillary. Application of pressure at both in- and outlet sides allows the maintenance of 
the gels inside. Since the proteins in the crude cellular homogenates are treated with a reaction 
buffer including 1% of sodium dodecylsulfate (SDS), they are incorporated into negatively 
charged micelles. All negatively charged proteins are then separated based on their molecular 
weights. Consequently, all proteins in the homogenate reach the detector, but only GFP-tagged 
proteins are selectively recorded at the LIF detector.   
 
Figure 40: Schematic representation for the detection of GFP-tagged proteins using CGE-LIF. Crude cellular 
homogenate containing recombinant GFP-tagged protein (green circle) and non-fluorescent cellular proteins 
(violet and blue circles) is diluted in a Tris buffer containing 1% SDS. The sample is then electrokinetically 
injected into a fused-silica capillary filled with a gel buffer containing semi-liquid gels. The complex mixture of 
cellular proteins in the cellular homogenate is resolved in the applied electric field based on their molecular 
weights by applying a high voltage. The proteins are negatively charged due to their inclusion in SDS micelles 
and then migrate from cathode to anode. Only the GFP-tagged proteins are detected by a LIF detector. CGE: 
capillary gel electrophoresis, GFP, green fluorescent protein, LIF: laser-induced fluorescence, SDS: sodium 
dodecylsulfate.  
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4.1.2 Calibration curve with GFP using CGE-LIF  
Initially the CGE-LIF method was used to monitor the concentration-dependent increase in 
peak area of various concentrations of free GFP ranging from 0.929 to 92.9 nM. A strict 
linearity was shown with a R2 value of 0.9701 (see Figure 41). We determined a limit of 
detection (LOD) of 5 nM (0.168 µg/ml) and a limit of quantification (LOQ) of 15 nM (0.508 
µg/ml). This value is similar to the determined LOD value of 3 nM by Korf et al., but 
considerably higher as compared to the determined LOD value of 2 pM in Turner et al., both 
using a free GFP standard protein but a CE-LIF method without filling with gels.246, 253 Turner 
et al. used a short and thin fused-capillary (20 cm of the effective length and 10 µm of the inner 
diameter) compared to the fused-capillary (50 cm of the effective length and 50 µm of the inner 
diameter) used in our investigations. This resulted in the better LOD into the picomolar range. 
Initially we also used a fused-silica capillary without any gels inside, however it resulted in 
high protein adsorption and non-reproducibility of measurements with the pure GFP protein, 
therefore we established a method using semi-liquid gel (in SDS-MW gel buffer). Our newly 
developed method showed high robustness and reproducibility of the results with less than 2% 
relative standard deviation (RSD) (see Table A1 in appendices). The calibration curve with the 
free GFP was subsequently used for quantification of recombinantly expressed GFP-fused 
transmembrane proteins in cellular homogenates.     
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Figure 41: Calibration curve with free GFP standard protein by CGE-LIF. (A) Electropherogram of free GFP 
used as standard at different concentrations analyzed at -15 kV and electrokinetic injection (peak 1: 
autofluorescence, peak 2: GFP). (B) Calibration curve obtained by plotting free GFP concentration in mg/ml on 
the X-axis and corresponding peak area on the Y-axis. Data points in the calibration curve show means ± SD of 
three independent experiments. LOD: limit of detection; LOQ: limit of quantification.  
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4.1.3 Calibration curve with GFP using direct fluorimetry 
For comparison we determined the LOD of GFP using a microplate fluorimeter. 
Concentration-dependent fluorescent signals were observed and a LOD of 25.7 nM and a LOQ 
of 78.0 nM was determined (see Figure 42). Thus, the sensitivity was about 5-fold lower than 
that of the newly developed CGE-LIF method. Importantly, the CGE-LIF method offers the 
great advantage of protein separation and allows the distinction of the protein to be analyzed 
from its degradation products and impurities. 
 
Figure 42: Calibration curve of GFP determined in a fluorimeter. The calibration curve was obtained by plotting 
the free GFP concentration in nM on the X-axis and the corresponding fluorescence intensity on the Y-axis. The 
fluorescence of free GFP was measured in a black solid-bottom 96 well plate with a fluorescence plate reader. 
Data points in calibration curve show means ± SD of three independent measurements. LOD: limit of detection, 
LOQ: limit of quantification, RFU: Relative fluorescence units.  
 
4.1.4 Quantification of recombinant GFP-fused proteins  
We showed by determining a GFP standard curve that the CGE-LIF method can efficiently 
detect very low amounts of GFP. This method was exploited to detect and quantify 
recombinantly expressed GFP-fused transmembrane proteins in cellular homogenates without 
any prior isolation or purification of the proteins. For the analyses, membrane proteins of 
various classes such as 12-, 7- and 4- transmembrane proteins were selected to assess the scope 
of the new method. Synaptic vesicle 2A protein (SV2A) is a 12-transmembrane domain protein 
(ca. 90 kDa) with intracellular N- and C- termini. SV2A is ubiquitously found in brain 
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(neuronal cells) and involved in neurotransmitter exocytosis.43, 64 The A2A adenosine receptor 
(A2AAR) is a seven-transmembrane receptor (ca. 45 kDa) with an extracellular N-terminus and 
an intracellular C-terminus.257-258 The A2AAR is expressed in the human body and mediates 
anti-inflammatory, immunosuppressive and hypotensive effects. It is a drug target for 
Parkinson’s disease and a potential target in immunooncology.257-258 Connexin 43 (Cx43) is a 
four-transmembrane protein (ca. 43 kDa) with intracellular N- and C- termini. Oligomerization 
of six Cx43 proteins gives rise to Cx43 gap junctions, the most abundant and widely expressed 
types of gap junctions.86 We used 1% SDS in sample buffer to solubilize the cell membrane 
preparations prior to CE analysis. 
Human SV2A with a GFP-tag at its C-terminus was stably expressed in CHO cells and the 
monoclones with the highest SV2A-GFP expression were picked by fluorescence assisted cell 
sorting (FACS). The cells were homogenized to prepare cellular homogenate. Before using the 
homogenate for the CGE-LIF method, we monitored the concentration-dependent fluorescence 
signals using a fluorimeter. The homogenate of non-transfected CHO cells was used as a 
negative control. The increase in fluorescence intensity was found to be directly proportional 
to the amount of homogenate containing SV2A-GFP, while for control, negligible increase in 
fluorescence could be determined (see Figure 43). 
 Figure 43: Determination of fluorescence in cellular homogenates of non-transfected CHO cells and hSV2A-
GFP-expressing CHO cells. RFU: relative fluorescence unit. Data shown are means ± SEM of three individual 
experiments performed in duplicate. 
 
Next for the CGE-LIF analysis we used the cellular homogenates of three CHO cell lines 
expressing GFP-tagged hSV2A, hA2AAR, and mCx43 proteins, respectively. As expected, the 
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electropherograms of SV2A-GFP-expressing solubilized cell homogenates showed 
reproducibly large peaks (see Figure 44A). A concentration of 26.7 pmol of SV2A-GFP per 
mg of protein was determined based on a calibration curve (see Figure 41 and for calculation 
see Section 6.6.4). Non-transfected CHO cell homogenates were used as negative controls. 
The electropherogram of the negative control was found to be background-free at the position 
of SV2A-GFP peak (see Figure 44A). Small peaks with shorter migration time in the 
electropherogram of SV2A-GFP might represent proteolytic degradation products. As an 
additional control to assess the resolution quality of proteins by this method, we spiked the 
SV2A-GFP-containing sample with free GFP and analyzed it with CGE-LIF. Two baseline-
separated peaks were obtained, free GFP showing a shorter migration time, while SV2A-GFP 
had a longer migration time due to its higher protein size (see Figure A1 in appendices).  
Next, the SDS-solubilized cellular homogenates containing GFP-tagged A2AAR and Cx43 
proteins, respectively, were subjected to CGE-LIF analysis. Figure 44B and C represent the 
electropherograms of the proteins. The calculated concentrations for the proteins based on the 
calibration curve for free GFP were 0.121 pmol of A2AAR-GFP per mg of protein and 0.0398 
pmol of Cx43-GFP per mg of protein.  
To find out whether SDS lead to mediate protein degradation, the hSV2A-GFP cellular 
homogenate was incubated with 1% SDS for up to 4 h. The results showed that the protein was 
stable in the presence of 1%SDS (see Figure A2 in appendices). 
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Figure 44: Detection and quantification of GFP-tagged recombinant proteins in SDS-solubilized CHO cell 
homogenates. (A) Electropherogram for the hSV2A-GFP (1:100 dilution), (B) Electropherogram for the hA2AAR-
GFP (1:20 dilution), and (C) Electropherogram for the mCx43-GFP (1:2 dilution). Samples were separated by -
15 kV after electrokinetic injection. The calculated amounts of proteins were 26.7  1.15 pmol of hSV2A-GFP 
per mg of protein, 0.121  0.006 pmol of hA2AAR-GFP per mg of protein, and 0.0398  0.0040 pmol of mCx43-
GFP per mg of protein. The experiments were performed in triplicates (T1 to T3) for each protein samples 
including wild-type CHO (wt  CHO) as a negative control. RFU, relative fluorescence unit; m, Mouse; h, Human. 
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4.1.5 Quantification of SV2A and A2AAR by radioligand binding assays 
Radioligand binding assays are considered as important tools in pharmacology to determine 
the protein’s affinity (Kd) for a ligand as well as the amount of protein (Bmax) in a given 
biological sample. Bmax values can be determined either by saturation binding assays or by 
homologous competition binding assays.259 In the latter method same compound in the labeled 
(single concentration) and the unlabeled (multiple concentrations) form is used in competition 
binding assays. Using this method for Bmax value determination requires a lower amount of 
radioligand.259 In our lab radioligand binding assays for the SV2A and the A2AAR are well 
established.260-261 For Cx43 we could not determine its Bmax value by radioligand binding since 
no radioligand is available for this protein. To validate our results obtained by the CGE-LIF 
method, we conducted homologous competition assays with hSV2A using [3H]BRV as a 
radioligand and unlabeled BRV as a competitor, whereas for hA2AAR, [3H]MSX-2 was 
employed as a radioligand and unlabeled MSX-2 was used as a competitor (see Figure 45). It 
should be noted that the same batches of cellular homogenates were used for the radioligand 
assays and for the CGE-LIF analysis. 
The density (Bmax) of hSV2A-GFP per mg of protein in the cell homogenate was found to be 
4.19 ± 0.52 pmol (see Figure 45A) which is significantly 5-fold lower than 26.7  1.15 pmol 
obtained by CGE-LIF method (unpaired two-tailed t-test) (For Bmax calculation see Section 
6.7.2). As mentioned earlier that monoclones with the highest expression of hSV2A-GFP, 
having highest plasmid copies, were used for preparation of homogenates. It is noteworthy that 
overexpression of heterologous proteins can lead to formation of protein aggregates and 
accumulation of unfolded proteins due to fully occupied cellular folding machinery.262 These 
factors might compromise the binding sites of the ligands, while fluorophore might stay intact 
and contribute to the fluorescence. Since the intact binding pocket is critical for ligand binding, 
this hypothesis might explain the reason behind the difference. The Bmax value for the hA2AAR-
GFP obtained in radioligand competition assays was found to be 0.319 ± 0.081 pmol/mg of 
protein (see Figure 45B) which is not significantly different from the value of 0.121 pmol/mg 
of protein determined by CGE-LIF (unpaired two-tailed t-test). These results indicate that the 
hA2AARs in the non-solubilized homogenate (no SDS added) are all in conformations with 
high-affinity for the radioligand and not partly in a denatured conformation. Considering the 
4 Quantification of GFP-tagged proteins by CGE-LIF 
113 
comparison of the two methods, our results suggest that CGE-LIF is a reliable and sensitive 
method for the detection and quantification of GFP-tagged membrane proteins. Moreover, this 
kind of comparison can provide important information e.g. for crystallization, NMR structural 
studies, and cryo-electron microscopy. 
 
 
Figure 45: Homologous competition binding assays to determine the amount of radioligand binding sites (Bmax) 
in cell homogenates. Binding assays were performed with specific radioligands for hSV2A and hA2AAR, 
respectively. (A) Concentration-dependent inhibition of [3H]BRV (3 nM) binding to hSV2A-GFP by unlabeled 
BRV yielded a Bmax value of 4.19 ± 0.52 pmol per mg of protein (IC50 = 87.6 ± 4.47 nM; Ki = 85.6 ± 4.47 nM). 
(B) Concentration-dependent inhibition of [3H]MSX-2 (1 nM) binding to hA2AAR-GFP by unlabeled MSX-2 
yielded a Bmax value of 0.319 ± 0.081 pmol per mg of protein (IC50 = 7.46 ± 1.83 nM; Ki = 6.76 ± 1.83 nM). Data 
points in the inhibition curves show means ± SEM of at least three independent experiments. Protein 
determination was performed by the Bradford method.263  
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4.2 Summary 
Detection and quantification of recombinant proteins fused to green fluorescent protein (GFP) 
are most frequently performed by fluorescence microscopy, flow cytometry, or by measuring 
fluorescence in suspension or in solution after solubilization. However, these methods have 
limitations such as low sensitivity and lack of precision due to high background 
autofluorescence. We have developed a fast, robust, and reproducible method to quantify GFP-
tagged membrane proteins in a complex matrix of cell homogenates by using capillary gel 
electrophoresis coupled to a laser-induced fluorescence detector (CGE-LIF). A semifluid gel 
for CGE-LIF to reduce protein adsorption on the fused-silica capillary and to enhance peak 
resolution. Based on a calibration curve obtained with purified GFP using the CGE-LIF 
method, the amount of GFP-tagged protein of interest in solubilized cell homogenates was 
determined. CGE-LIF was found to be highly sensitive, displaying a limit of detection (LOD) 
of 0.168 µg/ml (5 nM) for GFP. The CGE-LIF method showed at least 5-fold higher sensitivity 
as compared to fluorimetric measurement in a microplate. Using CGE-LIF method three 
different types of GFP-tagged membrane proteins expressed in Chinese hamster ovary (CHO) 
cells, namely human synaptic vesicle protein 2A (hSV2A), human A2A adenosine receptor 
(hA2AAR), and mouse connexin 43 (mCx43) were quantified. Quantification of hSV2A and 
hA2AAR using classical radioligand binding assays confirmed the results obtained with CGE-
LIF. Comparison allows to distinguish between correctly folded protein and total protein. 
Importantly, the new method involves separation of the target proteins and their degradation 
products prior to quantification. In the future, the CGE-LIF method may be extended to other 
fluorescent proteins such as red fluorescent protein (RFP) and yellow fluorescent protein 
(YFP). Moreover, it may be applied to detect native proteins without GFP-tag in cell 
homogenates by using fluorophore-conjugated antibodies.  
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5 Summary and outlook  
Despite the availability of more than twenty different antiepileptic drugs (AEDs) on the 
market, about one third of epileptic patients remains resistant to pharmacotherapy with existing 
drugs.264 All of the current AEDs exert their effects either by reducing excitatory or by 
enhancing inhibitory neurotransmission. Most of the AEDs produce these effects by 
modulating voltage-gated ion channels, ionotropic glutamate receptors, or by enhancing -
aminobutyric acid (GABA)-mediated neurotransmission. Contemporary AEDs thus dampen 
epilepsy symptoms by targeting mechanisms involved in seizure generation, but do not provide 
a cure.25 Thus major goals in the development of future AEDs include features like efficacy 
against refractory epilepsy, prevention for the onset of epilepsy “antiepileptogenic properties” 
in patients at risk (e.g. brain trauma, stroke, and tumor), disease-modifying properties, potential 
of broad use in non-epileptic central nervous system (CNS) disorders, and fewer adverse 
effects.47, 51 Investigating novel molecular targets and identifying antiepileptic agents with 
different mechanism(s) of action may substantially contribute to achieving these goals. 
The discovery of synaptic vesicle protein 2A (SV2A) in 2004 to be the main target of the AED 
levetiracetam (LEV, Keppra®) demonstrated that novel targets for AED could be identified 
(see Figure I).43 SV2A has been demonstrated to be involved in the recycling of vesicles 
containing neurotransmitters, however its exact function remains elusive. Moreover, SV2A-
deficient mice showed a proepileptic phenotype with reduced anticonvulsive activity and 
binding of LEV.74 LEV exhibits relatively a safe and tolerable profile and has shown promising 
disease-modifying properties in pharmacoresistant animal models of epilepsy like in the 
kindled rats and the 6-Hz mouse model.25 Exact functional consequences for SV2A upon LEV 
binding are not well understood, however studies suggest that LEV modulates the release of 
neurotransmitters. LEV exhibits additional mechanisms, and a striking characteristic of LEV 
is its ability to rescue connexin 43 (Cx43) gap junction (GJ) coupling in astrocytes which is 
impaired in epilepsy.48 Since LEV binds to SV2A with modest affinity, brivaracetam (BRV, 
Briviact®), a 10- to 15-fold more potent derivative of LEV, was developed for improved 
antiepileptic properties. Brivaracetam has recently been approved by EMA and FDA as an add-
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on AED to treat partial onset seizures. Our group has recently reported the development of 
LEV and BRV in radiolabeled form.57-58   
In the present study, a radioligand binding assay with [3H]BRV was established that is suitable 
for testing compound libraries for interaction with human SV2A expressed in Chinese hamster 
ovary (CHO) cells. The testing of 500 approved drugs in competition binding studies using 
[3H]BRV as a radioligand resulted in a  hit rate of 3%. Hits were defined as compounds 
inhibiting the radioligand by ≥ 90% at 20 µM test concentration. Subsequent testing at 2 µM 
resulted in the identification of the antihistaminic prodrug loratadine (Ki 1.16 µM), the 
antimalarial drug quinine (Ki 2.03 µM), and the anti-obesity drug rimonabant (Ki 2.73 µM) as 
the most potent SV2A ligands of the investigated library. Based on flexible alignment of 
brivaracetam, loratadine, and quinine, a pharmacophore model was generated which indicated 
an excellent steric and electronic fit of three drugs and in line with previously known structure-
activity relationships (SARs). There are no reports on antiepileptic effects of loratadine, and it 
is also not likely due to its poor penetration through the blood-brain barrier (BBB) and its 
prodrug properties. On the other hand, several studies showed quinine to act as an antiepileptic 
agent. We conclude that the interaction of quinine with SV2A may explain its anticonvulsive 
effects observed in animal and clinical studies. This hypothesis warrants further investigations, 
for instance in SV2A-deficient animal models, or in the presence of negative allosteric 
modulators of SV2A.  
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Figure I: Topology model of the human SV2A. The snake plot diagram was prepared by using the TOPO2 
program along with the transmembrane domain predictions using the HMMTOP software.80-81 Transmembrane 
domains are indicated with Roman numbers and N & C represent N-and C-termini. The amino acids depicted in 
blue color have been previously demonstrated to alter racetam binding by mutagenesis and docking studies.177-179 
Amino acids shown in purple within ICL3 have been previously mutated to test the affinity of mutants for 
racetams, however binding was not altered.38 The mutation of arginine within ICL3 depicted in orange color at 
position 383 is suggested to be a causal factor in intractable epilepsy.176 The green GFP tag at the C-terminus 
indicates a green fluorescent protein (GFP) and the amino acids in red color denotes the N-glycosylation sites.  
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Rimonabant is a potent antagonist of the 
cannabinoid CB1 receptor and activation of this 
receptor was reported to result in anticonvulsive 
effects, while its blockade exerts proconvulsive 
effects.143 However, paradoxically a single-time 
administration of rimonabant after a short interval 
of brain trauma prevented animals from 
developing seizures and we hypothesize that this 
might be due to its interaction with SV2A.144 This 
finding prompted the idea of testing 80 
cannabinoids including the most important 
components of the cannabis plant, the 
psychoactive Δ9-Tetrahydrocannabinol (THC) 
and the non-psychoactive cannabidiol (CBD). 
This screening campaign resulted in the 
identification of JWH-031 (Ki 0.618 µM), AM-
2232 (Ki 0.401 µM), and CBD (Ki 0.719 µM) (see 
Figure II & Figure III) as potent ligands for 
SV2A, however THC displayed no affinity for 
SV2A. Quite recently the CBD-containing 
preparation Epidiolex® obtained an orphan drug 
designation from EMA and FDA for the 
treatment of childhood-onset epilepsy syndromes, Lennox-Gastaut syndrome (LGS) and 
Dravet syndrome.141 Plausible CBD targets involved in translating its anticonvulsive effects 
are not well understood. The current results suggest that the anticonvulsive effects of CBD 
might be – at least partly – attributed to its interaction with SV2A, however further research in 
animal models is warranted. Moreover, since JWH-031 and AM-2232 are potent agonists at 
the CB1R, the resulting SARs may provide a basis for the development of dual-target 
antiepileptic compounds. 
The LEV/BRV binding site on SV2A remains elusive. As a contribution to the identification 
of the binding site, a possible involvement of the intracellular cytoplasmic loop 3 (ICL3) of 
Figure III: Concentration-dependent specific 
inhibition of [3H]BRV binding to recombinant human 
SV2A by CBD, Ki value: 0.719 ± 0.166 µM. 
Figure II: Chemical structures of cannabinoids. 
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SV2A to LEV/BRV binding was 
investigated. The ICL3 of SV2A contains an 
ATP binding site, and many SV2A-specific 
non-conserved amino acids. A point 
mutation (R383Q), which was reported to be 
responsible for intractable epilepsy in a 
patient, is also located in the ICL3 of 
SV2A.176 Competition binding experiments 
with [3H]BRV on the SV2A-R383Q mutant 
by unlabeled LEV (IC50 wt 1.81 µM vs. IC50 mutant 
2.14 µM) and BRV (IC50 wt 0.099 µM vs. IC50 
mutant 0.116 µM) showed no significant 
differences in the IC50 values compared to wild-
type SV2A. However, JWH-031 (IC50 wt 0.643 µM vs. IC50 mutant 5.99 µM, 9-fold shift) and 
CBD (IC50 wt 0.748 µM vs. IC50 mutant 20.7 µM, 28-fold shift) showed significant shifts in IC50 
values. Chimeric proteins were constructed with the whole ICL3 of SV2A exchanged for that 
of SV2B (SV2A-SV2B-ICL3) and the ICL3 of SV2B exchanged for that of SV2A (SV2B-
SV2A-ICL3). Interestingly, specific [3H]BRV binding was completely abolished in both 
chimeric proteins (see Figure IV), which is in line with the previous findings with exon 5 and/or 
exon 6 deletion mutants of SV2A.38 These results indicate a possible involvement of the ICL3 
of SV2A for LEV/BRV binding. To further narrow down the site within the ICL3 that is 
involved in LEV/BRV binding, chimeric proteins with small regions exchanged within the 
ICL3 should be constructed and tested in the future. Botulinum neurotoxin A (BoNT/A) and 
galactose are known to interact with SV2A. In the present study, investigations to find out the 
effects of (BoNT/A) and galactose on [3H]BRV binding to SV2A demonstrated that neither of 
them affected [3H]BRV binding. 
Cx43 is the most widely expressed GJ protein in humans, and it is the predominant Cx found 
in astrocytes. Over the last decade Cx43 GJs have gained increased attention as promising 
potential therapeutic targets for treating brain disorders including epilepsy. Since LEV was 
previously demonstrated to modulate Cx43 GJs in astrocytes, the affinity of [3H]BRV for Cx43 
was investigated using radioligand binding. The results indicated that there appears to be no 
Figure IV: Evaluation of [3H]BRV binding to 
recombinant wt hSV2A (green), hSV2A-hSV2B-
ICL3 chimera (red), and hSV2B-hSV2A-ICL3 
chimera (blue). Total binding was determined in the 
absence of LEV and non-specific binding was 
determined in the presence of LEV (1 mM). 
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direct high-affinity binding site for 
BRV neither on human nor on mouse 
Cx43. To date, only few, moderately 
potent and selective ligands of Cx43 are 
known, probably due to lack of suitable 
screening assays and test systems. In 
the current study, a new high-
throughput screening assay for Cx43 
GJ modulators was developed. The 
assay works based on the principle that 
activation of the Gs protein-coupled 
human adenosine receptor (A2AAR) in a 
donor cell line with a specific agonist (CGS21680) generates cAMP, which crosses via Cx43 
GJs into biosensor cells harboring cAMP sensitive luciferase. Upon cAMP-mediated 
activation the luciferase catalyzes the oxidation of luciferin producing luminescence (see 
Figure V). The Z’-factor of the current assay was determined to be 0.5, which confirms its 
suitability as an HTS assay. The newly developed assay has the potential to be deployed for 
screening large compound libraries for Cx43 GJ modulators, investigating Cx43 mutants and 
heterotypic GJ coupling, and the same method can be applied to other Cx subtypes.  
Membrane proteins constitute targets for around 60% of all approved drugs.236 Monitoring the 
expression of recombinant membrane proteins is mostly crucial to rely on the outcomes of 
pharmacological assays. Several types of tags are used for labeling recombinant membrane 
proteins to facilitate monitoring of their expression. Green fluorescence protein (GFP) is 
extensively used for tagging recombinant proteins. Detection and quantification of 
recombinant proteins fused to GFP are most frequently performed by fluorescence microscopy, 
flow cytometry, or by measuring fluorescence in suspension or in solution after solubilization. 
However, these methods have limitations such as low sensitivity and lack of precision due to 
high background autofluorescence. In the present study, a fast and robust method was 
Figure V: Design of the Cx43 GJ assay. HeLa cells expressing
hA2AAR and mCx43 are denoted as donor cells and HeLa cells 
expressing GSL and mCx43 are indicated as biosensor cells. 
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established to quantify GFP-
tagged membrane proteins in 
cell homogenates by using 
capillary gel electrophoresis 
coupled to a laser-induced 
fluorescence detector (CGE-
LIF) (see Figure VI). CGE-
LIF was found to be highly 
sensitive displaying a limit of 
detection (LOD) of 0.168 
µg/ml (5 nM) for GFP. The 
CGE-LIF method showed 
higher sensitivity (at least 5-
fold) as compared to 
fluorimetric measurement in a microplate. We quantified three different types of GFP-tagged 
membrane proteins expressed in CHO cells, namely SV2A, A2AAR, and Cx43. Quantification 
of SV2A and A2AAR using classical radioligand binding assays confirmed the results obtained 
with CGE-LIF. Importantly, the new method involves separation of the target proteins and 
their degradation products prior to quantification. We anticipate broad applicability of the 
method for any fluorophore-tagged proteins and for multiplex protein detection.  
 
 
 
 
 
 
 
Figure VI: Schematic representation for the detection of GFP-tagged
proteins using CGE-LIF. Cellular homogenate containing recombinant
GFP-tagged protein (green circle) and non-fluorescent cellular proteins
(violet and blue circles) is diluted in a Tris buffer containing 1% SDS. The
sample is then electrokinetically injected into a fused-silica capillary filled
with a gel buffer containing semi-liquid gel. The complex mixture of
cellular proteins in the homogenate is resolved in the applied electric field
based on their molecular weights by applying a high voltage. The proteins
are negatively charged due to their inclusion in SDS micelles and then
migrate from cathode to anode. Only the GFP-tagged proteins are detected
by a LIF detector. 
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6 Experimental section 
6.1 Materials  
6.1.1 Chemicals  
2-Arachidonylglycerol Sigma, 80676 
2-Mercaptoethanol Applichem, A4338 
Adenosine Sigma, A9251 
Agarose Roth, 2267.2 
AM-251 Biotrend, BN0063 
AM-281 Sigma, A0980 
AM-630 Tocris, 1120 
Ampicillin sodium salt Applichem, A0839 
Anandamide Tocris, 1339 
Anhydrotetracycline hydrochloride Riedel-de-Haen, 37919 
Brivaracetam Briviact® ampoules (10 mg/ml) 
Prof. Dr. Ivar von Kügelgen, University of Bonn 
Bromophenol blue sodium salt Applichem, 3640 
BSA/Albumin fraction V Applichem, A1391 
Calcium chloride dehydrate  Fluka, 21097 
Calcium-5 Molecular devices, R8186 
Carbenoxolone disodium salt Alfa Aesar, J63714 
CGS21680 Tocris, 1063 
Cinchonidine Merck-Schuchardt AG, 485-71-2 
Cinchonine Merck-Schuchardt AG, 118-10-5 
Coomassie BrilliantBlue G-250 Sigma, 27815-25G-F 
D-(+)-Galactose Alfa Aesar, A12813 
D-(+)-Glucose Sigma, G-7012 
D-(+)-Sucrose Applichem, A4734,5 
Desloratadine Tocris, 5958 
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DMSO Applichem, A3608 
DMSO for cell culture Applichem, A3672 
EDTA Roth, 8040.3 
Ethanol ZVE University of Bonn, 123974 
FCS Sigma, F-0804 
Fluo-4 ThermoFischer Scientific, F14201 
Forskolin Applichem, 66575-29-9 
G418 Calbiochem, 345810 
Glacial acetic acid  Merck, 1.00063.1011 
Glycerol AppliChem, A1123 
HEPES Sigma, H-3375 
Hydrochloric acid 37% Applichem, A 0659 
IBMX Fluka, 58620 
Isopropanol ZVE University of Bonn, 123903 
JWH-031, AM-2232, AM-679, JWH-
234, JWH-175, AM-1235, JWH-368, 
JWH-016, JWH-309 
Provided by Dr. Cornelius Hess, Institute of 
Forensic Medicine, Bonn 
Luria Bertani (LB) agar Invitrogen, 22700-041 
LB powder medium Applichem, A0954,901 
Levetiracetam Chemos GmbH, Art No. 134992 
Lipofectamine2000 Invitrogen, 11668019 
Liquid scintillation cocktail LumaSafeTM, Perkin Elmer, 3087 
Magnesium chloride Sigma, M8266 
MSX-2 Synthesis in AK Prof. Dr. C. E. Müller 
NECA Sigma, E-2387 
PEI solution (50% in H2O) Sigma, P-3143-1L 
Pen-strep solution  Gibco, 15140 
Polybrene (Hexadimethrine bromide) Aldrich, 10,768-9 
SDS solution 20% Applichem, A0675 
Sodium butyrate Fluka, 19364 
Sodium chloride Sigma, P-9541 
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Sodium hydroxide Fluka, 71689 
TRIS Roth, AE15.3 
Tween20 Sigma, P9416 
WIN 55,212-2 Tocris, 1038 
Zeocin™ Invitrogen, R25001 
All other test compounds used in this study and are not listed were obtained from Pharma-Zentrum Bonn 
compound library (https://www.pharmchem1.uni-bonn.de/pharmchem1-en/mueller-laboratory/compound-
library). 
 
6.1.2 Instruments and consumables  
Amicon Ultra-15 10k Centrifugal Filter  Amicon-Millipore 
Analytical balance Sartorius CP225D 
SBC 42, SCALTEC 
Autoclave  VX-95, Systec 
Cell culture flasks Cell Star – Greiner Bio-One 
Centrifuges Mikro 200, Hettich 
Allegra 21 R, Beckman Coulter 
Avanti J-201, Beckman 
Confocal microscope A1Eclispse Ti, Nikon 
Drying cabinet T6120, Heraeus 
Electrophoresis chamber Schütt Labortechnik 
Electrophoresis power supply Power Pac 300, ELITE 300 Plus, 
Schütt Labortechnik 
Gel documentation system Universal hood II Geldoc, BioRad 
Glass homogenizer, Potter Sartorius 
Glass-fiber filters (GF/C) and (GF/B) Whatman® 
Hamilton syringe Syringes 705, Roth 
Harvester Brandel M24 Gaithersburg, MD, USA and 
Brandel M48 Gaithersburg, MD, USA 
Hemocytometer (cell counting chamber) Marienfeld Germany 
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Incubator for cells  Heraeus HERAcell 240 and INC 246, 
Memmert 
Incubator/shaker for bacteria Innova 4200, New Brunswick Scientific  
Liquid scintillation analyzer Tri-Carb 2810 TR, Perkin-Elmer 
Microplates Greiner Bio-one 
Microscope Wilovert, Hund Wetzlar 
Axiovert 25, Zeiss 
Microwave Microwave 800, Severin 
Multimode microplate reader  Mithras LB 940, Berthold Technologies 
pH-meter 691 pH Meter, Metrohm 
Seven Easy, Mettler Toledo 
Photometer DU-530, Beckman 
Pipette tips  Sarstedt  
Pipettes Eppendorf 
Reaction tubes  Eppendorf  
Rocking shaker ELMI Digital Rocking Shaker DRS-12 
Safety cabinet NUNC® Safe flow 1.2 
NUNC® MICROFLOW 
Steril filter Filtropur 0.22 µm, 831826001, Sarstedt 
Thermal block Thermomixer comfort, Eppendorf 
Thermocycler T Personal, Biometra 
Tip Sonicator Sonoplus HD2070, Bandelin 
Tissue homogenizer Ultra-turrax T25 basic, IKA 
UV-Base UV-Star Biometra 
Vortex mixer UNIMAG Zx³, UniEquip 
Vortex Genius 3, IKA 
MS2 Minishaker, IKA  
Water bath WNB 14, Memmert 
Western blot equipment  BioRad and Invitrogen 
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6.1.3 Software 
Graphpad Prism, version 6, San Diego, California, USA 
ClustalW2, European Bioinformatics Institute  
DNAtrans 2.0, Dr. A. Schiedel / J. Bosmann  
Microsoft Office 2013  
Chromas Lite, sequence analysis, Conor McCarthy 
Clone Manager, version 9 
ChemDraw Prime 16, Cambridge Software 
TOPO2, http://www.sacs.ucsf.edu/cgi-bin/tmhmm.py 
Needle, EMBL-EBI, http://www.ebi.ac.uk/Tools/psa/emboss_needle/ 
Multiple Sequence Alignment Tools, http://www.ebi.ac.uk/Tools/msa/ 
Oligoanalyzer 3.1, https://eu.idtdna.com/calc/analyzer 
HMMTOP, Prediction of transmembrane helices, http://www.enzim.hu/hmmtop/ 
NisEelement viewer for Nikon microscope images 
NEBuilder assembly tool, http://nebuilder.neb.com/ 
Servier medical art, http://www.servier.com/Powerpoint-image-bank 
http://multalin.toulouse.inra.fr/multalin/ 
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6.1.4 Materials for molecular biology  
6X Gel Loading Dye, blue New England BioLabs, B7021S 
Bradford Assay Dye Reagent Concentrate Bio-Rad, 5000006 
EnduRen™ Live Cell Substrate Promega, E6481 
Enhanced GFP Protein (EU056363.1) ABM, 33P, Canada 
GelRed™ Biotrend, 41002 
GloSensor™ cAMP Reagent Promega, E1290 
Lamda DNA/EcoRI + HindIII Thermo Scientific, SM0281 
LipofectamineTM 2000 Transfection Reagent Invitrogen, 11668019 
Pierce™ ECL Western Blotting Substrate Thermo Scientific, 32106 
ProLong Gold antifade reagent  Invitrogen, P36930 
Protease inhibitor cocktail  Sigma, P8340 
Protein Marker Thermo Scientific, 26619 
RIPA Thermo Scientific, 89900 
ΦX174 DNA-HaeIII Digest Thermo Scientific, SM0251 
  
Enzymes   
PyrobestTM DNA Polymerase TaKaRa 
Q5® High-Fidelity DNA Polymerase New England BioLabs 
Restriction enzymes  New England BioLabs 
T4 DNA ligase New England BioLabs 
  
Antibodies  
Donkey anti-rabbit-HRP Jackson Immuno Research, Hamburg, 
Germany Goat anti-mouse-HRP  
Mouse monoclonal anti-eGFP Covance, Freiburg, Germany  
Rabbit polyclonal anti-Cx43  Provided by Prof. Dr. Christian Steinhäuser  
  
Kits  
DNA clean & concentrator™-5 Kit Zymo Research, D4003 
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Gibson Assembly® Master Mix  New England BioLabs, E2611S 
HiPure Plasmid Filter Midiprep kit  Invitrogen, K210014 
HisPur™ Ni-NTA, 3 ml resin bed Thermo Scientific, 88226 
Plasmid Miniprep Kit Classic  Zymo Research, D4015 
Zymoclean Gel DNA Recovery Kit Zymo Research, D4001 
ZymoPURE™ Plasmid Maxiprep Kit Zymo Research, D4028 
 
6.1.5 Plasmids  
pcDNA™4/myc-His A vector  Invitrogen, V863-20 
pGloSensor™-20F cAMP Plasmid  Promega, E1171 
pLVX-IRES-mCherry Clontech, 631237 
pASK-IBA43plus IBA GmbH, Germany 
pMK-RQ-BoNTA-HCR (codon optimized)  LifeTechnologies, 1562951 
pUC19 Thermo Scientific, SD0061 
pMJ-mCx43-IRES-GFP AK Prof. Dr. Klaus Willecke, 
LIMES Institute, Bonn pGEM-T-hCx43 
pCMV-hSV2A-GFP  (NM_014849.3) Dr. Simone Hildenbrand pCMV-hSV2B-GFP (NM_014848.4) 
pLXSN-hA2AAR (NM_001278500.1) Dr. Elisabetta De Filippo 
pcDNA3.1+Renilla luciferase8 (RLuc8) Dr. Benjamin Seibt  
 
6.1.6 Media and supplements for cell culture  
DMEM Dulbecco’s Modified Eagle Medium, Life Technologies, 41966029 
DMEM/F12 Life Technologies, 31330038 
FCS Sigma-Aldrich, F0804 
G418 Calbiochem, 345810 
Hygromycin B Merck, 400052 
PS Penicillin-Streptomycin solution, Gibco 15140 
Trypsin Lonza, 17-160 
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6.1.7 Primers  
The underlined and bold bases in primer sequences represent restriction sites. The underlined 
and bold single base in the primer sequences used for mutagenesis indicates mutated base. The 
overlapping regions in primers used for Gibson assembly are represented with lowercase bases 
and uppercase bases indicate the annealing sequence.     
Primers for cloning  
 Sequence (5’-3’) 
f-hSV2A-NotI GAGCTAGCGGCCGCACCATGGAAGAGGGCTTCCGAGAC 
r-GFP-HindIII CATCATAAGCTTTTACTTGTACAGCTCGTCCATGC 
f-hSV2B -NotI GAGCTAGCGGCCGCACCATGGATGACTACAAGTATCAG 
f-hSV2A- EcoRI GAGCTAGAATTCACCATGGAAGAGGGCTTCCGAGAC 
r-hSV2A- XhoI CATCATCTCGAGTTACTTGTACAGCTCGTCCATGC 
f-Cx43-XhoI (h, m) GAGCTACTCGAGACCATGGGTGACTGGAGCGCC 
r-hCx43-XbaI CATCATTCTAGATTAGATCTCCAGGTCATCATCAGGCCG 
r-mCx43-XbaI CATCATTCTAGATTAAATCTCCAGGTCATCAGGCCGAGG 
f-mCX43-HindIII AGACCCAAGCTGGCTAGTTAAGCTTACCATGGGTGACTGGAGC 
r-mCX43-XhoI AAGGGCCCTCTAGACTCGAGTTAAATCTCCAGGTCATCAGGC 
f-hCX43- HindIII AGACCCAAGCTGGCTAGTTAAGCTTACCATGGGTGACTGGAGC 
r-hCX43-XhoI AAGGGCCCTCTAGACTCGAGTTAGATCTCCAGGTCATCAGGC 
  
Primers for mutagenesis 
 Sequence (5’-3’) 
f-hSV2A-R383Q CAGGTCCATGATACCAACATGCAAGCCAAAGGACATCCTGAGCG 
r-hSV2A-R383Q CGCTCAGGATGTCCTTTGGCTTGCATGTTGGTATCATGGACCTG 
  
Primers for Gibson assembly 
 Sequence (5’-3’) 
f-(hSV2A-hSV2B-ICL3-GFP) 1 agacccaagctggctagttaagcttACCATGGAAGAGGGCTTCCG 
r-(hSV2A-hSV2B-ICL3-GFP) 1 ctggcatgaaGGTCAGAGCCCCAATGGCAAAC 
f-(hSV2A-hSV2B-ICL3-GFP) 2 ggctctgaccTTCATGCCAGAGAGCCCAAG 
r-(hSV2A-hSV2B-ICL3-GFP) 2 tcagagtgatCATTCTGTAGGGCCCCATCAC 
f-(hSV2A-hSV2B-ICL3-GFP) 3 ctacagaatgATCACTCTGATGATGATGGGTGTG 
r-(hSV2A-hSV2B-ICL3-GFP) 3 gttcgaagggccctctagactcgagTTACTTGTACAGCTCGTCCATGC 
f-(hSV2B-hSV2A-ICL3-GFP) 1 agacccaagctggctagttaagcttACCATGGATGACTACAAGTATCAGGAC 
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r-(hSV2B-hSV2A-ICL3-GFP) 1 caggctgcgtCTTCAGGGCCACCATGGACAC 
f-(hSV2B-hSV2A-ICL3-GFP) 2 ggccctgaagACGCAGCCTGAGAGCCCCCG 
r-(hSV2B-hSV2A-ICL3-GFP) 2 tcagtgtattGCGCCGATATTCGGGACCAAAACAGG 
f-(hSV2B-hSV2A-ICL3-GFP) 3 atatcggcgcAATACACTGATTCTGGCCGTGG 
r-(hSV2B-hSV2A-ICL3-GFP) 3 gtttttgttcgaagggccctctagaTTACTTGTACAGCTCGTCCATGC 
f-(mCx43-GFP) 1 agacccaagctggctagttaagcttACCATGGGTGACTGGAGC 
r-(mCx43-GFP) 1 cgcccccgtcgacAATCTCCAGGTCATCAGGC 
f-(mCx43-GFP) 2 cctggagattGTCGACGGGGGCGGCGGA 
r-(mCx43-GFP) 2 gttcgaagggccctctagactcgagTTACTTGTACAGCTCGTCCATGCCGAGAGTG 
f-(hA2A-GFP) 1  agacccaagctggctagttaagcttACCATGCCCATCATGGGC 
r-(hA2A-GFP) 1 cgcccccgtcgacGGACACTCCTGCTCCATC 
f-(hA2A-GFP) 2  aggagtgtccGTCGACGGGGGCGGCGGA 
r-(hA2A-GFP) 2 gttcgaagggccctctagactcgagTTACTTGTACAGCTCGTCCATGCCGAGAGTG 
f-mCx43 1 agacccaagctggctagttaagcttACCATGGGTGACTGGAGC 
r-mCx43 1 aagggccctctagactcgagTTAAATCTCCAGGTCATCAGGC 
f-hCx43 1 agacccaagctggctagttaagcttACCATGGGTGACTGGAGC 
r-hCx43 1 aagggccctctagactcgagTTAGATCTCCAGGTCATCAGGC 
  
Primers for sequencing 
 Sequence (5’-3’) 
f-hSV2A-1051 CTGACCACGCAGCCTGAG 
r-hSV2A-1341 AGTGATGCGCCGATATTCG 
r-hSV2A-1462 GGAACACTTTGGTGCGGGATG 
f-hSV2B-697 GGAGAACACCTCAGTTGGC 
f-hSV2B-1345 CACCAACATGGGAAACTTGTG 
f, forward; r, reverse; h, Human; m, Mouse. 
6.1.8 Bacteria and growth media  
Chemocompetent E. coli Top 10  
Invitrogen, C4040-10 
Untransformed cells were grown in basal Luria Bertani 
(LB) medium. Transformed cells depending on the 
antibiotic resistance were grown in LB medium 
supplemented with either 100 µg/ml ampicillin or 50 µg/ml 
kanamycin.  
 
Chemocompetent E. coli DH5α  
New England Biolabs, C2987I 
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6.1.9 Cell lines and culture media  
CHO-K1 
(Ovary cells) 
ATCC, CRL-61 
Non-transfected cells were cultivated in basal DMEM-F12 medium 
supplemented with 10% FCS, 100 U/ml penicillin G, and 100 µg/ml 
streptomycin (“full medium”). For transfected cells selection reagent 
either 200 – 800 µg/ml G418 or 100 – 200 µg/ml zeocin was additionally 
added to the medium (“selection medium”).   
  
GP+envAM12 
(Embryo-fibroblasts) 
ATCC, CRL-9641 
HXM medium was prepared by supplementing basal DMEM medium 
with 10% FCS, 100 U/ml penicillin G, 100 µg/ml streptomycin, 1% 
ultraglutamine, 200 µg/ml hygromycin B, 15 µg/ml hypoxanthine, 
250 µg/ml xanthine, and 25 µg/ml mycophenolic acid. 
  
HeLa 
(Cervical carcinoma) 
Prof. Dr. K. Willecke 
 
Non-transfected cells were cultivated in basal DMEM medium 
supplemented with 10% FCS, 100 U/ml penicillin G, and 100 µg/ml 
streptomycin (“full medium”). For transfected cells selection reagent 
either 200 – 800 µg/ml G418 or 100 – 200 µg/ml zeocin was additionally 
added to the medium (“selection medium”).   
ATCC, American Type Culture Collection  
6.1.10 Buffers, media and gels 
PBS buffer  
NaCl (137 mM), KCl (2.5 mM), Na2HPO4 (7.5 mM), and KH2PO4 (1.5 mM) were dissolved in 
deionized water and pH was adjusted to 7.4 with HCl (37%). The buffer was autoclaved and stored 
at room temperature.  
 
Tris-HCl buffer (50 mM), pH 7.4 (buffer for radioligand binding assays) 
Tris (50 mM) was dissolved in deionized water and pH was adjusted to 7.4 with HCl (37%). The 
buffer was stored at 4°C. 
 
MgCl2 solution (10 mM), pH 7.4 
MgCl2 (10 mM) was dissolved in Tris-HCl buffer (50 mM), pH 7.4. The buffer was stored at 4°C. 
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Polyethyleneimine (PEI) solution (0.1%) 
PEI solution (50% in H2O) was diluted (1:500) in deionized water. The solution was stored at 4°C. 
 
Tris (20 mM) / Sucrose (250 mM) solution, pH 7.4 (homogenization solution) 
Tris (20 mM) was prepared by dissolving D(+)-Sucrose (250 mM) in Tris (50 mM, pH 7.4) under 
stirring and concentration was corrected with deionized water. The solution was stored for 
maximum two weeks at 4°C. 
 
Tris-acetate-EDTA buffer (TAE), pH 8 (buffer for agarose gel electrophoresis) 
Tris (40 mM) was dissolved in in deionized water and pH was adjusted to 8.0 using acetic acid 
followed by addition of Na2EDTA (2 mM). The buffer was stored at room temperature.  
 
HBSS buffer with 0.1% BSA (buffer for Cx43 gap junction assay) 
HEPES (20 mM), NaCl (13 mM), Glucose (5.5 mM), KCl (5.4 mM), NaHCO3 (4.2 mM), CaCl2 
(1.25 mM), MgCl2 (1 mM), MgSO4 (0.8 mM), KH2PO4 (0.44 mM) and Na2HPO4 (0.34 mM) were 
dissolved in autoclaved water and pH was adjusted to 7.4. The buffer was stored at 4°C. BSA 
(0.1%, w/v) was dissolved in buffer prior to use. 
 
Laemmli sample buffer 5X 
SDS (10%, v/v), glycerol (50%, v/v), β-mercaptoethanol (25%, v/v), bromphenol blue (0.25% 
w/v), Tris-HCl (250 mM) were dissolved in deionized water and pH was adjusted to 6.8. The buffer 
was stored at 4°C and used under the fume hood.  
 
TBST buffer for Western blot 
Tris (20 mM), NaCl (150 mM), Tween 20 (0.1%) were dissolved in deionized water and pH was 
adjusted to 7.6. The buffer was stored at RT.  
 
Proteins transfer buffer for Western blot 
Tris (25 mM), glycine (190 mM), and methanol (20%, v/v) were dissolved in deionized water and 
pH was adjusted to 8.3. The buffer was stored at RT 
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Gel staining solutions with colloidal Coomassie BrilliantBlue G-250 
Solution A: Methanol (50%, v/v), phosphoric acid (2%, v/v) were diluted in deionized water.  
Solution B: Solution A was supplemented with ammonium sulfate (1.3 M). 
Solution C: Solution B was supplemented with Coomassie G-250 (0.066%, w/v). 
 
LB medium 
LB medium powder (25 g) was added to 1 L deionized water and the suspension was autoclaved. 
The medium was stored at 4°C. 
 
LB agar plates  
LB agar (32 g) was added to 1 L deionized water and the suspension was autoclaved. Antibiotic 
(ampicillin/kanamycin) was added after the solution has cooled down to about 50°C. The agar was 
then poured into the petridishes for solidification. The plates were stored at 4°C.  
 
6.1.11 Radioligands  
Precursors of the radioligands were synthesized in AK Prof. Dr. C. E. Müller and labeling was 
performed by Quotient Bioresearch, UK. 
Radioligand Specific activity Supplier code Supplier 
[³H]BRV 94 Ci/mmol TRQ40419 Quotient Bioresearch, UK 
[3H]LEV 98 Ci/mmol TRQ40411 Quotient Bioresearch, UK 
[3H]MSX-2 84 Ci/mmol TRQ40688 Quotient Bioresearch, UK 
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6.2 Molecular Biology  
6.2.1 Transformation  
Transformation refers to the taking up of exogenous DNA by bacteria. Bacteria were made 
chemocompetent by incubating the cells with calcium chloride (CaCl2). CaCl2 improves the 
binding of the DNA to the cell wall and further the uptake is improved by heat shock (raising 
the temperature to 42°C for 40 s). Plasmid-DNA which has to be transformed mostly contains 
resistance genes against antibiotics. Therefore, the selection of the transformed bacteria is done 
by adding the particular antibiotic to the growth medium.265  
6.2.1.1 Preparation of competent bacteria  
An overnight grown preculture (4 ml) of E. coli TOP10 was added to 40 ml LB medium and 
grown to an OD550 of 0.5 (37°C, 220 rpm). The culture was centrifuged (1700 g, 4°C, 20 min) 
and the pellet was resuspended in 20 ml of sterile ice cold 0.1 M CaCl2 solution followed by 
incubation for 30 min on ice. The suspension was centrifuged (1700 g, 4°C, 20 min) and the 
pellet was resuspended in 2 ml of ice cold 0.1 M CaCl2 solution and incubated for another 30 
min on ice. Glycerol (0.5 ml) was added to the bacterial suspension and 100 µl aliquots were 
stored at -80°C. 
6.2.1.2 Transformation of competent bacteria 
Transformation with the desired plasmid was performed using E. coli competent bacteria. A 
frozen aliquot (100 µl) of bacterial suspension was thawed on ice for 30 min. Plasmid (10 – 50 
ng) was mixed with the bacterial suspension and further incubated on ice for 30 min. The 
bacterial suspension was then heat shocked (42°C, 40 s) in a thermoblock. The mixture was 
again incubated on ice for 2 min. LB medium (200 µl) was added to the cells and the culture 
was incubated on a thermoblock (37°C, 300 rpm, 1 h). Finally the whole mixture was spread 
on an LB agar plate containing the antibiotic for which the plasmid confers resistance gene, 
e.g. ampicillin and kanamycin. The plates were inverted and incubated (37°C, 18 h) and single 
clones were picked for further analysis. 
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6.2.2 Isolation and purification of plasmids 
Most of the current methods used for isolation of amplified plasmids from bacteria are based 
on the procedure introduced by Birnboim and Doly.266 The bacterial pellet is treated with a 
mixture of sodium dodecylsulfate (SDS), sodium hydroxide (NaOH) and 
ethylenediaminetetraacetic acid (EDTA). The increased pH by NaOH helps to denature the 
bacterial DNA and SDS denatures the proteins. EDTA captures the divalent cations from the 
bacterial nucleases, thereby preventing the degradation of plasmid-DNA. The pH of the 
reaction is neutralized by the addition of a weak acid, e.g. acetic acid. The neutralization causes 
an incomplete renaturation of bacterial genomic DNA and it can be separated by centrifugation 
or filtration. The supernatant obtained by this procedure contains the plasmid-DNA. The 
plasmid-DNA is then precipitated with ethanol and can be separated by centrifugation or 
filtration. This method yields purified plasmid-DNA. 
6.2.2.1 Plasmid Mini-preparation 
Single clones were picked from the overnight grown LB plates and incubated in 4 ml of 
antibiotic containing LB medium followed by incubation in shaker (37°C, 220 rpm, 18 h). The 
Zymo Research miniprep-Classic kit was used for plasmid isolation and plasmid was eluted in 
sterile water. The procedure was performed according to the manufacturer’s protocol. 
6.2.2.2 Plasmid Maxi-preparation 
Maxi-preparation was used for larger yield of plasmids. Bacterial preculture was prepared by 
inoculating LB medium (4 ml) with bacterial glycerol stock (50 µl) followed by incubation in 
a shaker (37°C, 220 rpm, 6 h). The preculture was then transferred to LB medium (100 ml) 
containing antibiotics in an Erlenmeyer flask followed by incubation in the shaker (37°C, 220 
rpm, 18 h). The maxiprep kit from Zymo Research was used for the plasmid isolation according 
to manufacturer’s protocol and plasmid was eluted in sterile water.  
6.2.3 Preparation of glycerol stocks 
The glycerol stocks were prepared by adding 200 µl of sterile glycerol to 800 µl of bacterial 
suspension in fresh LB medium without antibiotics. The stocks were stored at -20°C for 24 h 
followed by long term storage at -80°C. 
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6.2.4 Gel electrophoresis 
Electrophoresis is a technique capable of separating macromolecules (DNA, RNA, and 
proteins) based on their sizes under electric current. DNA carries negative charge due to the 
phosphate group backbone, therefore it moves towards the positive electrode during 
electrophoresis. The size of the DNA molecule is the decisive factor for its separation, since 
the other two important factors for standard electrophoresis, i.e. the shape and charge-to-mass 
ratio of molecules are identical for DNA samples. A gel is prepared by boiling agarose in water 
which forms a meshwork of small pores. These pores are suitable to separate nucleic acids 
ranging from 1 – 30 kbp for 0.5% agarose gel and 1 – 300 bp with even single nucleotide 
differentiation for 40% agarose gels. For the visualization of the DNA fragments, a DNA 
intercalating dye, e.g. GelRed™ is used, which gives fluorescent signals when exposed to UV 
light.265  
Agarose was added to TAE buffer to get a final concentration of 1% and the solution was 
heated in a microwave oven until the agarose was dissolved and the solution was clear. After 
the solution reached a temperature of about 45°C, the GelRed™ DNA stain was added to the 
(1:10000) liquid gel. The liquid gel solution was added to gel casting chamber and combs were 
inserted. After the hardening of the gel, the whole chamber with the gel was placed in the 
electrophoresis chamber filled with TAE buffer. Samples were mixed with 6X gel-loading dye 
and loaded in the wells. Lamda DNA/HindIII and phiX174 DNA HaeIII were used as DNA 
ladders for size comparison. A voltage of 100 V was applied for 30 min and DNA bands were 
visualized under UV light in a gel documentation system. 
6.2.5 Restriction digest with endonucleases 
Restriction endonucleases were discovered in the early 1950s,265 when it was shown that some 
bacterial strains are immune to bacteriophage infection. Bacteria produce enzymes which add 
methyl groups to their DNA, so that it can be differentiated from the invading foreign DNA. 
Among all three types I, II and III of endonucleases, type II is the most important for foreign 
DNA digestion. The recognition sequence for endonuleases are palindromes (sequence read 
the same in either direction), when cut by restriction enzymes, they produce either blunt or 
sticky ends. The destruction of bacterial DNA is lethal for bacteria, therefore, it is protected 
from type II endonucleases due to the methylation of their DNA, which blocks the degrading 
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enzyme action. The type II endonucleases has a wide range of applications in molecular 
biology particularly in recombinant DNA technology. 
Different restriction enzymes were used for cloning and subcloning of DNA fragments. All 
components of the reaction mixture were pipetted as shown in Table 10. The restriction digest 
mixture was incubated at 37°C for 1 h with high fidelity enzymes and with fast digest enzymes 
at 37°C for 20 min followed by the deactivation of enzymes (80°C, 10 min) on a thermoblock. 
The restriction products were then purified using DNA clean and concentrator kit according to 
manufacturer’s protocol. In case the digested products were separated on agarose gel, the 
corresponding bands containing DNA were carefully cut-out and DNA was recovered using 
Gel DNA recovery kit.  
Table 10: General pipetting scheme of restriction digest for vectors and inserts 
Components  Concentration 
10X Reaction Buffer 1:10 dilution 
10X BSA (if required) 1:10 dilution 
Sterile H2O X µl 
Enzyme(s) 1 U/µg of DNA 
Template DNA (PCR product or vector) 0.5 – 1 µg 
Final volume  20 – 30 µl 
 
6.2.5.1 Dephosphorylation of digested vector  
Dephosphorylation of the digested vector was performed to prevent the re-ligation of the cut 
vector. The components of the dephosphorylation used and concentrations are listed in Table 
11. The reaction mixture was incubated at 37°C for 25 min on a thermoblock followed by heat 
inactivation at 65°C for 5 min.   
Table 11: Pipetting scheme of dephosphorylation reaction mixture 
Components Concentration 
NEB-Buffer 2 1:10 dilution 
10x Phosphatase buffer 1:10 dilution 
Sterile H2O X µl 
Antarctic phosphatase  1 µl 
Digested vector  ~ 100 ng 
Final volume  25 µl 
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6.2.6 Ligation 
The joining of two DNA fragments is known as ligation and the enzyme catalyzing this 
reaction is called the DNA ligase. Ligation takes place between the phosphate group (5’ 
terminus) and hydroxyl group (3’ terminus) by the formation of a covalent phosphodiester 
bond by DNA ligase. Ligation requires ATP and the reaction is carried out in three steps, i) 
adenylation (addition of AMP) to the active center of the enzyme, ii) transfer of AMP to the 
5’ phosphate end, and iii) formation of a phosphodiester bond by the release of AMP. In 
contrast to blunt end ligation, sticky end ligation is much more efficient and requires only a 
low concentration of DNA molecules.181, 265 
Ligation of the digested vector and the insert was performed using the T4 DNA ligase enzyme. 
The reaction mixture as listed in Table 12 was incubated at room temperature for at least 1 h 
or alternatively incubated overnight at 16°C.  
Table 12: Components of ligation reaction 
Material Concentration 
DNA Insert  ~ 150 ng 
Plasmid ~ 50 ng 
10X Buffer  1:10 dilution 
T4 ligase  5 U 
ATP  100 mM 
Sterile H2O X µl 
Total Volume 20 – 25 µl 
 
6.2.7 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) was invented by Kary Mullis in 1985 for which he 
received a Nobel Prize in 1993.267 PCR technique extended the range of DNA analysis such as 
DNA cloning, DNA-based phylogeny, functional analysis of genes, diagnosis of hereditary 
diseases, and detection of pathogens. PCR allows amplification of the target DNA-sequence 
using minute amounts of DNA. It is carried out in a reaction tube by mixing the template DNA 
with a set of oligonucleotides (primers), DNA polymerase, deoxynucleotides, and their 
corresponding buffers. The mixture is incubated at a series of preprogrammed temperatures in 
a thermal cycler. The DNA in the mixture is denatured by heating to 98°C resulting in the 
disruption of double and triple hydrogen bonds holding the complementary strands of DNA 
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together. Thereafter the mixture is cooled down to 50 – 60°C, allowing the annealing of two 
primers to the specific sequence site in the template DNA. The annealing temperature is usually 
kept 2 – 3°C lower than the melting temperature (Tm) of the primers to ensure efficient 
annealing. The approximate melting temperature of a primer can be calculated by the following 
Equation 1.265, 268 
Tm = 4 x (n*(C) + n(G) + 2 x (n(A) + n(T)) 
Equation 1: Calculation of melting temperature (Tm) of a primer.  
n: Number of nucleotides 
A, C, G, and T: adenine, cytosine, guanine, and thymine nucleotides  
 
The primers are chemically synthesized and are typically 18 – 30 bp long with ~50% GC 
nucleobase content. The temperature of the PCR mixture is raised to 72°C, which is the 
optimum working temperature of DNA polymerase (DNA pol). DNA pol attaches to the 3’ 
end of the primer which is annealed to the target DNA sequence and incorporates ~ 1000 
nucleotides/min synthesizing a new strand of DNA. Mg2+ is a cofactor for the DNA pol and 
also plays a role in the primer annealing, therefore, its concentration shall be taken into account 
during PCR. The denaturation-annealing-synthesis cycles are repeated 25 – 32 times which 
results in the exponential increase of double stranded template DNA.269 
The PCR reactions were performed using a high-fidelity DNA polymerase enzyme (Pyrobest 
or Q5). The addition of 2 – 5% of DMSO in some amplification reactions particularly with GC 
rich DNA resulted in a better yield. As a negative control water in place of DNA was used. A 
general PCR reaction scheme is shown in Table 13 and a general program cycle in Table 14.  
Table 13: General pipetting scheme for a PCR reaction 
Components  Concentration 
Forward-Primer 0.3 µM 
Reverse-Primer 0.3 µM 
dNTPs 1 mM 
10X buffer 1:10 dilution 
Polymerase  1 U / reaction  
Sterile H2O X µl 
Template DNA  ~ 20 ng 
Final volume  25.0 µl 
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Table 14: Standard PCR program 
 Process Temperature Time Cycles 
Step 1 Initial denaturation  98°C 4 min  1x 
Step 2 Denaturation  98°C 30 s  
32x 
 
Step 3 Primer hybridization  Tm – 4°C 30 s 
Step 4 Elongation 72°C 1 min / 1Kb 
Step 5 Terminal elongation  72°C 10 min 1x 
Step 6 Storage  4°C   
 
6.2.8 Site-directed mutagenesis 
Site-directed mutagenesis is a simple and versatile technique to create a desired mutation at 
any point in a gene using the PCR technique. The mutations are introduced in the gene by using 
a pair of complementary primers containing desired mutations and a plasmid containing the 
gene of interest. Generally a small plasmid such as pUC19 with ~ 2.7 kbp is used for site-
directed mutagenesis. The whole plasmid will be amplified with this method like a normal 
PCR reaction with minor changes of primer concentration and low temperature for primer 
hybridization as shown in Table 15 and Table 16. After amplification, the DNA was purified 
using DNA clean and concentrator kit according to manufacturer’s protocol.  
Table 15: General Pipetting scheme for a PCR-mediated site-directed mutagenesis reaction 
Components Concentration 
f-primer 1 µM 
r-primer 1 µM 
dNTPs 2 mM 
10X buffer 1:10 dilution 
Ster. H2O X µl 
Pyrobest enzyme  1 U / reaction 
Template DNA  ~20 ng 
Final volume  25.0 µl 
 
 
Table 16: PCR program for site-directed mutagenesis 
 Process Temperature Time Cycles 
Step 1 Initial denaturation  94°C 4 min  1x 
Step 2 Denaturation  94°C 30 s  
20x Step 3 Primer hybridization  55°C 30 s 
Step 4 Elongation 72°C 1 min / 1Kb 
Step 5 Terminal elongation  72°C 10 min 1x 
Step 6 Storage 4°C   
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After the PCR-mutagenesis the reaction mixture contains both the mutated plasmid and mother 
plasmid due to the semi-conservative nature of DNA replication. However, the mother 
plasmids without mutations can be selectively degraded by the action of restriction enzyme 
DpnI.270 DpnI digests the methylated DNA and since the mother plasmid is Dam methylated, 
they are sensitive to DpnI digestion.  
 
Figure 46: Recognition site of DpnI enzyme on methylated DNA. 
 
Pipetting scheme for the DpnI digestion mixture is demonstrated in Table 17. The reaction 
mixture was incubated for 90 min at 37°C in a thermoblock. Thereafter DpnI was inactivated 
at 80°C for 20 min. Subsequently mixture was used to transform chemocompetent E. coli cells 
for plasmid amplification.  
Table 17: Pipetting scheme for DpnI digestion of methylated DNA 
Components Volumes (µl) 
Purified PCR product 10 
10X NEB-4 buffer  2 
DpnI (20U) 1 
Sterile H2O 7 
Final volume 20 
  
6.2.9 Primer design 
The primers used in this study were longer than 18 bases. The primers were designed by 
keeping the GC-content of at least 48% and melting temperature below 70°C. The primers for 
site-directed mutagenesis contained at least 15 nucleotides complementary to the anti-sense 
strand flanking both 3’ and 5’ ends of the introduced mutation. The flanking with extra 
nucleotides on both ends provides stable annealing of the primer, despite the mismatch in the 
middle of the primer sequence. The primers used for the Gibson assembly method were 
designed by using the NEBuilder assembly online tool. Furthermore all the designed primers 
were analyzed using the online tool Oligoanalyzer 3.1 for formation of hairpins. 
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6.2.10 Sequencing 
Isolated and purified plasmids from putative positive clones were sequenced to verify the 
success of cloning and to confirm the mutation free sequences. The analysis was performed by 
GATC Biotech AG, Germany. Sample for sequencing was prepared by diluting 1 µg DNA in 
in 30 µl of sterile water.  
6.2.11 Gibson assembly: one-step assembly of multiple DNA fragments 
Gibson assembly method is a novel method for assembling multiple DNA fragments of 
variable lengths and end compatibilities. This method is highly suitable for assembling large 
and complex DNA constructs without relying on the availability of restriction sites. In this 
approach, multiple overlapping double stranded DNA fragments obtained by PCR 
amplification are combined with Gibson master mix and incubated at 50°C for 1 h. This single-
tube isothermal reaction then results in seamlessly joined DNA construct or plasmid (see 
Figure 47). The Gibson assembly method make use of the following three enzymes for 
assembling multiple DNA fragments:   
i. Exonucleases (5’-T5) recess double stranded DNA from 5’-end creating a single-
stranded 3’ overhang that is complementary to 3’ overhang of adjacent DNA fragment 
at overlap region. 
ii. DNA polymerase (Phusion® pol) fills the gaps in the annealed fragments. Taq pol can 
also be used in this method, however Phusion® pol is preferred due to its inherent proof-
reading activity and high-fidelity. 
iii. DNA ligase subsequently covalently seals the nicks in the assembled DNA. 
iv. The general pipetting scheme for the Gibson assembly method is given in Table 18. 
After mixing up the DNA fragments (0.02 – 0.05 pmols) with Gibson master mix. The 
mixture is incubated in a thermocycler at 50°C for 60 minutes, followed by subsequent 
transformation of competent E. coli directly with 2 µl of reaction mixture. The 
assembled DNA constructs can as well be stored at -20°C for future transformations.  
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Equation 2: Formula to calculate amount of DNA in moles 
 
Figure 47: Schematic diagram of Gibson assembly method for generating constructs with multiple DNA 
fragments. DNA fragments sharing terminal sequence are PCR amplified. The double-stranded DNA sequences 
are mixed with Gibson assembly master mix. This mix possesses three enzymatic activities, i.e. 5’-exonuclease 
creates single-stranded 3’ overhangs, polymerase fills the gaps in the annealed fragments and DNA ligase seals 
nicks in the assembled DNA.271 
 
Table 18: General pipetting scheme of Gibson assembly method 
Components 2 – 3 Fragment Assembly 4 – 6 Fragment Assembly 
Total amount of Fragments X µl  (0.02 – 0.5 pmol) X µl  (0.2 – 1 pmol) 
Gibson Assembly Master Mix (2X) 10 µl 10 µl 
Deionized H2O 10 – X µl 10 – X µl 
Total Volume  20 µl 20 µl 
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6.3 Expression and purification of BoNT/A-HCR  
BoNT/A-HCR sequence was used as described earlier by Benoit et al. (2014).173 Codon-
optimized cDNA of BoNT/A-RBD (871 – 1296 amino-acids, Swiss-Prot P10845) for 
expression in E. coli with restriction sites at 3´ SacII and at 5´ KpnI was subcloned into the 
bacterial expression vector pASK-IBA43plus with an N-terminus 6xHis-tag. E. coli top 10 
cells were transformed either with expression plasmid containing BoNT/A-HCR or only vector 
as control. Cultures were grown in 400 ml LB medium supplemented with 100 µg/ml 
ampicillin at 37°C for 4 – 8 h in a shaking incubator to an OD550 = 0.5. The cultures were then 
induced with 100 µg anhydrotetracycline and grown at lower temperature of 30°C for 16 h in 
a shaking incubator. The cells were harvested by centrifugation at 6000 g for 20 min and 1 g 
wet pellet was resuspended in 1 ml of ice cold lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 
10 mM Imidazole, pH 8) supplemented with protease inhibitor cocktail 10 µl/ml in lysis buffer. 
Cell lysis was performed by ultrasonication (3x, 10 s, 5 cycles, 50% power) on ice and lysate 
was cleared by centrifugation at 20000 g for 30 min at 4°C. The 6xHis-tagged BoNT/A-HCR 
was purified from the lysate via immobilized metal affinity chromatography (IMAC) by using 
3 ml spin columns containing nickel-charged nitrilotriacetic acid (Ni-NTA) according to 
manufacture’s protocol for purification under native conditions (HisPur™ Ni-NTA, 3 ml resin 
bed, 88226, Thermo Scientific™, Germany). The residual imidazole from the elute was 
removed, and BoNT/A-HCR was concentrated in assay buffer (50 mM Tris-HCl, pH 7.4) by 
using ultrafiltration with molecular weight cutoff of 10 kDa according to manufacturer’s 
protocol (Amicon-Millipore, Germany). For long term storage 30% glycerol was added to 
purified proteins and stored at -20°C for 24 h and subsequently at -80°C.   
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6.4 Cell culture 
6.4.1 Cultivation of cells 
Mammalian cells were cultivated in different cell culture flasks (25 cm2, 75 cm2, 175 cm2, and 
dishes) with required culture medium (see Section 6.1.9). All steps were performed under 
sterile conditions (laminar air flow hood). The cultures were incubated at 37°C in a humidified 
atmosphere with 5% CO2 in an incubator. Cells were regularly passaged after they had reached 
a confluence of 80 – 90%. The old medium was decanted and the cells were washed twice with 
sterile PBS to remove residual medium. The cells were detached using a trypsin 0.01% solution 
containing 0.6 mM EDTA with incubation at 37°C for 2 – 3 min. Cells adhere to the culture 
flask surface via integrin proteins present at the plasma membrane. Trypsin, which belongs to 
a family of serine proteases, cleaves these integrin proteins and cells get detached. 
Additionally, EDTA reduces the divalent cations, needed for the integrin stability.265  
6.4.2 Cryopreservation of cells  
Cell line stocks were prepared by trypsinization of a confluent 175 cm2 flask. Cells were 
resuspended in culture medium (10 ml) without antibiotics and centrifuged (1200 g, 5 min, 
RT). The pellet was then resuspended in 3 ml of the freezing medium containing 10% DMSO 
and 90% FCS. Freezing medium (2X) for HeLa cells was prepared by diluting DMSO (20%, 
v/v) and FCS (30%, v/v) in DMEM basal medium. Suspended HeLa cells were mixed (1:1) 
with freezing medium. Aliquots (1 ml each) were pipetted in cryovials and stored first in a 
freezing box for gradual cooling from RT to -80°C at a rate of 1°C/min and after 24 h stored 
at -80°C or in liquid nitrogen for long term storage.  
6.4.3 Counting and seeding of cells 
Cells were detached and resuspended in an appropriate amount of culture medium (5 – 10 ml) 
and centrifuged (5 min, 200 g, RT). The pellet was again resuspended in 5 – 10 ml of culture 
medium and 10 µl of cell suspension was added under the coverslip of a haemocytometer 
(Neubauer-chamber improved, depth: 0.100 mm). The cells were counted in two big squares 
and the average was multiplied by 104 which gave the number of cells/ml. The cell suspension 
was corrected to a defined number of cells per ml according to the following formula:  
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Equation 3: Formula for calculating the number of cells in a given suspension 
V: volume (ml) 
C: number of cells per milliliter (cells/ml) 
  
6.4.4 Lipofection 
Lipofection is a method to transfect cultured cells with a foreign DNA. This technique employs 
small liposomes, which contain synthetic catioinic lipids. Upon interaction with DNA, they 
form lipid-DNA complexes. These complexes get fused with the plasma membrane of cells, 
thereby transport the foreign DNA into the cytoplasm with high efficiency. Lipofection can be 
used for both transient and stable DNA expressions and is found to be more effective as 
compared to other methods like calcium phosphate or the DEAE-dextran transfection 
methods.272 
For transfection, cells (2 x 106) were seeded in a 25 cm2 culture flask containing full medium 
followed by incubation (37°C, 16 h). The old culture medium was exchanged against 6.25 ml 
of new full culture medium without antibiotics and the culture was incubated (37°C, 3 h). Basal 
medium (600 µl) without any supplements was mixed with 25 µl of Lipofectamine 2000 and 
incubated for 5 min at RT. plasmid-DNA (10 µg) was diluted in basal medium without any 
supplements to make a final volume of 625 µl. Both solutions were mixed giving a mixture of 
1225 µl, which was incubated for 20 min at RT. The transfection mixture was then dropwise 
added to the cells followed by incubation (37°C, 5% CO2, 24 – 48 h). The culture medium was 
then replaced against selection medium containing the antibiotic corresponding to selection 
markers. 
 
 
6 Experimental section 
147 
6.4.4.1 Retroviral transfection 
Various methods of gene delivery into the cells are available such as DNA injection, 
lipofection, and gene gun technology. However gene delivery using genetically engineered 
retroviruses is one of the most effective methods.273 Retroviruses are special viruses, which 
after infecting the cells can reverse transcribe their own RNA into DNA by the virally encoded 
enzyme reverse transcriptase.273 This DNA copy is then integrated into the host genome by a 
virally encoded enzyme called integrase. Thereafter the host transcriptional and translational 
machinery is used for the expression of viral genes.  
The retrovirus genome contains the essential genes for viral production, i.e. gag, pol, env, and 
the packaging signal (Ψ) along with other genes flanked on both ends by long terminal repeats 
(LTRs). The gag gene encodes for group-specific antigen on capsids, the pol gene for the viral 
polymerase and the env gene for the viral envelope. LTRs are large redundant DNA sequences 
where the viral promoters and transcriptional enhancers are located. These regions are essential 
for reverse transcription and replication. The packaging signal sequence (Ψ) interacts with the 
viral proteins to ensure proper packaging of the viral RNA into the virion.273 The use of 
competent retrovirus is not feasible, since the infected cell will die. Therefore, genetically 
engineered viruses are used in which all viral protein coding regions are removed other than 
genes responsible for viral RNA encapsulation, reverse transcription and integration.274 The 
packaging cell line is created using helper virus DNA in which gag and pol genes are encoded 
on one plasmid while the env gene is encoded on a separate plasmid. This strategy prevents 
the possibility of recombination events and their related dangers.275 The retroviral transfection 
mechanism is illustrated in Figure 48.  
The cell line GP+envAM12 is an example of packaging cell line derived from mouse fibroblasts 
and used for the retroviral vector system. These packaging cells harbor two plasmids, one 
contains the env gene and a selection marker for hygromycin B while the second plasmid 
contains the gag and pol genes of the murine leukemia virus (MuLV) and an additional gpt 
gene encoding a xanthine-guanine phosphoribosyltransferase.275-277 The presence of 
hygromycin B, hypoxanthine, xanthine and mycophenolic acid in the culture medium (HXM 
medium) causes a selection pressure on the cells preventing them from losing the three viral 
genes. Mycophenolic acid inhibits the de novo purine synthesis, therefore cells expressing 
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xanthine-guanine phosphoribosyltransferase for purine synthesis and confer hygromycin B 
resistance will survive. Since the viral packaging signal (Ψ) is missing in the packaging cells 
to avoid the formation of replication-competent viruses, a separate plasmid is used. This 
plasmid contains the gene of interest in the multiple cloning site and a packaging signal (Ψ). 
Both of these genes are flanked by LTRs. The retroviral plasmids have an origin of replication 
and antibiotic resistance for propagation in bacteria. Examples of such plasmids are pLXSN 
and pLVX-IRES-mCherry, which were used in this work. While retroviruses can infect 
mitotically active cell types, lentiviruses, a subtype of retroviruses, can infect almost all types 
of mammalian cells including non-dividing cell, stem cells, and primary cells.278 The lentiviral 
plasmid (pLVX-IRES-mCherry) was utilized in this study, which allowed the isolation of 
monoclones with high recombinant protein expression using fluorescence assisted cell sorting 
(FACS). However, a drawback of this plasmid was the absence of antibiotic selection marker 
which may result in low yield of recombinant protein over increasing passages.     
In order to increase the infectivity of viruses, a vector encoding the glycoprotein G of the 
vesicular somatitis virus (VSV-G) was co-transfected with retroviral plasmid. The VSV-G-
molecules gets integrated in the cellular membrane and eventually in the retrovirus envelope. 
The retrovirus with glycoproteins will not only infect by binding to specific receptors but also 
by binding to phospholipids non-specifically.279 The last step is the harvesting of viruses 
containing the gene of interest from the medium. These viruses are then added to the target 
cells. The successfully transfected cells can then be selected based on either a resistance gene 
such as neomycin or a fluorescence protein like mCherry.  
 
6 Experimental section 
149 
 
Figure 48: Production of retroviruses in helper cells. (1) A recombinant retroviral plasmid is constructed which 
contains the gene of interest (green), the virus packaging signal Ψ (black), and the essential sequences LTRs 
(blue). (2) A helper cell is co-transfected with a retroviral plasmid and a VSV-G encoding plasmid. (3) The viral 
mRNA is transcribed from the retroviral plasmid by the transcriptional machinery of the helper cell. (4) Helper 
cells harbor two separate plasmids responsible for expression of structural proteins of viruses. (5) The packaging 
sequence (Ψ) on the recombinant viral RNA is recognized by the packaging proteins resulting in the formation of 
virus cores which are enveloped by cell membrane containing VSV-G envelope proteins. (6) Subsequently 
infectious virions bud from the cell and are collected in the medium. These virions can be further utilized for 
transducing the target cells. LTR: long terminal repeat, Ψ: packaging signal, VSV-G: glycoprotein G of the 
vesicular somatitis virus. Diagram concept taken from Hu and Pathak (2000).273 
 
Packaging cells GP+envAM12 (1.5 x 106 cells) were seeded in a 25 cm2 flask with 5 ml of 
DMEM medium supplemented with FCS (10%), penicillin (100 U/ml), and streptomycin (100 
µg/ml) followed by incubation (37°C, 5% CO2, 24 h) prior to transfection. Next day the cells 
were transfected using Lipofectamine 2000 with 10 µg of DNA comprising the retroviral 
plasmid (6.25 µg) and VSV-G plasmid (3.75 µg). After 15 h of transfection, the old culture 
medium was exchanged with 3 ml of fresh medium DMEM medium containing FCS (10%), 
penicillin (100 U/ml), streptomycin (100 µg/ml), and sodium butyrate (5 mM) followed by 
incubation (32°C, 5% CO2, 48 h). The supernatant (3 ml) containing the virus particles was 
removed and sterile filtered using a 2 µm filter to harvest the viruses. The filtrate containing 
the viruses was mixed with 6 µl of polybrene solution (4 mg / ml in H2O, sterile filtered). 
Subsequently, the medium of the target cell line (CHO-K1 or HeLa) a 25 cm2 flask was 
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replaced with mixture and the cells were incubated at 37°C for 2.5 h. After the incubation, 
mixture containing the viruses was discarded and 5 ml of fresh culture medium supplemented 
with antibiotic like G418 dependent on the cell line (see Section 6.1.9) was added to the cells 
followed by incubation (37°C, 5% CO2, 48 – 72 h). After three days of incubation, the medium 
was regularly changed until the non-transfected cell death process ended. 
6.5 Protein sample preparations 
6.5.1 Rat cortical membrane preparations 
Membrane preparations of rat cortex were used for performing some of the radioligand binding 
assays. Frozen rat brains were thawed in ice-cold sucrose solution (0.32 M). The brains were 
then placed top side on an ice-cold glass plate and cortex was carefully dissected along the two 
hemispheres with a scalpel. The cortical tissue was stored in ice-cold sucrose solution (0.32 M). 
The cortical tissue in sucrose solution was disrupted with a Potter glass homogenizer for about 
3 min followed by centrifugation (1000 g, 4°C, 10 min). The supernatant was carefully 
collected and centrifuged (37000 g, 4°C, 1 h), whereas the pellet (P1) was discarded. The 
supernatant was decanted and pellet (P2) was resuspended and homogenized (Ultraturrax, 
setting 3, 10 s) in ice-cold deionized water. The homogenate was centrifuged (37000 g, 4°C, 
1 h) and again the resulting pellet was resuspended and homogenized (Ultraturrax, setting 3, 
10 s) in ice-cold Tris-HCl buffer and pelleted by centrifugation (37000 g, 4°C for 1 h). 
Subsequently, the supernatant was decanted and the pellet was resuspended and homogenized 
(Ultraturrax, setting 3, 10 s) in a small volume of ice-cold Tris-HCl buffer. The homogenized 
cortical membrane preparations were aliquoted in 1.5 ml tubes for shock-freezing in liquid 
nitrogen and stored at -80°C for future use. 
6.5.2 Preparation of cellular homogenates 
Mammalian expression plasmid pcDNA4-hSV2A-GFP was constructed by cloning cDNA of 
wt human SV2A (NM_014849.3) fused to green fluorescence protein (GFP) at the C-terminus 
into the pcDNA™4/myc-His-A vector with restriction enzyme HindIII and XhoI. CHO-K1 
cells were transfected with pcDNA4-hSV2A-GFP conferring zeocin resistance using 
Lipofectamine2000. A stable cell line expressing hSV2A-GFP was established by using 100 
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µg/ml zeocin in selection medium. Single clones with strong fluorescence signal were selected 
by fluorescence-assisted cell sorting (FACS, Aria™ III cell sorter, BD Biosciences). Single 
clones were further cultivated in selection medium and early cell passages (P4 – P8) were used 
for the preparation of cellular homogenate for binding assays. For homogenate preparation, 
cells in culture dishes (152 cm2) were grown to 80 – 90% confluence and washed with 10 ml 
of PBS followed by scraping them off with a rubber scraper in 3 –5 ml of ice-cold buffer (PBS 
/ 2 mM EDTA). The collected cells were then pelleted by centrifugation (1000 g, 10 min, 4°C). 
The pellet was resuspended in ice-cold homogenization solution (20 mM Tris-HCl, 250 mM 
sucrose, pH 7.4) and homogenized two times (Ultraturrax, setting 5, 15 s) with 5 min 
incubation on ice between two repetitions. The homogenate was then supplemented with a 
protease inhibitor cocktail, 10 µl/ml of homogenate, and aliquots with a concentration of 5 – 8 
mg/ml were shock-frozen in liquid nitrogen and stored at -80°C until further use.  
The cDNA of the human A2A adenosine receptor (hA2AAR, NM_001278500.1) and enhanced 
GFP from corresponding mother plasmids were amplified using overlapping primers for the 
pcDNA™4/myc-His A vector. The overlapping primers were designed with the NEBuilder 
Assembly tool (NewEngland Biolabs). Amplified cDNA of the hA2AAR and GFP were 
assembled with the pcDNA™4/myc-His A vector in such a way that the GFP was fused at the 
C-terminus of the hA2AAR using the Gibson assembly cloning kit (NewEngland Biolabs) as 
explained is Section 6.2.11. For the construction of an expression plasmid for mouse connexin 
43 (mCx43, NM_010288.3) fused to enhanced GFP at the C-terminus, the cDNA of mCx43 
was amplified using overlapping primers designed with the NEBuilder Assembly tool. The 
plasmid pcDNA4-mCx43-GFP was constructed as described for pcDNA4-hA2AAR-GFP, 
using the Gibson assembly cloning kit. The CHO-K1 cells were transiently transfected with 
each of the plasmid using Lipofectamine2000 as explained in Section 6.4.4. Cellular 
homogenates with both cell lines were prepared as described above for the hSV2A-GFP 
expressing cells.  
6.5.3 Cell membrane and cell debris preparations 
The cell membranes and cell debris were used in some radioligand binding assays. Cells were 
grown to a confluence of 80% in a culture dish and medium was aspirated followed by a 
washing step with 5 ml PBS. At this step dishes containing the cells were either stored at -80°C 
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until further use or the procedure was continued. Cells were scrapped off with a rubber scraper 
in 3 ml of ice-cold buffer (PBS / 2 mM EDTA) and collected in a beaker on ice. Cells were 
homogenized using Ultraturrax (level 6, 15 s) and the step was repeated. Cell homogenate is 
then centrifuged (4°C, 1000 g, 10 min) to separate pellet (P1) from supernatant (S1). The pellet 
(P1) contained the cellular components like cell debris and cell nuclei and the supernatant (S1) 
contained the membranes. The supernatant (S1) was centrifuged (4°C, 38000 g, 10 min) to 
obtain a pellet (P2). Meanwhile, the pellet (P1) was resuspended in small volume of Tris-HCl 
and aliquoted in 1.5 ml tubes, which after shock-freezing in liquid nitrogen were stored at -
80°C. The pellet (P2) was resuspended in 50 mM Tris-HCl (0.1 ml / dish) and small aliquots 
of 1 ml were prepared. The aliquots of cell membrane suspensions were also shock-frozen in 
liquid nitrogen and stored at -80°C until further use. Bradford method was used for the 
determination of protein concentration as explained in Section 6.6.2.   
6.6 Recombinant protein analysis 
6.6.1 Fluorescence microscopy 
CHO-K1 transfectants of SV2A-GFP or its variants were seeded on coverslips, 2 days prior to 
fixation in standard culture medium without zeocin. Cells were washed two times with PBS 
and third time with DAPI (1:10000, v/v) diluted in PBS. Coverslips were incubated with ice-
cold 1:1 methanol/aetone (v/v) mixture and incubated in freezer (-20°C, 20 min). After the 
incubation, cells were washed 3x with PBS. Subsequently, the coverslips were mounted onto 
the glass slides with mounting medium (ProLong Gold antifade reagent, Invitrogen). The 
enhanced GFP tagged proteins were excited by a wavelength of 488 nm and emission was 
detected at 515 nm using a confocal microscope.   
6.6.2 Bradford assay 
The Bradford protein assay (1976) is widely used to determine the total protein concentration 
in a given a sample.263 This method measures the presence of the basic amino acid residues 
arginine, lysine, and histidine, which form a complex with Coomassie dye under acidic 
conditions producing a dark blue color. Five to eight dilutions of BSA protein as standard with 
a range of 10 to 500 µg/ml were prepared. In a 96-well transparent plate 10 µl of protein sample 
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was diluted in 190 µl of Bradford reagent and incubated for 5 min at RT in dark. Subsequently, 
the absorbance of the samples were measured at 595 nm. A calibration curve was obtained by 
plotting the concentrations on the X-axis and their corresponding absorbance values on the Y-
axis (see Figure 49). Absorbance of the unknown protein was incorporated in the line equation 
and solving it for X gave the protein concentration (see Figure 49).  
 
Figure 49: Example of a calibration curve with BSA as standard for Bradford protein assay. Abs, absorbance; 
BSA, bovine serum albumin. 
 
6.6.3 Fluorimetric measurement 
Samples containing pure GFP or GFP-fused proteins were diluted in buffer (50 mM Tris-HCl, 
pH 7.4) and added to the wells in a 96-well solid-bottom black plate (Nunc, ThermoScientific). 
For fluorescent measurements the volume was corrected and either 50 or 100 µl of sample/well 
was used. Background fluorescence was measured using either buffer for purified GFP or 
cellular homogenate of non-transfected CHO cells for GFP-fused proteins in cellular 
homogenates. Fluorimetric measurements of enhanced GFP were conducted with a microplate 
fluorimeter (Mithras LB940) at room temperature using an either of the two filter set 
combinations (excitation: 485/14 nm and emission: 535/25 nm) or (excitation: 450/30 nm and 
emission: 510/12 nm).   
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6.6.4 Capillary gel electrophoresis system 
The capillary gel electrophoresis with laser-induced fluorescence detector (CGE-LIF) studies 
have been performed by Dr. Sangyong Lee (AK Müller, University of Bonn).  
All experiments were performed on a P/ACE MDQ Capillary Electrophoresis system with a 
laser–induced fluorescence detector (Beckman Instruments, Fullerton, CA, USA). Data 
processing was performed by 32 Karat software supplied with the CE instrument. The analysis 
was performed on 50 µm ID bare-fused silica capillaries with a total length of 60 cm (50 cm 
effective length) obtained from Polymicro Technologies (Kehl, Germany).  The excitation and 
emission wavelengths of the laser-induced fluorescence detector were 488 and 520 nm, 
respectively. The capillary and sample tray were kept at 25°C during the measurement. In order 
to form a semiliquid gel in the capillary, preconditioning was performed with 0.1 N NaOH, 0.1 
N HCl, and water at 50 psi (3.4 bar) for 5, 2 and 2 min, respectively, followed by SDS-MW 
gel buffer (AB Sciex, Darmstadt, Germany) at 40 psi (2.8 bar) for 10 min, and eventually a 
separation voltage of – 15 kV was applied for 30 min. This preconditioning step was carried 
out twice and repeated again after 6 sample runs. Electrokinetic injection was at – 5 kV for 20 
s and separation took place with an applied voltage of – 15 kV. To keep the semi-liquid gel 
inside the capillary, a pressure of 30 psi (2.0 bar) was applied to both sides of the capillary 
during the separation. 
6.6.4.1  Protein quantification with CGE-LIF 
Initially a calibration curve was determined with the standard green fluorescence protein using 
various concentrations. The protein samples were diluted in the reaction buffer (100 mM Tris, 
pH 9.0 supplemented with 1% SDS). The dilution factors for each protein sample are shown 
in the results section. The unknown protein concentration was calculated as shown in the 
following example using hSV2A-GFP protein:      
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Calculation example using hSV2A-GFP 
Peak area of hSV2A: 69044 
Equation of calibration curve:           ܻ ൌ 423700000 ∗ ܺ െ 0.00002178 
                                                           69044 ൌ 423700000 ∗ ܺ െ 0.00002178 
Solving equation for X:                      ܺ ൌ 162.95492	݊݃/݈݉ 
The crude cellular homogenate containing hSV2A-GFP was diluted (1:100) in reaction buffer, 
therefore concentration corrected:  
 162.95492 ng/ml * 100 
= 16295.4921 ng/ml 
Since molecular weight of hSV2A-GFP is 117 kDa:  
= 117 x 1000 Da = 117000 Da = 117000 g/mol 
= (16295.4921 ng/ml) / (117000 g/mol) 
= 0.1393 (ng/ml * mol/g) 
= 0.1393 nmol/ml 
= 139.3 pmol/ml 
Total protein concentration in cell homogenate measured with Bradford assay: ~5.00 mg/ml  
Hence, the concentration of hSV2A-GFP in the cellular homogenate can be calculated as 
follows: 
139 pmol/ml / 5.00 mg/ml protein  
= 139 pmol / 5.00 mg protein 
= 27.9 pmol/mg protein 
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6.6.5 SDS PAGE  
Crude cellular homogenates were solubilized using 10% RIPA buffer and solution was cleared 
by centrifugation (10,000 g, 20 min, 4°C). The protein samples (20 µg – 100 µg of protein) 
were mixed with the required volume of 5X Laemmli sample buffer. Samples were reduced 
and denatured by heating for 5 min, BoNT/A-HCR sample at 50°C, SV2A sample at 40°C, 
GFP sample at 95°C, and Cx43 at 65°C. The samples were then loaded into the wells of a 10% 
SDS-PAGE gel along with the standard protein ladder and separated by electrophoresis using 
running buffer (25 mM Tris base, 192 mM glycine, 0.1% SDS, pH 8.3) for 40 min at 200 V. 
After the proteins were separated on the gel, the gel was used for Western blot. The gel used 
to analyze the purity of BoNT/A-HCR was further stained for protein bands with colloidal 
Coomassie BrilliantBlue G-250 solutions (see Section 6.1.10 for A, B, C solutions). The gel 
was incubated under shaking in solution A for 1 h at RT and washed 3x with deionized water. 
The gel was then incubated in solution B under shaking for 1 h at RT. The solution B was 
discarded and the gel was incubated overnight under shaking in solution C. Subsequently, the 
gel was washed several times with water until the bands became clear and the gel was scanned.     
6.6.6 Western Blot analysis  
Proteins from the SDS PAGE gel were transferred onto a nitrocellulose membrane (Protran – 
Whatman, Sigma, Germany) using transfer buffer (see Section 6.1.10). The protein transfer 
was monitored by staining the membrane with Ponceau S solution (0.1%) for 2 min. The 
membrane was blocked for 1 h at room temperature in blocking solution, 5% skimmed milk 
powder in TBST buffer (see Section 6.1.10). After discarding the blocking solution, the 
membrane was incubated overnight at 4°C with the appropriate dilution of the primary 
antibody in dilution solution (2.5% milk in TBST). The primary antibodies were discarded and 
the membrane was washed three times with TBST for 5 min each. Finally, the membrane was 
incubated for 1 h at room temperature with horseradish peroxidase (HRP) conjugated 
secondary antibodies appropriately diluted in dilution solution. After the incubation, the 
membrane was again washed three times with TBST for 5 min each. Subsequently, the HRP 
substrate was added to the membrane (Pierce™ ECL Western Blotting Substrate) and an X-
ray film was developed in the dark room according the manufacturer’s protocol. 
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6.7 Radioligand binding assays  
Radioligand binding assays are highly useful tools to characterize the interaction between a 
radioligand and its protein target such as receptor, transporters, and enzymes.280 These assays 
can be used to determine the affinity of various ligands for a specific protein target as well as 
to determine the density and distribution of this target in a given tissue or protein sample. 
Radioligand binding experiments can be majorly subdivided into three types, i) saturation 
binding experiments, ii) competition binding experiments, and iii) kinetic binding experiments. 
Saturation binding experiments are performed to determine the affinity of a radioligand (Kd) 
for a protein target and the target density (Bmax) in specific tissues or samples. Competition 
binding experiments are useful to determine the affinity (Ki) of unlabeled ligands, which 
compete with the radioligand for specific protein target. Kinetic binding experiments provide 
the information of association kinetic constant (Kon) and dissociation kinetic constant (Koff) of 
the radioligand. 
Radioligand binding experiments work based on the law of mass action: 
ܴ݁ܿ݁݌ݐ݋ݎ	ሺܴሻ ൅ ܮ݅݃ܽ݊݀	ሺܮሻ	 	ܮ݅݃ܽ݊݀ െ ܴ݁ܿ݁݌ݐ݋ݎ	ܿ݋݉݌݈݁ݔ	ሺܴܮ
							ೖ೚೑೑					
ርۛ ۛۛ ۛۛ ۛۛ ሲۛ
							ೖ೚೙							ሱۛ ۛۛ ۛۛ ۛۛ ሮ ሻ 
Equation 4: Equillibrium of receptor-ligand binding based on law of mass action 
Kon: association rate constant (1/M * min) 
Koff: dissociation rate constant (1/min) 
 
ܭௗ ൌ 	݇௢௙௙݇௢௡  
Equation 5: Calculation of equilibrium dissociation constant Kd  
Kd: kinetic equilibrium dissociation constant (M) 
 
Radioligand assays are performed by incubating the radioligand with a preparation containing 
protein of interest for a certain amount of time to reach steady-state conditions. After the 
incubation period the protein-bound radioligand is separated from free radioligand generally 
by using filtration technique. It is important to note that the radioligands should possess high 
affinity (Kd < 5 nM) for target protein, high specific activity ([3H]ligands > 30 Ci/mmol), and 
low non-specific binding (10 – 30%). Unfortunately there is no general procedure for all 
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radioligand assays and therefore assay conditions like temperature, ionic strength of buffer, 
and presence of divalent ions are mostly required to be optimized.280-281 
6.7.1 Competition radioligand binding assay  
Competition experiments are extremely useful to determine the affinity of an unlabeled 
compound indirectly by measuring its ability to compete binding of a fixed concentration of 
the radioligand. By plotting logarithmic concentrations of the competitor on the X-axis against 
the specific binding of the radioligand on the Y-axis, a sigmoidal inhibition curve is obtained 
with inflection point corresponding to the IC50 value of the unlabeled drug. The IC50 value 
corresponds to the concentration of the unlabeled compound at which specific binding of the 
radioligand is inhibited by 50%. The equilibrium inhibition constant Ki of the unlabeled 
compound, which gives affinity of compound for a receptor, is obtained from IC50 value and 
Kd of the radioligand using Cheng-Prusoff equation (see Equation 6). The higher the Ki of the 
unlabeled compound, the lower will be its affinity to the receptor. 
 
Figure 50: Typical curve of a competition binding experiment. Different concentrations of unlabeled compound 
are incubated with the same amount of protein and fixed concentration of the radioligand. The concentration of 
the unlabeled compound at which specific binding of the radioligand is inhibited by 50% corresponds to the IC50 
value.  
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ܭ௜ ൌ 	 ܫܥହ଴1 ൅	 ܮܭௗ
 
Equation 6: Cheng-Prusoff equation 
Ki: equilibrium inhibition constant (M)  
IC50: half maximal inhibitory concentration (M)  
L: concentration of radioligand (M)  
Kd: equilibrium dissociation constant of radioligand (M) 
 
 
Competitive [3H]BRV binding assays were performed essentially as described.49, 104 However, 
protein preparations were adapted according to the requirements of the investigation. Cellular 
homogenate (200 µg of protein / assay vial) was incubated with [3H]BRV (3 nM) and the test 
compound for 240 min at 4°C in 500 µl of cold (4°C) assay buffer (50 mM Tris-HCl, pH 7.4), 
supplemented with 2 mM MgCl2 (see Table 19). The assay racks were placed on a rocking 
shaker and the whole setup was placed in the refrigerator during incubation. The test 
compounds were dissolved either in the assay buffer or in DMSO. The final DMSO 
concentration in the assay did not exceed 0.5% since this concentration had no effect on the 
results. Non-specific binding was determined in the presence of a high concentration of 
unlabeled LEV (1 mM), whereas total binding was determined in the absence of LEV. Specific 
binding was determined by subtracting non-specific binding from total binding. For 
compounds dissolved in DMSO, non-specific and total binding was determined in the presence 
of the corresponding DMSO concentration. [3H]BRV bound to SV2A was separated from 
unbound [3H]BRV by rapid vacuum filtration using double-layered GF/C glass fiber filters 
pre-soaked for 30 min at 4°C in aqueous polyethylenimine (PEI) solution (0.1%). The filters 
were rapidly washed three times with ice-cold assay buffer (1 ml each) using a manual 
harvester and subsequently dried in a drying oven (50°C, 90 min). Filters were transferred to 
scintillation vials and radioactivity on the filters was determined by incubating them in 2.5 ml 
of scintillation cocktail for at least 9 h before measuring with a liquid scintillation counter (Tri-
Carb 2810 TR). The Cheng-Prusoff equation282 was used to calculate Ki values inserting the 
previously determined Kd value of 75 nM for [3H]BRV and the employed radioligand 
concentration of 3 nM.38 For data analysis Prism 6 (GraphPad Inc., La Jolla, CA) was used.  
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Table 19: Pipetting scheme for competition experiments using [3H]BRV 
 Total binding 
(µl) 
Non-specific 
binding (µl) 
Competitive 
binding (µl) 
MgCl2 solution (10 mM) 100 100 100 
Tris-HCl buffer (50 mM, pH 7.4) 200 190 190 
levetiracetam solution (50 mM) - 10 - 
dilution of competitor - - 10 
[3H]BRV in Tris-HCl buffer 100 100 100 
protein in Tris-HCl buffer 100 100 100 
total volume 500 500 500 
 
6.7.2 Homologous competition binding assay 
A competition binding assay is called “homologous binding assay” when the same compound 
in the labeled and the unlabeled form is used and both show the same affinity for the protein 
target.283 This assay can be used as an alternative to the saturation assay to calculate the Bmax 
and the Kd values, where much less amount of the expensive radioligand is needed.259 The 
calculations are performed using the equations shown below:  
For homologous competition assay:  
ܭௗ ൌ 	 ܫܥହ଴ െ 	ܮ 
 
Equation 7: Calculation of Kd in homologous binding assay which is equal to Ki 
Kd: equilibrium dissociation constant (M) 
Ki: equilibrium inhibition constant (M) 
IC50: half maximal inhibitory concentration (M) 
L: concentration of radioligand (M) 
 
The maximum number of binding sites (Bmax) in homologous competition assay (De Blasi et 
al. 1989)259 are calculated as follows:  
ܤ௠௔௫ ൌ 	 ሺܶ݋݌ െ ܤ݋ݐݐ݋݉ሻ ∗ 	ܫܥହ଴ܮ  
 
Equation 8: Calculation of Bmax in homologous competition assay 
Bmax: maximum number of binding sites (cpm) 
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Top: total binding of radioligand (cpm) 
Bottom: non-specific binding of radioligand (cpm) 
IC50: half maximal inhibitory concentration (M) 
L: concentration of radioligand (M) 
 
The Bmax (cpm) is converted to Bmax (fmol/mg) according to Deupree et al. (2002)283 follows:  
 
ܤ௠௔௫	ሺ݂݉݋݈/݉݃ሻ 	ൌ 	 ܤ௠௔௫	ሺܿ݌݉ሻ ∗ 100	݂݂݁. ሺ%ሻ ∗ 2.2 ∗ ݏ݌݁ܿ. ܽܿݐ݅ݒ݅ݐݕ	 ቀ ܥ݅݉݉݋݈ቁ ∗ ܲݎ݋ݐ݁݅݊	ሺ݉݃ሻ
 
 
Equation 9: Conversion of Bmax (cpm) to Bmax (fmol/mg) 
Bmax: maximum number of binding sites 
eff.: counter efficiency (cpm/dpm = cpm in %) 
2.2: conversion factor for cpm to dpm (1 Ci ≅ 2.2 x 1012 dpm) 
spec. activity: specific activity of radioligand (Ci/mmol) 
Protein: total amount of protein per vial  
 
Concentration-dependent homologous competition of [3H]BRV binding using unlabeled BRV 
was performed as described for levetiracetam (LEV) (see Section 6.7.1). Non-specific binding 
was determined in the presence of high concentration of LEV (1 mM). Bound [3H]BRV was 
separated from unbound radioligand by rapid filtration with a manual harvester using a double 
layer of  GF/C filter which had been pre-soaked in 0.1% polyethylenemine (PEI) for 30 min. 
The filters were washed three times (1 ml each) with ice-cold assay buffer and were dried at 
50°C for 90 min in a drying oven. The dried filters with [3H]BRV were transferred into 
scintillation vials and 2.5 ml of scintillation cocktail (Luma Safe, Perkin Elmer) was added. 
The vials were incubated for 9 h and radioactivity was counted with a liquid scintillation 
counter with 52% counting efficiency (Tri-Carb 2810 TR). 
Homologous competition assays with hA2AAR-GFP were essentially performed as 
described.260 Cellular homogenate of CHO-hA2AAR-GFP (400 µg of protein) were incubated 
with [3H]MSX-2 (1 nM) and increasing concentrations of unlabeled MSX-2 in a final volume 
of 400 µl of assay buffer (50 mM Tris-HCl, pH 7.4) at room temperature for 30 min (see Table 
20). Non-specific binding was determined in the presence of CGS15943 (10 µM), whereas 
total binding was determined in the absence of CGS15943. Specific binding was calculated by 
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subtracting the non-specific binding from the total binding. Bound [3H]MSX-2 was separated 
from unbound radioligand by rapid filtration with a manual harvester using a GF/B filter that 
was pre-soaked in 0.3% PEI for 30 min. Filters were rapidly washed three times (2 ml each) 
with ice-cold assay buffer. The filters with [3H]MSX-2 were transferred into scintillation vials 
and 2.5 ml of scintillation cocktail (Luma Safe, Perkin Elmer) was added. After an incubation 
of 9 h, radioactivity was counted with a liquid scintillation counter with 52% counting 
efficiency (Tri-Carb 2810 TR). For data analysis Prism 6 (GraphPad Inc., La Jolla, CA) was 
used.  
Table 20: Pipetting scheme for homologous competition experiments with [3H]MSX-2 
 Total binding 
(µl) 
Non-specific 
binding (µl) 
Competitive 
binding (µl) 
Tris-HCl buffer (50 mM, pH 7.4) 196 196 196 
100% DMSO 4 - - 
CGS15943 solution (4 mM) - 4 - 
dilution of competitor - - 4 
[3H]MSX-2 in Tris-HCl buffer 100 100 100 
protein in Tris-HCl buffer 100 100 100 
total volume 400 400 400 
 
6.8 Cx43 gap junction assay 
6.8.1 Plasmids and cell lines for Cx43 gap junction assay  
The cDNAs of wt mouse Cx43 (NCBI sequence: NM_010288.3) and wt human Cx43 (NCBI 
sequence: NM_000165.4) were amplified from the plasmids pmj-mCX43-IRES-GFP and 
pGEM-T-hCx43 (generous gift from Prof. Klaus Willecke) using overlapping primers 
containing restriction sites, HindIII at 5’ and XhoI at 3’ end, respectively (for primers see 
Section 6.1.7). After the restriction digest, mCx43 and hCx43 were cloned into the mammalian 
expression vector pcDNA™4/myc-His A to obtain the plasmids pcDNA4-mCx43 and 
pcDNA4-hCx43 suitable for transient transfections. The HeLa cell line stably expressing the 
hA2AAR was transiently co-transfected with pcDNA4-mCx43 using Lipofectamine2000 to 
establish the donor cells for generating cAMP. Native HeLa cells were transiently co-
transfected with the plasmid pGloSensor-20F cAMP (Promega) and pcDNA4-mCx43 using 
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Lipofectamine 2000 (Invitrogen) to establish the biosensor cell line containing the cAMP 
sensitive GloSensor luciferase. For the experiments to evaluate the intercellular 
communication in native HeLa cells, donor and biosensor cells were without additional 
transfection of the pcDNA4-mCx43 plasmid were obtained. 
6.8.2 Plate preparation for the Cx43 gap junction assay  
On the day of the experiment donor and biosensor cells were harvested by trypsinization, 
resuspended in full DMEM medium, cell aggregates were dislodged by slow pipetting, and 
cells were counted. Initially 30,000 biosensor cells per well were dispensed in a 96-well solid 
bottom white plate followed by 90,000 donor cells to maintain a 3:1 ratio of donor and 
biosensor cells. Both, donor and biosensor cells, were mixed by pipetting and the co-culture 
was incubated for 4 h at 37°C in an incubator. After the incubation, the full DMEM medium 
was replaced by HBSS buffer supplemented with 0.1% BSA, 200 µM IBMX and 2% 
GloSensor cAMP reagent (“assay buffer”) followed by incubation for 45 min in the dark at 
room temperature. For the evaluation of Cx43 GJ inhibitors, the compounds were added 
directly when DMEM full medium was replaced with the assay buffer. The plate was then 
placed in a plate reader without any filter for the basal luminescence readout. Subsequently, 
either CGS21680 (1 µM), or DMSO (1%), or forskolin (10 µM), respectively, was added, and 
luminescence from each well was measured in a kinetic mode for 1 s with an interval of 2 min 
over a total duration of 20 min (see Figure 51).  
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Figure 51: Workflow for performing Cx43 gap junction assay 
 
6.9 Pharmacophore modeling 
The pharmacophore modeling studies have been performed by Dr. Vigneshwaran 
Namasivayam (AK Prof. Dr. C. E. Müller, University of Bonn) 
The three selected drugs brivaracetam, loratadine, and quinine, which showed high affinity for 
SV2A, were flexibly aligned using the flexible alignment module implemented in Molecular 
Operating Environment (MOE 2014.09).284 This method utilizes the stochastic search 
procedure and simultaneously searches for the conformational space of the defined molecules 
and the space of alignment of those molecules.285 The method flexibly aligns the selected small 
molecules by maximizing steric and feature overlap using the MMFF94x forcefield.286 Each 
resulting alignment is given a score that quantifies the quality of the alignment in terms of both 
internal strain and overlap of molecular features. The similarity terms including hydrogen bond 
donor, acceptor, hydrophobicity and volume, were used in the flexible alignment with the 
default settings for the other parameters. The presented flexible alignment of the three drugs 
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was selected on the basis of overall score, strain energy and visual inspection of the alignment. 
This alignment was then used as a template for the pharmacophore model generation. The 
pharmacophore model was generated using the pharmacophore elucidator feature in MOE 
2014.09. The pharmacophore features were calculated automatically with the consensus 
pharmacophore function. This function clusters the features into potential pharmacophore 
features which are more conserved than a tolerance and threshold value. For the presented 
pharmacophore model, the tolerance distance of 1.5 Å and the threshold of 50% conservation 
was used. 
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7 Abbreviations 
2-AG 2-arachidonylglycerol 
A2AAR adenosine A2A receptor 
AA-5HT N-arachidonylserotonin 
AED antiepileptic drug 
AM acetoxymethyl ester 
AM-404 N-arachidonylaminophenol 
AMPA α-amino-3-hydroxy-5-methyl-4 isoxazole propionoic acid 
ANOVA analysis of variance  
AP action potential 
ATP adenosine-5’-triphosphate 
b base(s) 
BBB blood-brain barrier 
Bmax maximum number of binding sites 
BoNT Botulinum neurotoxin 
bp base pair(s) 
BRV brivaracetam 
BSA bovine serum albumin 
cAMP 3’,5’-cyclic adenosine monophosphate 
CBD cannabidiol 
CBX carbenoxolone 
cDNA complementary DNA  
CGE capillary gel electrophoresis 
cGMP 3’,5’-cyclic guanosine monophosphate 
CGS21680 2-(4-[2-carboxyethyl]-phenethylamino)adenosine-5’-N-ethyluronamide 
CHO Chinese hamster ovary 
Ci Curie 
CK1 casein kinase 1 
CMV cytomegalovirus 
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CNS central nervous system 
cpm counts per minute 
CRE cAMP response element 
CSF cerebrospinal fluid 
Cx connexin 
Da Dalton 
DAPI 4’,6-diamidino-2-phenylindole 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dpm disintegrations per minute 
dsDNA double-stranded DNA 
E. coli Escherichia coli 
e.g. exempli gratia (for example) 
EDTA ethylenediaminetetraacetic acid 
EEG electroencephalogram 
EMA European Medicines Agency 
et al. et alii (and others) 
f forward 
FACS fluorescence-assisted cell sorting 
FC flow cytometry 
FDA Food and Drug Administration 
FRAP fluorescence recovery after photobleaching 
g gram 
GABA γ-aminobutyric acid 
GABA-T GABA transaminase 
GAD glutamic acid decarboxylase 
GFP green fluorescent protein 
GJ gap junction 
GJIC gap junctional intercellular communication 
GPCR G protein-coupled receptor 
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GSL GloSensor luciferase 
GSS GloSensor substrate 
h hour(s) 
h human 
HC hemichannel 
HCR heavy chain C-terminal receptor 
HEPES N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
HRP horseradish peroxidase 
HTS high-throughput screening 
HVA high voltage- activated  
HXM hypoxanthine xanthine mycophenolic acid  
Hz hertz 
i.p. intraperitoneal 
IBE International Bureau for Epilepsy 
IBMX 3-isobutyl-1-methylxanthine 
IC50 half maximal inhibitory concentration 
ICL intracellular cytoplasmic loop 
ICL3 intracellular cytoplasmic loop three 
ILAE International League Against Epilepsy 
KA kainic acid 
KD equilibrium dissociation constant 
Ki equilibrium inhibition constant 
koff dissociation kinetic constant 
kon association kinetic constant 
l liter 
L ligand 
L4 Luminal loop four  
LacY lactose permease 
LAMP local activation of molecular fluorescence probe 
LC light chain 
LEV levetiracetam 
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LIF laser-induced fluorescence detector 
LOD limit of detection 
LOQ limit of quantification 
LTR long terminal repeat 
LVA low voltage-activated 
LY Lucifer yellow 
m meter 
M Molar 
MES maximal electroshock 
MFS major facilitator superfamily 
min minute(s) 
MRI magnetic resonance imaging 
mRNA messenger RNA 
MSX-2 3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine 
MTLE mesial temporal lobe epilepsy 
MTLE-HS MTLE and hippocampal sclerosis 
MuLV murine leukemia virus 
NECA N-ethylcarboxamidoadenosine 
NMDA N-methyl-D-aspartate 
NMR nuclear magnetic resonance 
OD optical density 
ODDD Oculodentodigital Dysplasia 
PAM positive allosteric modulator 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PDE phosphodiesterase  
PEI polyethylenimine 
PET positron emission tomography 
PKA cAMP-dependent protein kinase 
PKC protein kinase C 
PKG cGMP-dependent protein kinase 
7 Abbreviations 
170 
PSG polysialoganglioside 
PTZ pentylenetetrazole 
r reverse 
R receptor 
RFU relative fluorescence units 
RIPA radioimmunoprecipitation assay 
RNA ribonucleic acid 
rpm rounds per minute 
RSD relative standard deviation 
RT room temperature 
s second(s) 
s.c. subcutaneous(ly) 
SARs structure-activity relationships 
SDS sodium dodecylsulfate 
SDS PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis  
SEL seletracetam 
SEM standard error of the mean 
SNAP synaptosome-associated protein 
SSA succinic semialdehyde 
SSA-D SSA-dehydrogenase 
SV2 synaptic vesicle protein 2 
SV2A synaptic vesicle protein 2A 
Syt synaptotagmin 
TAE Tris Acetate EDTA buffer 
Taq Thermus aquaticus 
TBI traumatic brain injury 
TBST Tris-buffered saline with 0.1% Tween 20 
TGFβ1 transforming growth factor β1 
THC Δ9-Tetrahydrocannabinol 
Tm melting temperature 
TMD transmembrane domain 
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TRE treatment-resistant epilepsy 
Tris tris(hydroxymethyl)aminomethane 
TRPV1 transient receptor potential vanilloid receptor type 1 
Trx thioredoxin reductase system 
VAMP vesicle-associated membrane protein 
vs. versus 
VSV-G vesicular stomatitis virus 
WHO World Health Organization 
wt wild-type  
YFP yellow fluorescent protein 
ZO-1 zona occludens-1 
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Table A1: Quantification of GFP-tagged proteins by CE-LIF 
hSV2A-
GFP 
peak 
area mg/ml ng/ml 
1:100 dilution 
(ng/ml) nmol/l pmol/ml 
total amount 
(mg/ml) pmol/mg 
Test 1 69044 0.00016295 162.95492 16295.4921 0.1393 139.3 5.00 27.9 
Test 2 60554 0.00014292 142.91716 14291.7158 0.1222 122.2 5.00 24.4 
Test 3 69134 0.00016317 163.16734 16316.7335 0.1395 139.5 5.00 27.9 
       mean 26.7 
         
hA2AAR-
GFP 
peak 
area mg/ml ng/ml 
1:20 dilution 
(ng/ml) nmol/l pmol/ml 
total amount 
(mg/ml) pmol/mg 
Test 1 2011 0.00000475 4.74628 94.9257 1.3184119 1.32 12.0 0.110 
Test 2 2412 0.00000569 5.69271 113.8541 1.5813075 1.58 12.0 0.132 
Test 3 2245 0.00000530 5.29856 105.9712 1.4718223 1.47 12.0 0.123 
       mean 0.121 
         
mCx43-
GFP 
peak 
area mg/ml ng/ml 
1:2 dilution 
(ng/ml) nmol/l pmol/ml 
total amount 
(mg/ml) pmol/mg 
Test 1 2341 0.00000553 5.52514 11.0503 0.1579 0.158 4.70 0.0336 
Test 2 3282 0.00000775 7.74605 15.4921 0.2213 0.221 4.70 0.0471 
Test 3 2692 0.00000635 6.35355 12.7071 0.1815 0.182 4.70 0.0386 
       mean 0.0398 
 
 Figure A1: Separation of free GFP (standard) and hSV2A-GFP in cellular homogenate. RFU: relative 
fluorescence unit. 
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Figure A3: Effect of 1% SDS in sample buffer on peak area of hSV2A-GFP measured at different incubation 
time points. RT: room temperature, RFU: relative fluorescence unit. 
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Figure A3: Multiple sequence alignment of human SV2A, SV2B, and SV2C. The alignment was performed using 
Multalin tool.287 
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Amino acid sequences of SV2A, SV2B and their chimeric variants 
 
Protein sequence of human wild-type SV2A  
MEEGFRDRAAFIRGAKDIAKEVKKHAAKKVVKGLDRVQDEYSRRSYSRFEEEDDDDDFPAPSDGYYRGEGTQDE
EEGGASSDATEGHDEDDEIYEGEYQGIPRAESGGKGERMADGAPLAGVRGGLSDGEGPPGGRGEAQRRKEREEL
AQQYEAILRECGHGRFQWTLYFVLGLALMADGVEVFVVGFVLPSAEKDMCLSDSNKGMLGLIVYLGMMVGAFLW
GGLADRLGRRQCLLISLSVNSVFAFFSSFVQGYGTFLFCRLLSGVGIGGSIPIVFSYFSEFLAQEKRGEHLSWL
CMFWMIGGVYAAAMAWAIIPHYGWSFQMGSAYQFHSWRVFVLVCAFPSVFAIGALTTQPESPRFFLENGKHDEA
WMVLKQVHDTNMRAKGHPERVFSVTHIKTIHQEDELIEIQSDTGTWYQRWGVRALSLGGQVWGNFLSCFGPEYR
RITLMMMGVWFTMSFSYYGLTVWFPDMIRHLQAVDYASRTKVFPGERVEHVTFNFTLENQIHRGGQYFNDKFIG
LRLKSVSFEDSLFEECYFEDVTSSNTFFRNCTFINTVFYNTDLFEYKFVNSRLINSTFLHNKEGCPLDVTGTGE
GAYMVYFVSFLGTLAVLPGNIVSALLMDKIGRLRMLAGSSVMSCVSCFFLSFGNSESAMIALLCLFGGVSIASW
NALDVLTVELYPSDKRTTAFGFLNALCKLAAVLGISIFTSFVGITKAAPILFASAALALGSSLALKLPETRGQV
LQ 
 
Protein sequence of human wild-type hSV2B 
MDDYKYQDNYGGYAPSDGYYRGNESNPEEDAQSDVTEGHDEEDEIYEGEYQGIPHPDDVKAKQAKMAPSRMDSL
RGQTDLMAERLEDEEQLAHQYETIMDECGHGRFQWILFFVLGLALMADGVEVFVVSFALPSAEKDMCLSSSKKG
MLGMIVYLGMMAGAFILGGLADKLGRKRVLSMSLAVNASFASLSSFVQGYGAFLFCRLISGIGIGGALPIVFAY
FSEFLSREKRGEHLSWLGIFWMTGGLYASAMAWSIIPHYGWGFSMGTNYHFHSWRVFVIVCALPCTVSMVALKF
MPESPRFLLEMGKHDEAWMILKQVHDTNMRAKGTPEKVFTVSNIKTPKQMDEFIEIQSSTGTWYQRWLVRFKTI
FKQVWDNALYCVMGPYRMNTLILAVVWFAMAFSYYGLTVWFPDMIRYFQDEEYKSKMKVFFGEHVYGATINFTM
ENQIHQHGKLVNDKFTRMYFKHVLFEDTFFDECYFEDVTSTDTYFKNCTIESTIFYNTDLYEHKFINCRFINST
FLEQKEGCHMDLEQDNDFLIYLVSFLGSLSVLPGNIISALLMDRIGRLKMIGGSMLISAVCCFFLFFGNSESAM
IGWQCLFCGTSIAAWNALDVITVELYPTNQRATAFGILNGLCKFGAILGNTIFASFVGITKVVPILLAAASLVG
GGLIALRLPETREQVLI 
 
Protein sequence of human hSV2A-hSV2B-ICL3 
MEEGFRDRAAFIRGAKDIAKEVKKHAAKKVVKGLDRVQDEYSRRSYSRFEEEDDDDDFPAPSDGYYRGEGTQDE
EEGGASSDATEGHDEDDEIYEGEYQGIPRAESGGKGERMADGAPLAGVRGGLSDGEGPPGGRGEAQRRKEREEL
AQQYEAILRECGHGRFQWTLYFVLGLALMADGVEVFVVGFVLPSAEKDMCLSDSNKGMLGLIVYLGMMVGAFLW
GGLADRLGRRQCLLISLSVNSVFAFFSSFVQGYGTFLFCRLLSGVGIGGSIPIVFSYFSEFLAQEKRGEHLSWL
CMFWMIGGVYAAAMAWAIIPHYGWSFQMGSAYQFHSWRVFVLVCAFPSVFAIGALTFMPESPRFLLEMGKHDEA
WMILKQVHDTNMRAKGTPEKVFTVSNIKTPKQMDEFIEIQSSTGTWYQRWLVRFKTIFKQVWDNALYCVMGPYR
MITLMMMGVWFTMSFSYYGLTVWFPDMIRHLQAVDYASRTKVFPGERVEHVTFNFTLENQIHRGGQYFNDKFIG
LRLKSVSFEDSLFEECYFEDVTSSNTFFRNCTFINTVFYNTDLFEYKFVNSRLINSTFLHNKEGCPLDVTGTGE
GAYMVYFVSFLGTLAVLPGNIVSALLMDKIGRLRMLAGSSVMSCVSCFFLSFGNSESAMIALLCLFGGVSIASW
NALDVLTVELYPSDKRTTAFGFLNALCKLAAVLGISIFTSFVGITKAAPILFASAALALGSSLALKLPETRGQV
LQ 
 
Protein sequence of human hSV2B-hSV2A-ICL3 
MDDYKYQDNYGGYAPSDGYYRGNESNPEEDAQSDVTEGHDEEDEIYEGEYQGIPHPDDVKAKQAKMAPSRMDSL
RGQTDLMAERLEDEEQLAHQYETIMDECGHGRFQWILFFVLGLALMADGVEVFVVSFALPSAEKDMCLSSSKKG
MLGMIVYLGMMAGAFILGGLADKLGRKRVLSMSLAVNASFASLSSFVQGYGAFLFCRLISGIGIGGALPIVFAY
FSEFLSREKRGEHLSWLGIFWMTGGLYASAMAWSIIPHYGWGFSMGTNYHFHSWRVFVIVCALPCTVSMVALKT
QPESPRFFLENGKHDEAWMVLKQVHDTNMRAKGHPERVFSVTHIKTIHQEDELIEIQSDTGTWYQRWGVRALSL
GGQVWGNFLSCFGPEYRRNTLILAVVWFAMAFSYYGLTVWFPDMIRYFQDEEYKSKMKVFFGEHVYGATINFTM
ENQIHQHGKLVNDKFTRMYFKHVLFEDTFFDECYFEDVTSTDTYFKNCTIESTIFYNTDLYEHKFINCRFINST
FLEQKEGCHMDLEQDNDFLIYLVSFLGSLSVLPGNIISALLMDRIGRLKMIGGSMLISAVCCFFLFFGNSESAM
IGWQCLFCGTSIAAWNALDVITVELYPTNQRATAFGILNGLCKFGAILGNTIFASFVGITKVVPILLAAASLVG
GGLIALRLPETREQVLI  
 
Colors: Red color indicates the intracellular loop 3 (ICL3) in SV2A, SV2B, and chimeric variants. Yellow 
highlighted amino acid in SV2A wt depicts the arginine at position 383
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